A reader’s question then led to Restoring sleep architecture, where I unpacked hypnograms, sleep architecture, and the fascinating dance between deep and REM sleep throughout the night.

This next article gets a bit more clinical because a clinical question was asked by a reader. So this is intended to help practitioners think through common causes of disrupted sleep architecture. There’s something here, though, for everyone.

I’ve created a patient guide that summarizes the primary drivers of sleep architecture disruption discussed in this article. It is designed to facilitate patient-provider conversations and may be shared directly with patients or adapted for use within clinical practice.

The following is intended for educational purposes only, and although it is evidence-supported, it is not medical advice and does not replace the advice of your medical provider. If you are suffering from sleep deprivation, insomnia, prolonged stress, or other symptoms discussed in this article, please seek the advice of a medical professional.

Our sleep is a precisely orchestrated biological program that cycles through distinct stages every night: light sleep (N1/N2), slow-wave deep sleep (N3), and rapid eye movement (REM) sleep. As discussed in Restorative sleep stages, each stage serves unique physiological functions that cannot be fully replicated by the others.

These stages are measured directly using polysomnography (PSG), the gold standard for sleep assessment, or estimated by consumer wearables such as the RingConn, Apple Watch, Oura Ring, and Whoop. Data collection is displayed in a hypnogram, a graph illustrating the rhythmic progression through sleep stages across the night. Together, these recurring cycles comprise sleep architecture.

In healthy adults, sleep architecture follows a relatively predictable pattern. After falling asleep, individuals typically progress from N1 sleep into N2 sleep and then into N3 slow-wave (deep) sleep before cycling back through lighter stages and entering REM sleep. This sequence repeats throughout the night, with N2 sleep comprising the largest proportion of total sleep time, while N3 and REM sleep occupy smaller but physiologically important portions of the sleep period.

Although the exact distribution varies by age and individual factors, healthy sleep is generally marked by a stable cycling pattern between NREM and REM stages rather than frequent fragmentation or prolonged wakefulness [14].

When that architecture becomes disrupted, the consequences extend far beyond feeling tired the next day. Alterations in sleep-stage distribution have been associated with impaired cognitive performance, metabolic dysfunction, cardiovascular risk, immune dysregulation, and reduced recovery capacity.

A landmark 2024 prospective cohort study published in Sleep helped reframe this discussion. demonstrating that sleep regularity, the day-to-day consistency of sleep-wake timing, is a stronger predictor of mortality risk than sleep duration [18].

A subsequent 2025 review in Circulation Research confirmed that greater sleep irregularity is consistently associated with worse cardiometabolic outcomes across diverse populations [5].

The mechanism that disrupts sleep architecture over time is the same one that disrupts regularity, and this irregularity carries a measurable mortality risk independent of how many hours the patient reports sleeping.

In many common clinical presentations, sleep architecture disruption is dominated by one or more of three upstream physiological patterns: hypothalamic-pituitary-adrenal (HPA) axis dysregulation, circadian misalignment, and metabolic dysfunction. These patterns frequently coexist and interact with other sleep-disrupting conditions.

Driver One: HPA Axis Dysregulation

Mechanism

The stress response and restorative sleep are physiologically antagonistic. Sleep onset requires a precipitous drop in cortisol and central norepinephrine (NE), both of which must remain suppressed through the first two-thirds of the night for slow-wave sleep (SWS) to occur and be maintained. When the HPA axis is chronically activated, this suppression fails.

The pathway begins in the paraventricular nucleus (PVN) of the hypothalamus, which releases corticotropin-releasing hormone (CRH) in response to psychological, physiological, or inflammatory stressors. CRH stimulates pituitary adrenocorticotropic hormone (ACTH) secretion, which in turn drives adrenal cortisol release. Elevated nocturnal cortisol acts directly on sleep circuitry: it suppresses the growth hormone (GH) pulse that normally anchors N3 (our deep sleep) in the first sleep cycle, blunts slow-wave activity (SWA) amplitude, and fragments the continuity required to sustain deep non-rapid eye movement (NREM) sleep.

Nightlong recordings confirm that awakenings are positively correlated with ACTH levels, and both ACTH and cortisol are inversely related to slow-wave sleep. This pattern is consistent with CRH hypersecretion [7].

The locus coeruleus (LC) is the second critical node.

A 2025 landmark study published in Nature Neuroscience provided the first mechanistic proof of what clinicians have observed empirically for decades. Using optogenetics and fiber photometry, the authors demonstrated that infra-slow fluctuations in LC neuronal activity directly partition NREM sleep into two distinct brain-autonomic states that govern the entire NREM-REM cycle [12].

High LC activity, precisely the state produced by stress, induces subcortical-autonomic arousal that facilitates cortical microarousals and blocks REM entries entirely. Low LC activity is an obligatory prerequisite for NREM-to-REM transitions. Critically, a stress-promoting wakefulness experience was shown to elevate LC activity during subsequent NREM sleep, producing more microarousal-induced NREM fragmentation and delayed REM onset.

This is not a correlation. It is the identified circuit mechanism by which stress suppresses REM [12].

The result is a sleep architecture characterized by excess N1/N2, reduced SWS, fragmented or absent REM, and a hyperarousal phenotype that persists even when sleep duration appears adequate on actigraphy or upon self-report.

Psychosocial stress and its cognitive correlates, rumination (perseverative past-focused cognition) and worry (anticipatory threat processing), produce the same neuroendocrine signature with documented associations in [8]:

• Prolonged sleep onset latency

• Shorter and more fragmented sleep

• Excess N1

• Reduced REM

• Reduced SWS

• Prolonged SWS latency

This means a patient does not require an objectively measurable stressor, as the internal stress response is sufficient to produce full architectural disruption.

Clinical Fingerprint

• Sleep initiation is often preserved or mildly impaired

• Early morning awakening, characteristically between 2:00–4:00 AM, with cognitive hyperarousal and “the mind is already running”

• Sleep is described as light, thin, or unrefreshing despite adequate duration

• Night-to-night variability that correlates with identifiable stressors

• Suppressed nocturnal heart rate variability (HRV); elevated resting heart rate during sleep (wearable data is clinically useful here)

• Blunted cortisol awakening response (CAR) in chronic HPA exhaustion states; the patient wakes groggy, not alert, and takes 60+ minutes to feel functional

First-line treatment

Cognitive Behavioral Therapy for Insomnia (CBT-I) is the evidence-based standard and can be offered before or alongside any pharmacologic intervention. Meta-analyses and five clinical guidelines now unanimously recommend multicomponent CBT-I as first-line treatment for chronic insomnia [19].

The sleep restriction and stimulus control components directly address hyperarousal and conditioned arousal, respectively, while cognitive restructuring targets the perseverative cognition that sustains HPA activation. A 2025 FDA-authorized digital CBT-I trial (SleepioRx) confirmed sustained efficacy at 6 months in a decentralized nationwide randomized controlled trial [6].

When to refer

Refer to psychiatry or psychology if CBT-I is unavailable or has failed after 6–8 weeks; if comorbid anxiety disorder, post-traumatic stress disorder (PTSD), or major depressive disorder (MDD) is suspected; where clinically indicated, assessment of diurnal cortisol rhythm may provide additional information regarding neuroendocrine regulation, although interpretation remains context dependent.

Driver Two: Circadian Misalignment

Mechanism

The circadian system gates specific sleep stages to specific biological times of night through a precisely orchestrated program governed by the suprachiasmatic nucleus (SCN) of the hypothalamus. The SCN receives photic input from intrinsically photosensitive retinal ganglion cells (ipRGCs) via the retinohypothalamic tract and synchronizes peripheral clocks in virtually every tissue, including the brainstem circuits that govern sleep-stage timing [10].

REM sleep is the most clock-dependent stage.

Within Borbély’s two-process model of sleep regulation, process S (homeostatic sleep pressure, driven by adenosine accumulation) governs SWS, which is why SWS is more resilient to timing shifts.

Process C (the circadian pacemaker), operating through the SCN, tightly gates REM propensity to the final third of the biological sleep period [2].

This is not a passive effect: the SCN actively promotes REM during the subjective late-night/early-morning window and suppresses it at other times. A patient with a biological sleep midpoint of 4:00 AM who is forced awake at 6:00 AM by an alarm or other means is losing two or more hours of peak REM propensity every single night because process C has not yet permitted maximal REM expression.

The architecture consequence is REM compression or frank REM deprivation, with SWS relatively preserved.

REM sleep is typically the earliest and most sensitive casualty of circadian misalignment because REM expression is tightly gated by the circadian clock, whereas slow-wave sleep remains more strongly governed by accumulated sleep pressure. Although SWS is generally more resilient, chronic or severe circadian misalignment can eventually fragment overall sleep architecture and reduce slow-wave sleep quality [27].

The chronic discordance between a person’s endogenous chronotype and their socially imposed schedule (social jetlag) is now recognized as a major population-level source of circadian misalignment. A 2023 population-representative longitudinal study in Sleep found that social jetlag is independently associated with adverse cardiovascular and metabolic biomarkers, including unfavorable lipid profiles, after controlling for chronotype, age, sex, and body mass index [16].

Shift workers carry a 40% increased risk of type 2 diabetes compared with non-shift workers, driven in part by circadian-mediated glucose dysregulation and sleep architecture fragmentation [14].

The 2025 Circulation Research review established that internal deviations in sleep timing, not just sleep duration, represent the most prevalent cause of circadian disruption at the population level, and that sleep irregularity may be a more significant predictor of cardiometabolic disease risk than sleep duration itself [5].

A patient who “sleeps enough hours” may be incurring significant metabolic and mortality risks due to timing irregularity alone.

Emerging evidence also demonstrates that combining CBT-I with circadian rhythm support (consistent scheduling, timed light, meal timing) yields superior outcomes compared with either approach alone [13].

Clinical Fingerprint

• Sleep quality and architecture improve substantially on free days when no alarm intervenes (the “vacation test”)

• Disproportionate sleep inertia on required-schedule mornings causes dense, prolonged grogginess, suggesting waking during biological night

• Natural sleep midpoint (estimated as the midpoint between spontaneous sleep onset and natural waking) is significantly later than required wake time demands

• Patient identifies as a “night owl” and performs better cognitively and physically in evening hours

• Daytime sleepiness despite adequate reported duration (Epworth Sleepiness Scale [ESS] ≥10 warrants formal evaluation)

• Mood and energy are markedly better when sleeping on a natural schedule

First-line treatment

Chronotherapy targets realignment of internal circadian rhythms with the external light-dark cycle and the patient’s required schedule. Four levers are available: light, melatonin timing, meal timing, and schedule consistency.

Timed morning bright light: The American Academy of Sleep Medicine (AASM) Clinical Practice Guideline for delayed sleep-wake phase disorder (DSWPD) identifies timed bright light exposure as a primary treatment. Morning light (10,000 lux, 30–60 minutes) delivered at biological dawn begins to advance the phase response curve (PRC). Light exposure at the wrong time will shift the clock in the wrong direction; timing relative to the individual’s dim light melatonin onset (DLMO) is key [1].

Timed melatonin: The AASM guideline recommends timed exogenous melatonin for DSWPD. Melatonin administered 5–6 hours before the patient’s current sleep onset (i.e., in the late afternoon for a severely delayed patient) produces the maximum phase-advance on the PRC [1]. The standard dose is 0.3–0.5 mg; higher doses do not produce a proportionally greater phase shift and may cause next-day grogginess.

Schedule anchoring: Consistency of wake time, even on weekends, is the single most powerful behavioral anchor for circadian entrainment. A 2025 preprint narrative review confirmed that combining CBT-I with circadian rhythm support yields superior outcomes compared with either alone [13].

Meal timing: Time-restricted eating (TRE) aligned with the light phase (front-loading calories to morning/midday) supports peripheral circadian entrainment and reduces social jetlag effects on metabolic health.

Peripheral to the master clock are tissues that have their own rhythmic clocks. These include the liver, muscle, adipose, pancreas, and the gut (among many others) and run a self-sustaining transcription-translation feedback loop driven by CLOCK/BMAL1 protein cycling.

These peripheral clocks cannot directly sense light so they entrain primarily to feeding-fasting cycles, making the timing of food intake one of the most potent zeitgebers (”time-givers”) available outside of light itself.

When meals are shifted late, as is typical for individuals with social jetlag or night owls, peripheral clocks in the liver and gut decouple from the central SCN clock. This internal desynchrony between brain time and organ time is metabolically costly because it produces insulin resistance, blunts postprandial glucose clearance, elevates triglycerides, and disrupts the nocturnal suppression of hepatic glucose output [29], which as been demonstrated in controlled feeding studies in humans.

TRE consolidates the feeding-fasting signal and strengthens peripheral clock entrainment independent of caloric restriction. The circadian relevance is distinct from the metabolic effects of calorie reduction, which has made TRE an increasingly studied tool for circadian medicine specifically.

When to refer

Refer to a sleep medicine specialist if DSWPD, advanced sleep-wake phase disorder (ASWPD), non-24-hour sleep-wake disorder, or shift work disorder is suspected and fails to respond to behavioral chronotherapy within 4–6 weeks. Actigraphy over 14 days can be an appropriate objective assessment tool prior to referral. Consider salivary DLMO testing to personalize melatonin timing; home-based DLMO kits are increasingly available and clinically actionable.

Driver Three: Metabolic Dysfunction

Mechanism

This is the most underappreciated and underdiagnosed driver of sleep architecture disruption in primary care and the one with the highest downstream systemic stakes. The relationship is bidirectional and self-amplifying: metabolic dysfunction degrades sleep architecture, which worsens insulin sensitivity, which further disrupts sleep.

A January 2025 review of current evidence confirmed that insufficient sleep and poor sleep quality are independently associated with increased risks of obesity, type 2 diabetes, and cardiovascular disease, with bidirectionality well established in prospective cohort data [21].

The specific sleep-stage mechanism is now well characterized.

In a 2023 study published in Cell Reports Medicine, Vallat et al. examined over 600 people with overnight polysomnography and next-morning glucose and insulin measurements, then replicated their findings in an independent cohort of over 1,900 adults.

Subscribe now

The key finding was that the coupling of NREM sleep spindles and slow oscillations during N3 (the electrophysiological signature of deep sleep) was the strongest predictor of next-day peripheral glucose control, outperforming traditional sleep metrics, including total sleep time and sleep efficiency [17].

The mechanism operates through altered insulin sensitivity rather than pancreatic beta cell function, running from the sleeping brain through cardiac autonomic pathways to peripheral glucose regulation [17].

A 2024 review in the Journal of Clinical Medicine further confirmed that diabetes is consistently associated with reduced SWS even in the absence of sleep-disordered breathing, and that selective SWS suppression, without reducing total sleep time, leads to significant increases in insulin resistance and decreased glucose tolerance [11].

Glucose instability and nocturnal arousal: Blood glucose dips during the early morning hours trigger a sympathoadrenal counterregulatory cascade of epinephrine and cortisol release, producing an arousal pattern clinically indistinguishable from HPA-driven insomnia.

A patient may wake at 3:00–4:00 AM, feeling physiologically alert but not cognitively anxious from a glucose recovery response. Research using continuous glucose monitoring (CGM) during polysomnography has demonstrated that patients with moderate-to-severe obstructive sleep apnea (OSA) exhibit rising blood glucose levels after sleep onset, directly linking nocturnal glucose dysregulation to sleep-architecture disruption [20].

Sleep-disordered breathing: OSA and upper airway resistance syndrome (UARS) fragment both SWS and REM through repeated micro-arousals that typically last 3–15 seconds. The patient may never consciously register it, but that prevents sustained stage consolidation. The sleep architecture of OSA is characterized by increased N1 and N2 sleep and decreased SWS and REM sleep, with arousal frequency as the primary driver [15].

Many patients do technically enter N3 and REM sleep, but repeated respiratory events and microarousals prevent these stages from being sustained long enough to deliver their normal restorative benefits [28].

Intermittent hypoxia and frequent arousal increase sympathetic tone, oxidative stress, systemic inflammation, and hormonal imbalances, producing insulin resistance and beta cell dysfunction through pathways distinct from chronic sleep deprivation.

Systemic inflammation: IL-6 and TNF-α are elevated in disorders associated with excessive daytime sleepiness, including [7]:

• Sleep apnea

• Narcolepsy

• Idiopathic hypersomnia

Obesity-mediated chronic low-grade inflammation shifts sleep toward lighter stages and blunts slow-wave amplitude through these cytokine pathways.

Clinical Fingerprint

• Sleep consistently feels unrefreshing regardless of duration; the patient sleeps 8 hours and wakes exhausted

• Fatigue that tracks with meals, carbohydrate load, or weight fluctuation

• Nocturnal arousal at 3:00–4:00 AM that feels physiological rather than cognitive; the patient wakes alert but not anxious

• Morning headaches, dry mouth, or sore throat on waking

• Snoring reported by bed partner, even intermittently

• ESS ≥10 despite reported adequate sleep duration

• BMI >30, neck circumference >17 inches (male) or >16 inches (female), or retrognathia on exam

• Resistant hypertension or atrial fibrillation; OSA association is strong enough to warrant screening automatically

First-line treatment

Metabolic stabilization:

• Stabilize nocturnal glucose: Reduce refined carbohydrate load, particularly in the evening. Consider CGM for 10-14 days to assess whether nocturnal awakening coincides with overnight glucose fluctuations. In patients with suspected nocturnal glucose instability, adjustment of evening meal composition may be considered, although evidence remains limited, and individualized assessment is warranted.

• HOMA-IR: Assess insulin resistance as a baseline metabolic marker, particularly in patients with unrefreshing sleep and fatigue-meal correlation.

• Inflammatory biomarkers, including hs-CRP and, where available, IL-6, may provide additional context regarding systemic inflammatory burden.

Sleep-disordered breathing:

• Home sleep testing (HST) is an appropriate first-line for suspected uncomplicated OSA in adults without significant cardiopulmonary comorbidity. In-laboratory polysomnography (PSG) is indicated when HST is negative but clinical suspicion remains high, when UARS is suspected, when significant cardiac or pulmonary comorbidity is present, or when full staging data are needed [9].

• Continuous positive airway pressure (CPAP) initiation for confirmed OSA produces a well-documented rebound in both SWS and REM, with REM percentage exceeding normal values in the first weeks of treatment as architecture reconsolidates [15]. This rebound is expected and should be communicated to the patient.

• UARS without classic apneic events, normal oxygen saturation, profoundly unrefreshing sleep, is routinely missed on HST and requires full PSG for diagnosis. Consider it in patients with the metabolic fingerprint above and a negative home study.

When to refer

Refer to sleep medicine for PSG when HST is negative, and suspicion remains, when UARS is suspected, when ESS ≥10 fails to respond to initial interventions, when REM behavior disorder (RBD) is suspected, or when the clinical picture remains unexplained after thorough primary evaluation. Refer to endocrinology if significant insulin resistance, cortisol dysregulation, or thyroid dysfunction is identified on workup.

The Interaction Problem

These three drivers do not operate in isolation. Chronic stress promotes insulin resistance through cortisol-mediated hepatic glucose output and peripheral insulin receptor downregulation. Metabolic dysfunction worsens circadian timing by disrupting the hormonal milieu on which peripheral clocks depend. Circadian disruption elevates cortisol through SCN-HPA crosstalk, closing the loop. The cascade can initiate from any node and can propagate.

Common Mimics and Amplifiers

HPA-axis dysregulation, circadian misalignment, and metabolic dysfunction account for many presentations of disrupted sleep architecture, but several additional conditions can independently fragment sleep or amplify disruption arising from these primary drivers. A brief orientation follows; thorough treatment of each is beyond the scope of this article.

Restless Legs Syndrome and Periodic Limb Movement Disorder

These are two important differential considerations in patients with sleep-maintenance insomnia, non-restorative sleep, or unexplained daytime sleepiness. Repetitive limb movements during sleep produce recurrent micro-arousals that impair continuity even when total sleep duration appears adequate [22].

The 2025 AASM clinical practice guideline represents a significant shift: routine assessment of iron status is now emphasized, dopamine agonists are deprioritized due to augmentation risk, and iron replacement (when indicated) alongside alpha-2-delta ligands are now the favored approaches. Low ferritin, an evening urge to move the legs, and a bed partner reporting repetitive movements are the key clinical signals.

Menopause and Perimenopause

These mid-life chapters produce a distinct sleep disruption phenotype characterized primarily by increased nighttime awakenings and greater wake after sleep onset (WASO), with reduced sleep efficiency — and notably, these disturbances may occur even in the absence of vasomotor symptoms [23].

Emerging literature further links menopausal sleep disruption to increased prevalence of sleep-disordered breathing, creating overlap with the metabolic and circadian mechanisms above [24]. New-onset insomnia during midlife in women warrants this differential.

Medication and Substance-Induced Disruption

SSRIs and SNRIs reliably prolong REM latency and alter REM expression in susceptible patients. Systemic corticosteroids commonly increase CNS activation, prolonging sleep onset and increasing nighttime awakenings. Stimulants, nicotine, and sympathomimetics delay sleep onset and increase nocturnal arousal through noradrenergic signaling.

Alcohol deserves particular attention because it reliably creates the illusion of improved sleep. While it often reduces sleep-onset latency, controlled studies and systematic reviews consistently show that alcohol disrupts architecture during the second half of the night: it delays REM expression, reduces REM duration, increases fragmentation, and exacerbates sleep-disordered breathing in susceptible individuals [25, 26].

A patient who reports “sleeping fine” with a nightly drink and wakes unrefreshed is a candidate for a structured trial without it.

Restoring Sleep Architecture for Patients

Sleep medications and supplements may have a role in selected patients, but they do not address the underlying reason sleep architecture became disrupted in the first place. Effective intervention begins with pattern recognition: identifying whether disruption is being driven by circadian misalignment, glycemic instability, stress physiology, sleep-disordered breathing, medication effects, or another upstream cause.

The goal is not simply to increase deep sleep or REM sleep. The goal is to restore the conditions that allow healthy sleep architecture to emerge naturally.

To support that process, I have created a patient-facing guide that organizes common causes of sleep architecture disruption into the three-driver framework described in this article. Clinicians may share it directly or adapt the recommendations to fit their own practice and treatment philosophy.

You can also download it here.

Clinical Patient Guide

This guide is designed to be shared with or adapted for patients to fit individual practice styles and treatment approaches.

To support clinical pattern recognition, I built an accompanying patient guide, which organizes common causes of sleep architecture disruption into three broad categories: stress physiology, circadian misalignment, and metabolic dysfunction. While many patients will exhibit features of more than one category, these patterns can provide a useful starting point for clinical investigation and patient education.

What’s Next?

Over the past several articles, we’ve taken a progressively deeper look at sleep. We began by exploring what healthy sleep patterns actually look like and how sleep architecture changes throughout the night. We then examined hypnograms and wearable data, learning both the value and limitations of the sleep metrics many of us check each morning. Finally, we turned our attention to restorative sleep itself, focusing less on scores and stages and more on the biological recovery processes that determine how we feel when we wake up.

Through this happy accident of a sleep series, I have been waiting to have an important conversation with you.

Sleep is not the system in charge, it is an output. It is not even the beginning of the story.

So we must now move beyond sleep and into the fascinating world of circadian biology, chronotypes, and the molecular clocks ticking inside nearly every cell of the human body.

Leave a comment

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

References

1. Auger, R. R., Burgess, H. J., Emens, J. S., Deriy, L. V., Thomas, S. M., & Sharkey, K. M. (2015). Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: Advanced sleep-wake phase disorder (ASWPD), delayed sleep-wake phase disorder (DSWPD), non-24-hour sleep-wake rhythm disorder (N24SWD), and irregular sleep-wake rhythm disorder (ISWRD). Journal of Clinical Sleep Medicine, 11(10), 1199–1236. https://doi.org/10.5664/jcsm.5100

2. Bes, F. (2025). Treatise on an alternative perspective on the two-process model of sleep regulation. npj Biological Timing and Sleep, 2, Article 38. https://doi.org/10.1038/s44323-025-00038-0

3. Bonilla, D. A., Moreno, Y., Gho, C., Petro, J. L., Odriozola-Martínez, A., & Kreider, R. B. (2026). Effects of multi-herb and ashwagandha root formulas on stress modulation: A randomized, double-blind, placebo-controlled clinical study. Trials, 27, Article 495. https://doi.org/10.1186/s13063-026-09495-9

4. Brendler, T. (2025). Evaluation of potential hormonal activities of Ashwagandha (Withania somnifera). Phytotherapy Research. Advance online publication. https://doi.org/10.1002/ptr.70155

5. Chung, J., Goodman, M. O., Huang, T., Castro-Diehl, C., Redline, S., & Bhatt, D. L. (2025). Sleep irregularity, circadian disruption, and cardiometabolic disease risk. Circulation Research. Advance online publication. https://doi.org/10.1161/CIRCRESAHA.125.325613

6. Espie, C. A., Emsley, R., Kyle, S. D., Gordon, C., Drake, C. L., Siriwardena, A. N., Cape, J., Ong, J. C., Carr, A., Wills, G., & Luik, A. I. (2025). The effectiveness of digital cognitive behavioral therapy to treat insomnia disorder in US adults: Nationwide decentralized randomized controlled trial. JMIR Mental Health, 12, e84323. https://doi.org/10.2196/84323

7. Irwin, M. R., Piber, D., & Olmstead, R. (2025). Sleep and psychiatric disorders: Bidirectional interactions and shared mechanisms. PLOS Mental Health, 2(12), e0000531. https://doi.org/10.1371/journal.pmen.0000531

8. Kalmbach, D. A., Cuamatzi-Castelan, A. S., Tonnu, C. V., Tran, K. M., Anderson, J. R., Roth, T., & Drake, C. L. (2018). Hyperarousal and sleep reactivity in insomnia: Current insights. Nature and Science of Sleep, 10, 193–201. https://doi.org/10.2147/NSS.S138823

9. Kapur, V. K., Auckley, D. H., Chowdhuri, S., Kuhlmann, D. C., Mehra, R., Ramar, K., & Harrod, C. G. (2017). Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 13(3), 479–504. https://doi.org/10.5664/jcsm.6506

10. Kolbe, I., Linde, K., Oster, H., & Keshet, G. (2024). Circadian dysfunction and cardio-metabolic disorders in humans. Frontiers in Endocrinology, 15, Article 1328139. https://doi.org/10.3389/fendo.2024.1328139

11. Mao, Y. (2024). Sleep architecture changes in diabetes. Journal of Clinical Medicine, 13(22), Article 6851. https://doi.org/10.3390/jcm13226851

12. Osorio-Forero, A., Foustoukos, G., Cardis, R., Cherrad, N., Devenoges, C., Fernandez, L. M. J., & Lüthi, A. (2025). Infraslow noradrenergic locus coeruleus activity fluctuations are gatekeepers of the NREM–REM sleep cycle. Nature Neuroscience, 28, 84–96. https://doi.org/10.1038/s41593-024-01822-0

13. Preprints.org. (2025, November 28). Circadian-based sleep interventions in clinical applications: A narrative review (Preprint). https://doi.org/10.20944/preprints202511.2169.v1

14. Rogers, M. A. (2024). The effects of sleep disruption on metabolism, hunger, and satiety, and the influence of psychosocial stress and exercise: A narrative review. Diabetes/Metabolism Research and Reviews, Article e3667. https://doi.org/10.1002/dmrr.3667

15. Shen, C. H., Huang, Y. S., Tseng, W. J., Yu, C. C., Lin, Y. N., Wang, C. Y., & Guilleminault, C. (2021). Rapid eye movement sleep and slow wave sleep rebounded and related factors during positive airway pressure therapy. Scientific Reports, 11, Article 7686. https://doi.org/10.1038/s41598-021-87149-3

16. Sládek, M., Klusáček, J., Hamplová, D., & Sumová, A. (2023). Population-representative study reveals cardiovascular and metabolic disease biomarkers associated with misaligned sleep schedules. Sleep, 46(4), zsad037. https://doi.org/10.1093/sleep/zsad037

17. Vallat, R., Shah, V. D., & Walker, M. P. (2023). Coordinated human sleeping brainwaves map peripheral body glucose homeostasis. Cell Reports Medicine, 4(7), Article 101100. https://doi.org/10.1016/j.xcrm.2023.101100

18. Windred, D. P., Burns, A. C., Lane, J. M., Saxena, R., Rutter, M. K., Cain, S. W., & Phillips, A. J. K. (2024). Sleep regularity is a stronger predictor of mortality risk than sleep duration: A prospective cohort study. Sleep, 47(1), zsad253. https://doi.org/10.1093/sleep/zsad253

19. Yan, P., Feng, S., Ma, M., Li, B., & Liu, J. (2026). Summary of the best evidence that cognitive behavioral therapy for insomnia improves sleep quality in patients with chronic insomnia. Frontiers in Psychiatry, 16, Article 1688561. https://doi.org/10.3389/fpsyt.2025.1688561

20. Yoshikawa, M., Yamauchi, M., Fujita, Y., Ono, M., Ushijima, S., Kinoshita, T., & Kimura, H. (2020). Dynamic changes in nocturnal blood glucose levels are associated with sleep-related features in patients with obstructive sleep apnea. Scientific Reports, 10, Article 17873. https://doi.org/10.1038/s41598-020-74908-x

21. Zhu, S., Shi, X., Chen, M., Shi, Y., Li, Y., Zheng, X., & Li, Y. (2025). The effect of sleep disruption on cardiometabolic health. Life, 15(1), Article 60. https://doi.org/10.3390/life15010060

22. Winkelman, J. W., Berkowski, J. A., DelRosso, L. M., Koo, B. B., Scharf, M. T., Sharon, D., Zak, R. S., Kazmi, U., Falck-Ytter, Y., Shelgikar, A. V., Trotti, L. M., & Walters, A. S. (2025). Treatment of restless legs syndrome and periodic limb movement disorder: An American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 21(1), 137–152. https://doi.org/10.5664/jcsm.11390

23. Maki, P. M., Panay, N., & Simon, J. A. (2024). Sleep disturbance associated with the menopause. Menopause, 31(8), 724–733. https://doi.org/10.1097/GME.0000000000002386

24. Sparks, J. R., Burgess, H. J., & colleagues. (2025). Menopause-related changes in sleep and the associations with cardiometabolic health: A narrative review. Healthcare, 13(17), 2085.

25. Gardiner, J., et al. (2025). Systematic review and meta-analysis examining alcohol and sleep in healthy adults.

26. McCullar, J., et al. (2024). Presleep alcohol consumption and objective sleep architecture outcomes. Sleep, 47(4).

27. Deantoni, M., Reyt, M., Dourte, M. et al. Circadian rapid eye movement sleep expression is associated with brain microstructural integrity in older adults. Commun Biol 7, 758 (2024). https://doi.org/10.1038/s42003-024-06415-y

28. Feriante J, Singh S. REM Rebound Effect. [Updated 2024 Sep 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560713/?utm_source=chatgpt.com

29. Greenhill, C. Feasibility and effectiveness of time-restricted eating in different populations. Nat Rev Endocrinol 18, 715 (2022). https://doi.org/10.1038/s41574-022-00770-8

The question was really two-fold:

“I use an Apple Watch to track my sleep, and I’m a little dubious about how it divides my night into sleep stages. Does that matter? And is it actually helpful to know how much deep and REM sleep I’m getting every night?”

It’s a sharp question. And the evidence-based answer is: yes, but with nuance.

So let’s walk through the stages of nightly sleep, what a healthy hypnogram looks like compared with a fragmented one, and how to interpret your wearable data without spiraling every morning. I even made you a downloadable list of metrics worth paying attention to.

As any smart ring wearer will notice, sleep is a rhythmic state.

What might not be so obvious is that our brain cycles through four distinct stages about every hour and a half. And it does this four to five times each night.

These are rather fixed stages and are not interchangeable, meaning you cannot skip one stage and make up for it with extra time at the end. All the stages in your nightly sleep journey do something physiologically distinct and irreplaceable.

There are two stages of light sleep, a deep sleep stage, and, of course, the infamous REM (rapid eye movement) stage. Before I nerd out on the physiological processes in each of the stages, you might be wondering:

How important are sleep stages for health?

That answer, fortunately, is not nuanced. The science is clear on this one: yes, our sleep stages matter. Substantially.

In 2024, a landmark study in Nature Medicine tracked 6,785 participants who wore Fitbit devices for a median of 4.5 years. The collected data were cross-referenced with electronic health records, and the findings were striking: REM sleep and deep sleep were inversely associated with the odds of developing atrial fibrillation, and sleep duration, stage distribution, and irregularity were all independently associated with the incidence of obesity, cardiovascular disease, and psychological disorders [19].

This means that the more REM and deep sleep you get, the lower your odds of developing atrial fibrillation. Fewer of those stages = higher risk. More of those stages = lower risk.

The mechanistic picture is consistent with these population findings.

• Deep sleep deprivation impairs immune function and hormone output, and glymphatic clearance (your brain's dedicated waste disposal network).

• REM deprivation disrupts emotional regulation and cognitive integration.

• Chronically fragmented sleep, where stages are interrupted before their functions are complete, compounds these deficits even when total sleep time appears adequate.

So that is the straight answer to the first question, “Do sleep stages matter?” Unequivocally, yes. But the second part of that question matters is where the nuance lies: …is it actually helpful to know how much deep and REM sleep I’m getting every night?

Let’s be nerdy about the fun physiology of sleep stages and get to the bottom of tracking nightly metrics.

Light Sleep: Stages N1 and N2

When you are snug and comfy in bed and close your eyes, you begin to drift into your first stage of sleep. This is appropriately named N1 and lasts only a few minutes. N1 is when the brain begins to disengage from the day and the environment; muscle twitches may occur, and we enter a deeper, more moderate light sleep called N2. The sleep scientists made this first part incredibly easy to remember. Thank you.

N2 is where the majority of light sleep occurs and where two highly specialized electrical events take place [12]:

1. Sleep spindles: brief bursts of neural oscillations

2. K-complexes: large bi-phasic waves that appear to serve a protective function, suppressing our attention so that deeper sleep can be maintained

Sleep spindles in particular are now understood to be critical for motor learning and procedural skill consolidation. Research has linked higher spindle density to better performance on tasks learned the previous day.

Light sleep is also the stage in which the brain transitions between deeper stages. Without adequate N2, sustained deep sleep and REM become harder to maintain. The National Sleep Foundation defines ideal sleep architecture as spending no more than 5% of the night in stage N1, and less than 81% in N2.

Deep sleep: Stage N3

This is our most physically restorative stage of sleep. The brain produces large delta waves in synchrony with one another, and our entire system shifts into repair and consolidation mode. The National Sleep Foundation defines ideal sleep architecture as spending 16–20% of sleep time in slow-wave sleep.

Deep sleep is front-loaded into the night. The first one to two sleep cycles contain the longest, deepest slow-wave sleep periods. By cycles four and five, the brain barely descends into deep sleep at all.

Several key processes converge across the deep sleep cycles:

Growth hormone release.

The majority of the day's growth hormone secretion occurs during deep sleep, not just for children, but throughout adult life. This hormone drives tissue repair, fat metabolic regulation, muscle recovery, bone density maintenance, immune function, and cellular regeneration. A chronic shortfall of deep sleep measurably reduces growth hormone output.

If you are cutting sleep short, drinking alcohol (which suppresses that first deep sleep block), or chronically getting fragmented sleep, you are systematically under-producing growth hormone night after night. Over the years, the cumulative effect on body composition, metabolic health, and tissue integrity is substantial.

Glymphatic clearance.

This is our brain’s dedicated waste-drainage network. Cerebrospinal fluid pulses through channels surrounding blood vessels, flushing out metabolic byproducts that accumulate during waking hours, including amyloid-beta and tau, both of which are associated with Alzheimer's disease [18].

A 2025 paper published in Cell identified the precise mechanism: norepinephrine levels oscillate in slow waves during NREM sleep, driving synchronized fluctuations in cerebral blood volume and CSF flow that power the clearance process [10].

A concurrent review confirmed that glymphatic insufficiency, caused by chronically poor deep sleep, is now implicated in the accumulation of neurotoxic proteins, including alpha-synuclein, relevant to Parkinson's disease [6].

Cardiovascular restoration.

Heart rate and blood pressure drop to their lowest levels of the day during deep sleep, giving the cardiovascular system a sustained period of reduced demand. This nightly dip is considered cardioprotective; people whose blood pressure fails to drop during sleep (a phenomenon called non-dipping) have significantly higher cardiovascular risk.

Memory consolidation.

Newly acquired facts and memories that you learned, experienced, or were told that day are replayed and transferred from the hippocampus to the neocortex for long-term storage. This process is why sleep deprivation so reliably impairs learning retention [16].

Immune system amplification.

Cytokines are molecules that coordinate the immune response, and their levels peak during deep sleep. This is one reason that sleep deprivation can impair vaccine response and immune function, and why febrile illness increases slow-wave sleep: the body is attempting to run its repair programs at higher intensity.

Because deep sleep stages lengthen as the night goes on, even a modestly shorter total sleep (losing the first or last 90 minutes) has very different consequences. Losing the beginning of sleep disproportionately costs deep sleep; losing the end costs REM.

REM sleep stage

The National Sleep Foundation defines ideal sleep architecture as spending 21-30% of the night in REM. This stage of sleep is neurologically extraordinary. The brain's metabolic rate and regional blood flow resemble those of the waking state, yet the body is functionally paralyzed, with voluntary muscles actively inhibited by the brainstem to prevent the physical enactment of dreams.

This is the time in dreams when we can’t seem to find our legs to sprint away from danger, or toward something we love. REM serves several functions that cannot be replicated by other stages:

Emotional memory processing.

The amygdala, our brain's primary emotional processing center, is highly active during REM, replaying emotional experiences in a neurochemical environment stripped of norepinephrine, the stress hormone. This is thought to allow the brain to re-encode emotional memories with reduced affective charge, essentially processing difficult experiences without retriggering the full stress response [3]. Chronic REM deprivation is associated with heightened emotional reactivity, worsened anxiety, and impaired trauma recovery.

Procedural memory and creativity.

Motor skill learning, pattern recognition, creative problem-solving, and insight (the ability to suddenly connect disparate pieces of information) all depend heavily on REM consolidation. The expression "sleep on it" is physiologically grounded: REM sleep reshuffles and integrates information in ways that waking cognition does not.

Emotional regulation for the coming day.

REM periods grow progressively longer across the night, with later cycles heavily REM-dominant, which is why the final one to two hours of sleep are disproportionately valuable for emotional regulation and cognitive function [16]. This is why people who regularly sleep six hours instead of eight often report heightened irritability, anxiety, and emotional dysregulation.

What a healthy sleep pattern versus a fragmented sleep pattern might look like on your hypnogram in the morning [21,22,23,24]:

How to use your hypnogram without spiraling into analysis paralysis

Waking up to a poor sleep score and spending the next day convinced the night was a disaster, or obsessing over a single low deep-sleep reading and trying to "fix" it the following night through earlier bedtimes, supplements, or behavioral changes, is straight up “sleep score anxiety,” and we do not like this for you.

The anxiety is understandable, but it fundamentally misreads what wearable data is good for. The most important principle, supported consistently across the research literature and clinical guidance, is this: trust the trend, not the night.

A 2025 benchmark analysis by Terra Research stated this plainly: the real value of a sleep tracker lies in recognizing patterns over time, rather than obsessing over single-night accuracy [18]. Clinical guidance on consumer sleep trackers similarly advises clinicians to emphasize behavioral trends and multiday averages rather than nightly readings [4].

Why does this matter so much? Night-to-night variability in sleep-stage data from wearables is substantial. Variability can be caused by both genuine biological variation and measurement imprecision. A single night in which your device shows low deep sleep may reflect a true deficit, an algorithmic misclassification, a body-position artifact, or simply normal night-to-night fluctuation.

You cannot know which.

However, a trend of consistently low deep sleep over two to three weeks is worth paying attention to.

What your wearable may be getting wrong

We want so badly for technology to be perfect so we can trust it. But alas, even our smartest smart ring has failure modes worth noting.

A March 2025 study in SLEEP Advances tested the Apple Watch Series 8 alongside five other wrist-worn devices against in-lab polysomnography (PSG) and found that while some devices showed clinically acceptable accuracy for certain parameters, all showed significant differences from the holy grail of sleep measurement, the PSG.

These differences included total sleep time, sleep efficiency, and wake after sleep onset [13].

Because a PSG measures brain waves, and our cute little smart ring captures data from an accelerometer and heart rate rather than brain waves, it infers sleep stages from physiological proxies and frequently misclassifies N3 as lighter sleep.

Deep sleep is the most mislabeled stage. According to Apple’s own validation data, when the Apple Watch predicts “Core Sleep,” the true PSG stage is actually deep sleep 38% of the time [2].

REM fares better because heart rate variability during REM is distinctive enough to be detected reasonably well without an EEG. N1 is nearly invisible to wearables, which is acceptable since it is brief and functionally minor.

There is also an epoch-resolution problem: PSG scores sleep in 30-second windows, while most wearables use 1–5-minute windows, smearing brief stage transitions into adjacent categories.

Metrics worth trusting

1. Averages and trends over time.

   Look at 7- and 30-day averages first. Most wearable apps display weekly and monthly summaries. These are the numbers to anchor on. A 30-day average deep sleep percentage below 10% or REM below 15% is more meaningful than any single night’s reading.

2. Hypnogram shapes, not just labels.

   The overall architecture of your sleep, whether you descend into deeper stages and return in recognizable cycles, is more reliably captured than the specific stage labels. A hypnogram showing chaotic, fragmented transitions every night is more concerning than one showing smooth cycling with occasional mislabeling, which smart rings are notorious for doing.

3. Identify your personal patterns.

   Does your sleep score reliably drop after alcohol? After a late dinner? After high-stress workdays? After exercise in the evening? Wearables are excellent at helping you detect your personal behavioral sensitivities and use them as a feedback tool for your own habits, not as a nightly report card.

4. Track wake after sleep onset (WASO).

   This metric shows how long you were awake after initially falling asleep and is among the most reliably measured by wearables. Consistently high WASO (greater than 30 minutes) across multiple nights warrants attention and possibly a conversation with a clinician.

5. Don’t chase the score.

   Optimizing behavior specifically to improve a wearable sleep score can be counterproductive, particularly if it leads to performance anxiety at bedtime. The behaviors that genuinely improve sleep (consistent sleep and wake times, limiting alcohol, managing evening light exposure, time-restricted eating, and addressing stress) will improve your average score over time. The nightly number is a byproduct, not the target.

6. Sleep and wake timing, every night.

   Consistent timing across seven days is one of the strongest behavioral predictors of sleep quality and circadian health, and it is also the metric wearables measure most accurately.

I also dropped these same metrics into a convenient one-pager you can download and share.

Subscribe now

The practical bottom line

Use your sleep data in the following order of trust:

1. Most reliable: Total sleep time, consistency of sleep and wake timing, and overall fragmentation patterns across weeks.

2. Directionally useful: Stage trends over time. If your REM or deep sleep consistently appears low across multiple weeks, it is worth exploring with a sleep specialist. Do not optimize nightly based on a single reading.

3. Treat with caution: Any single night’s stage breakdown. Architecture is more trustworthy than labels; trends across nights are far more trustworthy than any individual reading.

Happy sleeping, everyone.

Leave a comment

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

References

1. Alblewi, S. M., & Mirghani, H. (2025). Chronotype’s effect on academic achievement and absence from classrooms and clinical sessions among clinical phase medical students. Frontiers in Psychology, 16, 1664598. https://doi.org/10.3389/fpsyg.2025.1664598

2. Apple Inc. (2025). Estimating sleep stages from Apple Watch (White paper, updated October 2025). https://www.apple.com/health/pdf/Estimating_Sleep_Stages_from_Apple_Watch_Oct_2025.pdf

3. Bartsch, U., & Bhatt, D. L. (2023). Emotional memory processing during REM sleep with implications for post-traumatic stress disorder. Journal of Neuroscience, 43(3), 433–448. https://doi.org/10.1523/JNEUROSCI.0590-22.2022

4. CHEST Physician. (2025, October). Using consumer sleep trackers in clinical practice. CHEST Physician. https://www.chestphysician.org/consumer-sleep-trackers-in-clinical-practice/

5. Cho, Y. W., Lee, J. H., Han, S. Y., & Lee, M. Y. (2024). Validity and reliability of the Korean version of reduced Morningness-Eveningness Questionnaire: Results from a general population-based sample. Journal of Korean Medical Science, 39(28), e257. https://doi.org/10.3346/jkms.2024.39.e257

6. Corbali, O., & Levey, A. I. (2025). Glymphatic system in neurological disorders and implications for brain health. Frontiers in Neurology, 16, 1543725. https://doi.org/10.3389/fneur.2025.1543725

7. Hilditch, C. J., Dorrian, J., & Banks, S. (2025). The linkage between chronotype, social jetlag, and responses to sleep inertia. Scientific Reports, 15, 12858. https://doi.org/10.1038/s41598-025-93057-7

8. Horne, J. A., & Ostberg, O. (1976). A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. International Journal of Chronobiology, 4(2), 97–110.

9. Huang, X., et al. (2024). Misalignment between circadian preference and accelerometer-derived actual sleep-wake cycle is associated with increased risk of cardiometabolic diseases: A prospective cohort study in UK Biobank. medRxiv. https://doi.org/10.1101/2024.06.28.24309628

10. Kiviniemi, V., Nedergaard, M., et al. (2025). Norepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep. Cell, 188(1). https://doi.org/10.1016/j.cell.2024.11.027

11. Li, M., et al. (2025). Social jet lag and mental health outcomes: A systematic review and meta-analysis. Acta Psychologica. https://doi.org/10.1016/j.actpsy.2025.104954

12. Patel, A. K., Reddy, V., Shumway, K. R., & Araujo, J. F. (2024). Physiology, sleep stages. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK526132/

13. Schyvens, A.-M., Peters, B., Van Oost, N. C., Aerts, J.-M., Masci, F., Neven, A., Dirix, H., Wets, G., Ross, V., & Verbraecken, J. (2024). Accuracy of Fitbit Charge 4, Garmin Vivosmart 4, and WHOOP versus polysomnography: Systematic review. JMIR mHealth and uHealth, 12, e52192. https://doi.org/10.2196/52192

14. Schyvens, A.-M., Peters, B., Van Oost, N. C., Aerts, J.-M., Masci, F., Neven, A., Dirix, H., Wets, G., Ross, V., & Verbraecken, J. (2025). A performance validation of six commercial wrist-worn wearable sleep-tracking devices for sleep stage scoring compared to polysomnography. SLEEP Advances, 6(2), zpaf021. https://doi.org/10.1093/sleepadvances/zpaf021

15. Sladek, M., Klusacek, J., Hamplova, D., & Sumova, A. (2023). Population-representative study reveals cardiovascular and metabolic disease biomarkers associated with misaligned sleep schedules. Sleep, 46(5), zsad037. https://doi.org/10.1093/sleep/zsad037

16. Slowik, J. M., Collen, J. F., & Yow, A. G. (2023). Physiology of sleep. In StatPearls [Internet]. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK482512/

17. Stickgold, R. (2005). Sleep-dependent memory consolidation. Nature, 437(7063), 1272–1278. https://doi.org/10.1038/nature04286

18. Terra Research. (2025). Benchmarking wearable sleep data reliability. Terra Research. https://tryterra.co/research/sleep-tracking-accuracy

19. Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., O’Donnell, J., Christensen, D. J., Nicholson, C., Iliff, J. J., Takano, T., Deane, R., & Nedergaard, M. (2013). Sleep drives metabolite clearance from the adult brain. Science, 342(6156), 373–377. https://doi.org/10.1126/science.1241224

20. Zheng, N. S., Annis, J., Master, H., Han, L., Gleichauf, K., Ching, J. H., Nasser, M., Coleman, P., Desine, S., Ruderfer, D. M., Hernandez, J., Schneider, L. D., & Brittain, E. L. (2024). Sleep patterns and risk of chronic disease as measured by long-term monitoring with commercial wearable devices in the All of Us Research Program. Nature Medicine, 30(9), 2648–2656. https://doi.org/10.1038/s41591-024-03155-8

21. American Academy of Sleep Medicine. (2020). The AASM manual for the scoring of sleep and associated events: Rules, terminology and technical specifications (Version 2.6). American Academy of Sleep Medicine.

22. National Heart, Lung, and Blood Institute. (2024). Your guide to healthy sleep: The stages of sleep. National Institutes of Health. NHLBI Sleep Stages Overview

23. Sleep Foundation. (2024). Sleep stages: REM, NREM, and how they work. Sleep Foundation Sleep Architecture Review

24. Cleveland Clinic. (2023). Sleep cycles: Stages, how long they last, and why they matter. Cleveland Clinic Sleep Cycles Explanation

This generation seems dramatically more health-conscious than my Gen X counterparts ever were. Pretty sure we spent most of our early 20s standing in a field drinking canned beer, saying things like “I will sleep when I’m dead,” but I digress.

As someone working in circadian and lifestyle medicine, and more importantly, in my quest to become the coolest auntie, I wanted to map out the fastest ways to hack a sleep score beyond just going to bed earlier.

So here are the cheat codes for all the other cooler-than-me 20-somethings wearing smart rings and optimizing their REM sleep.

I even wrote a downloadable one-pager for you at the end. May the best sleeper win.

Let’s start with what data the ring is actually collecting

The sleep score pulls from five data streams: sleep stages (light, deep, REM), heart rate variability (HRV), blood oxygen saturation (SpO2), skin temperature, and something most people scroll past entirely: social jetlag, the difference in your sleep timing between weekdays and weekends [18,19].

A smartwatch or ring tracks your sleep using two main sensors: an accelerometer that detects movement and an optical heart rate sensor that measures heart rate and heart rate variability.

It then uses algorithms to infer which sleep stage you're likely in based on those movement and heart rate patterns, making an educated guess about your brain state from signals recorded at your wrist or finger.

Heart Rate Variability (HRV) is the beat-to-beat variation in your heart rate during sleep. High variability generally reflects a recovered, adaptable nervous system. Low variability means something kept it activated overnight: stress, alcohol, a late meal, schedule inconsistency. Your ring uses this as a proxy for actual recovery, not just time asleep.

Skin temperature is a newer feature in consumer wearables but physiologically important, as your core temperature needs to drop by around 3-5°F to initiate deep sleep. The ring tracks peripheral thermal changes, and an elevated overnight skin temp reading could mean something got in the way.

Social jetlag is where it gets interesting. RingConn now directly scores sleep rhythm regularity, flagging more than 1 hour of difference between your weekday and weekend sleep midpoints as disrupted biological timing [20].

By contrast, a polysomnogram, which you would have during a proper sleep study, directly measures brain electrical activity using scalp electrodes (EEG), along with eye movements, muscle tone, breathing, and oxygen levels. This gives a complete, unambiguous picture of exactly what your brain and body are doing at every moment of the night.

Some quick biology levers to pull

Deep Sleep

Deep sleep is your body’s overnight maintenance window during which tissue repair, growth hormone secretion, immune consolidation, and memory processing occur. It’s also the stage most sensitive to thermal interference, and three things reliably suppress it:

• evening alcohol

• late eating, and

• a warm room.

Alcohol is worth understanding specifically because it feels like a sleep aid.

A 2024 systematic review and meta-analysis confirmed that even low doses reduce REM sleep, with larger doses producing progressive disruption across sleep architecture. Alcohol is not an appropriate sleep strategy at any dose [5] because it works like this: alcohol’s sedative effect front-loads heavier sleep, but as it metabolizes into acetaldehyde mid-night, your nervous system rebounds.

HRV drops, skin temperature rises, REM in the second half of the night gets suppressed. The ring sees all of it. The sleep data is one chapter of a longer story and I’ve written the full metabolic case against alcohol in Why You Should Never Drink Alcohol.

Late eating disrupts the same thermal process through a different pathway.

Digestion raises core temperature through diet-induced thermogenesis, and a 2024 scoping review found that this thermal elevation can persist beyond your tummy emptying when the meal-to-bedtime window is short. The result is delayed sleep onset and suppression of that coveted deep sleep [2].

Beyond temperature, late eating raises blood glucose and activates daytime hormones, specifically insulin, cortisol, and digestive enzymes, at the exact moment your body is trying to switch into its night-mode hormonal program. Late eating biologically signals that the day is still ongoing.

Room temperature is the simplest lever most people never pull.

The target range is 60–67°F. Your body is actively trying to lose heat to reach deep sleep, and a warm room works against that physiology all night, not just at onset.

Heart rate variability and sleep regularity

A study of over 60k UK participants across the span of 8 years found that sleep regularity was a stronger predictor of all-cause mortality than sleep duration. Higher regularity in sleep-wake times was associated with up to 57% lower cardiometabolic mortality risk [17].

Your master clock, the suprachiasmatic nucleus, (SCN) in the hypothalamus coordinates with the outside environment using light (or lack of), and then tells your cells and organs (the peripheral clocks) the time to sync to. This happens through myriad ways, two important ways being hormones and the nervous system.

The SCN uses your wake time as a calibration signal because we are biologically positioned to awake, presumably, when the sun starts showing its face. A consistent wake time triggers a reliable cortisol peak, which synchronizes peripheral clocks throughout the body: liver, gut, immune cells, pancreas, lungs, etc. Keep shifting by two hours and eventually every downstream timing signal drifts away from the central timing mechanism.

The cortisol awakening response (CAR) is a surge in cortisol in the 30–45 minutes after waking, and a key marker in metabolic medicine [15]. A blunted or absent CAR reflects dysregulation and has been associated with obesity, insulin resistance, and type 2 diabetes. A consistent wake time is anchoring, and along with morning sunlight, signals the central clock precisely where it is in the 24-hour cycle. Overnight, your HRV responds accordingly.

Social jetlag

Let’s say during the week you’re up at 7am, but Saturday you sleep until 10. That three-hour shift actually moves your biological clock. By Sunday night your hormones and functions could be running two to three hours behind the clock on the wall and you end up lying awake.

A 2024 meta-analysis found that social jetlag was significantly associated with components of metabolic syndrome, specifically elevated fasting glucose and raised blood pressure [8]. Then in 2025, NHANES (the U.S. National Health and Nutrition Examination Survey) estimated that about 69% of adults carry at least one hour of social jetlag, with associations extending to obesity, type 2 diabetes, and cardiovascular disease [14].

Your ring is scoring this because the downstream metabolic consequences are real, and in a large portion of the population.

Screens at night aren’t the problem you think they are

Most people understand that screens before bed are disruptive. The reason, though, is deeper than we think.

We’ve long thought of melatonin as the sleep hormone. That framing is correct but also incomplete. Melatonin rises at night precisely when cells need protection from oxidative stress. It is made in two different areas of our body: the pineal gland and the mitochondria.

Pineal melatonin is released into circulation at night as a hormonal time signal (“it’s dark outside”), and mitochondrial melatonin is produced locally inside cells and functions more like a protective molecule.

When our internal rhythms are intact, antioxidant defenses rise when oxidative stress has risen. The body anticipates the oxidative stress from daytime activity and sends in missile defenses at night to fight the good fight. When the internal rhythms are disrupted, antioxidant defenses essentially die, but that daily reactive oxygen species continues to be made [9].

Even 10 lux of blue-spectrum light, well below the typical brightness of a phone screen in a dark room, can suppress melatonin by over 50%. A phone in a dark room from 10pm to midnight is removing a mitochondrial stabilizer during its peak activity window, every night.

Block melatonin with screen light and you remove that protection at exactly the wrong moment. This becomes much bigger than a sleep issue, venturing into an oxidative stress problem.

The biological signal your body needs to initiate melatonin production is not darkness. It is the drop in light intensity. Dim light melatonin onset (DLMO) is the clinical marker for when this begins, typically 2–3 hours before habitual sleep onset under normal light conditions [12].

Bright evening environments push DLMO later and sleep onset is shifted later. The ring captures the consequence in shortened REM and compressed early deep sleep.

Why this matters beyond the score

It’s a lot of fun to gamify sleep scores but here is what I actually care about for you: the biological system your ring is measuring your sleep against governs considerably more than recovery. We are now in circadian biology territory. I know, cool. Right?

In 2016 a group of scientists conducted a controlled study where participants were put into a very controlled lab environment. They were tested for their daytime-ness or nighttime-ness (whether they were a morning lark or a night owl + their DLMO we talked about earlier). Each participant was restricted to a specific activity window the either aligned or misaligned with their internal clocks.

Zero changes to their diet, how long they slept, or what exercise they did. For the misaligned group, within days of the study starting, their lab markers showed an increase in systolic blood pressure, increased inflammatory markers, and lowered glucose tolerance [10,11].

In October 2025, the American Heart Association published a scientific statement linking internal timing disruption to obesity, type 2 diabetes, hypertension, and cardiovascular disease, and named behavioral timing optimization as a disease prevention strategy [1].

That same year, a paper in Current Issues in Molecular Biology confirmed that irregular sleep-wake cycles and mistimed eating are now recognized as independent cardiovascular risk factors that accumulate years before anything surfaces in a standard lab panel [13].

The data on your finger at night is telling you something your blood work may not show for another decade, which is, to me, a tremendous opportunity to start locking in a great quality of longer life ahead. If you are interested in learning about your smart ring hypnogram and why restorative sleep is THE game changer, read my next article on Restorative Sleep Stages.

P.S. I built a free cheat sheet that details all the hacks you can implement to move your sleep score, and you can download that here:

Sleep Score Cheat Sheet

34.8KB ∙ PDF file

Download

Download

Leave a comment

Some additional reading if you want to nerd out further:

I wrote recently about why biological timing is likely to become one of medicine’s most consequential levers, in Why timing may become medicine’s next major frontier.

The sleep data your ring is generating nightly is exactly the early signal that makes that case. For the full mechanistic picture, read Circadian timing as a systems-level regulator of chronic disease; that is the paper I’ve spent the better part of this year building, and this article is its clinical summary.

The gut runs on its own biological clock and is acutely sensitive to the same timing disruptions affecting your sleep score. Gut health and chronic disease (Part I) gives a lot more detail on that connection if you want to follow the thread.

Subscribe now

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

References

1. American Heart Association. (2025). Role of circadian health in cardiometabolic health and disease risk: A scientific statement from the American Heart Association. Circulation. https://doi.org/10.1161/CIR.0000000000001388

2. Bagues, A., et al. (2024). Chrono-nutrition and sleep: Lessons from the temporal feature of eating patterns in human studies. A 2024 systematic scoping review. Sleep Medicine Reviews. https://doi.org/10.1016/j.smrv.2024.101951

3. Baranowska-Bosiacka, I., et al. (2025). Melatonin and lipid peroxidation: Antioxidant shield and therapeutic potential. Frontiers in Bioscience (Landmark Edition), 30(12). https://doi.org/10.31083/FBL45321

4. Gabriel, B. M., Altıntaş, A., Smith, J. A. B., Sardon-Puig, L., Zhang, X., Basse, A. L., Laker, R. C., Gao, H., Liu, Z., Dollet, L., Treebak, J. T., Zorzano, A., Huo, Z., Rydén, M., Lanner, J. T., Esser, K. A., Barrès, R., Pillon, N. J., Krook, A., & Zierath, J. R. (2021). Disrupted circadian oscillations in type 2 diabetes are linked to altered rhythmic mitochondrial metabolism in skeletal muscle. Science Advances, 7(43), eabi9654. https://doi.org/10.1126/sciadv.abi9654

5. Gardiner, C., Weakley, J., Burke, L. M., et al. (2024). The effect of alcohol on subsequent sleep in healthy adults: A systematic review and meta-analysis. Sleep Medicine Reviews. https://doi.org/10.1016/j.smrv.2024.101951

6. Lei, Y., Xu, Y., Huang, J., Huang, Y., Tu, Z., Xu, Y., & Liu, Y. (2024). The potential influence of melatonin on mitochondrial quality control: A review. Frontiers in Pharmacology, 14, 1332567. https://doi.org/10.3389/fphar.2023.1332567

7. Lempesis, I. G. (2025). Illuminating the metabolic effects of circadian misalignment. Nature Reviews Endocrinology, 21(3), 202. https://doi.org/10.1038/s41574-024-01085-6

8. Lin, M. Y., Kang, Y. N., Apriliyasari, R. W., & Tsai, P. S. (2024). Association between social jetlag and components of metabolic syndrome: A systematic review and meta-analysis. Journal of Nursing Research, 32(5), e354. https://doi.org/10.1097/jnr.0000000000000628

9. Mezhnina, V., Ebeigbe, O. P., Poe, A., & Kondratov, R. V. (2022). Circadian control of mitochondria in reactive oxygen species homeostasis. Antioxidants & Redox Signaling, 37(10–12), 647–663. https://doi.org/10.1089/ars.2021.0274

10. Morris, C. J., Purvis, T. E., Hu, K., & Scheer, F. A. J. L. (2016). Circadian misalignment increases cardiovascular disease risk factors in humans. Proceedings of the National Academy of Sciences, 113(10), E1402–E1411. https://doi.org/10.1073/pnas.1516953113

11. Morris, C. J., Purvis, T. E., Hu, K., & Scheer, F. A. J. L. (2017). Circadian misalignment increases C-reactive protein and blood pressure in chronic shift workers. Journal of Biological Rhythms, 32(2), 154–164. https://doi.org/10.1177/0748730417697537

12. Murray, J. M., Stone, J. E., Abbott, S. M., et al. (2025). A modified at-home methodology for measuring dim light melatonin onset timing in healthy adults. Chronobiology International, 42(5), 653–663. https://doi.org/10.1080/07420528.2025.2500404

13. Nuszkiewicz, J., Rzepka, W., Markiel, J., et al. (2025). Circadian rhythm disruptions and cardiovascular disease risk: The special role of melatonin. Current Issues in Molecular Biology, 47(8), 664. https://doi.org/10.3390/cimb47080664

14. Santos, P. M., et al. (2025). Social jetlag, sleep, and metabolic syndrome in adults: Insights of circadian misalignment from NHANES 2017–2020. Sleep Science and Practice. https://doi.org/10.1186/s41606-025-00158-3

15. Stalder, T., Oster, H., Abelson, J. L., Huthsteiner, K., Klucken, T., & Clow, A. (2025). The cortisol awakening response: Regulation and functional significance. Endocrine Reviews, 46(1), 43–59. https://doi.org/10.1210/endrev/bnae024

16. van Moorsel, D., Hansen, J., Havekes, B., Scheer, F. A. J. L., Jörgensen, J. A., Hoeks, J., Schrauwen-Hinderling, V. B., Duez, H., Lefebvre, P., Schaper, N. C., & Schrauwen, P. (2020). Human skeletal muscle exhibits a day–night rhythm in mitochondrial oxidative capacity. Proceedings of the National Academy of Sciences, 117(15), 8758–8764. https://doi.org/10.1073/pnas.1916823117

17. Windred, D. P., Burns, A. C., Lane, J. M., Saxena, R., Rutter, M. K., Cain, S. W., & Phillips, A. J. K. (2024). Sleep regularity is a stronger predictor of mortality risk than sleep duration: A prospective cohort study. Sleep, 47(1), zsad253. https://doi.org/10.1093/sleep/zsad253

18. RingConn. (2025a). Sleep pattern analysis: Smart ring sleep tracking. https://ringconn.com/pages/how-ringconn-helps-with-sleep-pattern

19. RingConn. (2025b). Your RingConn scores explained: Master your health. https://ringconn.com/blogs/news/guide-ringconn-health-scores

20. RingConn. (2025c). Unlock better sleep with RingConn Gen 2 smart ring. https://ringconn.com/blogs/news/unlock-better-sleep-with-ringconn-gen-2-smart-ring

In Part I, I introduced you to five scientists whose work is shaping the future of circadian medicine, from translating research into clinical trials to wearable tools and longevity interventions. What I hoped came through in that article was that this is a field that has been doing serious, layered, painstaking work for a very long time.

So when I say that circadian medicine is at an inflection point, I am not saying the science just arrived. I am saying that science has been arriving steadily for 40 years, and that what I witnessed at the 2026 SRBR conference was the field beginning to build the institutional architecture to match what biology has already shown.

What I watched unfold over five days was a field seriously considering a scenario that basic science alone cannot answer: How do we build this into clinical medicine?

Clinicians in attendance were direct about it: to bring circadian medicine into practice, they need overwhelming evidence. Randomized controlled trials. Indisputable proof. That is a high bar, but it is the right bar, and the encouraging news is that the evidence is increasingly clearing it.

What is also becoming clear is that the gap between the science and clinical adoption is no longer primarily a data problem. It is:

• an infrastructure problem

• a training problem

• a language problem

• a collaboration problem

And perhaps most of all, a silo problem. The same one that has kept too many good ideas trapped within the disciplines that generated them, never quite reaching the patients who need them.

The Evidence Is No Longer the Barrier

The common assumption that circadian medicine is still emerging, still preliminary, still “promising” is no longer accurate across the board.

Consider what Francis Levi, of the University of Paris-Saclay, presented at the conference. Across 38 retrospective studies and one randomized trial published between 2021 and 2026, involving more than 10,000 cancer patients over three continents and eleven cancer types, the timing of immunotherapy treatments consistently appeared to matter. Morning administration was associated with a risk ratio of 0.55 for earlier death, while the first randomized trial reported an even stronger effect at 0.42.

In practical terms, patients receiving immunotherapy earlier in the day experienced nearly half the risk of earlier mortality compared to those treated later. What is particularly notable is that this signal has now appeared across multiple cancer types and populations, suggesting timing may influence treatment response more than previously recognized. Eleven additional randomized trials are currently underway to determine whether these effects hold across broader clinical settings and cancer populations.

The slide Levi showed carried a subtitle that should stop any administrator or payer in their tracks: “Chronotherapy for Improving Survival at No Cost.” Not a new drug or device. No referrals or additional appointments. Just a different time on the infusion schedule.

I don’t believe evidence is the barrier. The barrier is the infrastructure of traditional medicine across clinical, institutional, educational, and financial tenets. The barrier is a medical system built around the ‘what’ of disease, not the ‘when’. And the barrier is a set of disciplinary silos that have grown independently, without whole-person health in mind.

The Infrastructure Is (Finally) Being Considered

At Amelia Island, the leaders of this field were not just presenting research. They were also doing institution-building.

The International Association of Circadian Health Clinics (IACHC) presented its mission and its founding working group to the assembled community. The founding roster spans virtually every major clinically oriented circadian researcher worldwide: Czeisler, Scheer, Klerman, Zee, Boivin, Rajaratnam, Kramer, and more than a dozen others. Their stated goals include:

1. Develop clinical guidelines

2. Establish screening tools

3. Educate health professionals

4. Influence funding priorities

Their first annual conference was held in 2025, and the committee is gearing up for round two, which will take place in Tokyo this November. The theme is titled “Advancing Clinical Practice: Integrating Circadian Medicine into Patient Care and Treatment.”

The local organizing committee includes leading Japanese chronobiologists and, notably, Masashi Yanagisawa, the discoverer of orexin (one of the brain’s “stay awake and stay engaged” signaling systems), whose entry into the circadian medicine conversation signals an important convergence between sleep science and circadian biology.

The roadmap panel at SRBR this year, chaired by Steven Shea, included notables like John Hogenesch, Phyllis Zee, Joe Bass, and Francis Levi, who laid out the specific problems that need solving:

• independent accreditation boards for each country

• training curricula that introduce circadian health earlier in medical education

• clinical practice models across behavioral, pharmacological, and occupational settings

• reimbursement and funding structures

• frameworks that account for how practice will vary across healthcare systems and cultures.

In Europe, the Circamed initiative has articulated a five-action framework — Align, Decode, Reveal, Empower, Inspire — covering everything from treatment timing in patients to biomarker development to regulatory infrastructure to public education.

This is serious, coordinated, international infrastructure work. It deserves to be recognized as such.

And yet there are real, unsolved problems that the field has been honest about. Actigraphy and dim-light melatonin onset testing are not easy to implement across diverse patient populations.

The self-administered biomarker that could tell a clinician or patient where someone’s biological clock sits right now, readable from saliva, blood, or urine, based on RNA expression, DNA methylation, or protein levels, doesn’t yet exist in clinically validated form.

The field doesn’t yet have a firm consensus on two foundational clinical questions: How much circadian misalignment is too much? And how much dampening of circadian amplitude becomes clinically significant? Without quantitative thresholds, clinical decision-making remains more art than protocol.

These are real gaps being addressed, but they won’t close on their own, and they won’t close quickly if circadian medicine remains a niche interest of a specialized research community rather than a recognized dimension of clinical practice.

The Partnership That’s Been Waiting Right There

Here is the argument I want to make, as someone who sat in those sessions and watched this field wrestle with how to get its knowledge into clinical practice:

The infrastructure you’re trying to build already exists in part. It’s called Lifestyle Medicine.

Lifestyle medicine has, over the past decade, done something remarkable: it has taken a set of evidence-based behavioral interventions (nutrition, physical activity, restorative sleep, stress management, substance avoidance, and social connection) and built a clinical discipline around them.

Board certification, fellowship training programs, clinical practice guidelines, international societies, and a growing base of clinicians in primary care, internal medicine, cardiology, and beyond who are already asking their patients about sleep, diet, and daily routine.

Restorative sleep is already one of the six pillars of lifestyle medicine. The field already frames sleep not as a symptom to be treated but as a primary health behavior to be optimized.

Chronotype assessment, meal timing guidance, light hygiene, and circadian-aligned scheduling are natural extensions of what lifestyle medicine practitioners are already doing, or already trying to do, without the mechanistic framework that circadian science provides.

There are lifestyle medicine clinics operating around the world that are already implementing circadian-adjacent practices without the formal circadian medicine vocabulary or infrastructure to support them. They are asking patients when they eat. They are talking about sleep regularity. They are counseling on evening light exposure.

This represents an extraordinary opportunity and perhaps a cautionary tale about what happens when fields don’t talk to each other.

Because the inverse is also true: lifestyle medicine, for all its strengths, often lacks the mechanistic depth that circadian biology provides. It knows that sleep timing matters. Circadian medicine knows why, and increasingly how much, and for whom, and by what biological pathway.

The partnership between these two fields could be genuinely synergistic, rare in medicine, in which one field provides the clinical infrastructure and patient relationships, and the other provides the biological specificity and measurement tools.

The patient who walks into a lifestyle medicine clinic with metabolic syndrome, poor sleep, and irregular eating patterns is already the patient that circadian medicine is designed to help.

The Myopia We Can’t Afford

This is the larger problem, and it extends well beyond the circadian medicine-lifestyle medicine interface.

We have built modern medicine into a collection of increasingly narrow specialties, each with its own journals, conferences, funding streams, training pipelines, and clinical fiefdoms. This structure has produced an extraordinary depth of knowledge across domains. It has also produced a healthcare system that is structurally incapable of seeing the whole person, which pays the price in outcomes, costs, and the frustration of patients who see six specialists and come away with six different answers that are not integrated.

The IACHC’s founding working group includes cardiologists, sleep physicians, neurologists, endocrinologists, psychiatrists, and public health researchers. The SRBR roadmap panel included not just chronobiologists but a practicing cardiologist. The clinical tracks at the 2026 SRBR covered cardiovascular medicine, neurology, psychiatry, oncology, pulmonology, endocrinology, and hypertension in a single day.

This cross-disciplinary reach is not accidental; it reflects an understanding that the clinical home for circadian medicine cannot be a single specialty, because the biology doesn’t respect specialty boundaries.

But understanding it doesn’t automatically produce the cross-disciplinary training, shared clinical protocols, integrated electronic health records, or joint funding mechanisms that would make whole-person circadian care possible in practice. Those require deliberate institutional choices that medicine has historically been slow to make.

The patients who stand to benefit most from circadian medicine are not, for the most part, people seeking boutique wellness services. They are shift workers, such as nurses, paramedics, factory workers, and long-haul drivers, whose circadian systems are chronically disrupted by the economy’s demand for 24-hour operations.

They are people with metabolic syndrome who eat within a twelve-hour window that starts at noon and ends at midnight, unaware that moving that window earlier and narrowing it could change their metabolic trajectory without changing a single calorie. They are cancer patients whose treatment timing is still being set by scheduling convenience rather than biological optimization. They are elderly patients whose circadian amplitude is declining, taking them steadily toward metabolic dysfunction, immune senescence, and cognitive decline, with no clinical system watching the clock on their behalf.

What “It’s About Time” Actually Means

The phrase keeps coming up in circadian medicine — it’s about time — as both pun and argument. It is about time in the literal sense: the biological dimension of rhythm organization that medicine must integrate. And it is about time in the colloquial sense: this has been delayed long enough.

The infrastructure is being built. The evidence, in key domains, is ready. The clinical partnerships with lifestyle medicine, with preventive medicine, with integrative health are there to be made.

What remains is will: the willingness of medical educators, clinical leaders, health systems, and payers to recognize that timing is not a curiosity or a fringe concern, but a fundamental parameter of human health that belongs in every clinical encounter.

Leave a comment

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

Subscribe now

A thread running through the work of leading scientists in circadian science helps explain why circadian medicine is generating so much momentum right now. It is that timing is a dimension of health that traditional medicine has largely ignored. When we eat, when we sleep, when we take a drug, when we exercise, and when we are exposed to light. These are not incidental variables, as the science is now showing.

What the 2026 SRBR meeting made clear to me is that the field is passing through an inflection point. Circadian science is now mature enough that the translational question is no longer whether timing matters, but rather how we measure it, how we intervene on it, and how we build systems that make it accessible in clinical care.

The leading scientists attending this year’s conference are bringing three complementary solutions to that challenge: population-level phase measurement, cardiovascular precision medicine, and behavioral interventions people can actually implement.

From our Nobel Laureate to the pioneer in longevity, here are the top researchers from SRBR you should know, what they’ve been talking about, and how they are leading the charge in circadian science.

1. Michael Rosbash. 2017 Nobel Laureate

Who He Is Michael Rosbash is a professor and Howard Hughes Medical Institute investigator at Brandeis University, and the 2017 Nobel Laureate in Physiology or Medicine, an honor shared with Jeffrey Hall and Michael Young, “for their discoveries of molecular mechanisms controlling the circadian rhythm.” Sitting in the same room with a person of such contribution was, for me, like being near the red carpet with one of your all-time favorite rock stars.

What He Built Rosbash’s contribution is foundational in the most literal sense: without his work, the field of circadian medicine as we know it wouldn’t exist. In 1984, his lab (alongside Hall) cloned the first clock gene, period. Then, in 1990, following the discovery by postdoctoral fellow Paul Hardin that the period protein oscillated in a 24-hour cycle, Rosbash and Hall proposed the Transcription-Translation Negative Feedback Loop (TTFL), the core conceptual model that explains how biological clocks keep time at the molecular level. This model, now confirmed across species from fungi to humans, explains how a set of proteins essentially “count” 24 hours by building up and breaking down in a self-sustaining loop. In 1998, his lab went on to discover the cycle gene, the clock gene, and the cryptochrome photoreceptor. Without his work, circadian anything would not be where it is today.

What He Discussed at SRBR 2026 Rosbash chaired and spoke in the Saturday session titled “What is Ready — or Almost Ready — for Prime Time, and What Is Not?” I thought this was a deliberately provocative framing, asking the field’s leadership to draw honest lines between what circadian science has proven and what remains aspirational. With so much commercial and clinical interest now flowing into chronobiology, the risk of overpromising is real, and a conversation I believe the field needs. That he was chosen to anchor this session is also telling. He also spoke Tuesday evening in “Where Should Circadian Biology Go Next? A Community Conversation,” And this was one of SRBR’s closing, open-floor dialogue about the field’s future direction.

Current Focus At 81, Rosbash remains a working scientist, not a figurehead, and I was struck by his willingness to publicly ask “what is not ready?” His active research at Brandeis explores RNA processing and transcriptional regulation in the context of circadian clocks.

2. Charles Czeisler. Defined How Light Controls the Human Clock

Who He Is Charles Czeisler is the Professor of Sleep Medicine at Harvard Medical School, Chief of the Division of Sleep and Circadian Disorders at Brigham and Women’s Hospital, and arguably the single most influential figure in translating circadian biology into human clinical practice. He has been researching this field for over 40 years.

What He Built Czeisler’s career is defined by a series of landmark human studies. He was among the first to rigorously characterize the intrinsic period of the human circadian clock (approximately 24.2 hours, not exactly 24) and the precise mechanisms by which light resets it. His lab demonstrated that the wavelength, duration, timing, and intensity of light independently affect circadian phase (work that later helped explain why blue-rich evening light from screens is so disruptive to sleep). He investigated how blind individuals without vision can still retain circadian responsiveness to light through melanopsin-containing retinal ganglion cells, a finding that reshaped understanding of non-visual photoreception in humans.

Beyond basic science, Czeisler has been the field’s most prominent voice on public health implications: he conducted influential studies on the consequences of physician sleep deprivation during residency, helped reform hospital work-hour policies, and has worked extensively on shift work, jet lag, and occupational safety. In 2023, together with Elizabeth Klerman, he organized a Harvard seminar on whether daylight saving time should be abolished (a policy question with genuine circadian biology underpinning it, and a very passionate topic at the SRBR this year). His lab’s most recent work includes circadian proteomics (mapping how the blood proteome oscillates over 24 hours) and the development of tools to estimate circadian phase from wearable data. This work is a critical step toward clinical deployment.

What He Discussed at SRBR 2026 Czeisler delivered a keynote on sleep and circadian rhythms in clinical practice. His speech set the proverbial stage for the conference’s opening day. He also participated in a panel discussion on what it would look like for circadian rhythms to be routinely assessed and treated as part of standard medical care.

Current Focus His lab is actively working on wearable-based circadian phase estimation using melanopic irradiance (spectral light data), work that could eventually let clinicians or patients alike, assess their internal clock state at home without expensive laboratory protocols. He is also continuing research on the effects of sleep restriction on glucose metabolism, cardiovascular risk, and immune function.

3. Frank Scheer. Bridging clock and clinic work

Who He Is Frank Scheer is a Professor of Medicine at Harvard Medical School and Director of the Medical Chronobiology Program at Brigham and Women’s Hospital. He is consistently among the most-cited researchers in human circadian physiology, with NIH funding that has run continuously since 2005 (which, I have learned, is an incredible feat in and of itself). I use so much of his studies in my own research, and getting to meet him was definitely a rock start moment for me.

What He Built Scheer’s lab occupies a really cool space between circadian science and chronic disease. His long-term research integrates our circadian system with cardiovascular, metabolic, and pulmonary regulation in living humans and documents how our internal clock governs daily fluctuations in blood pressure, heart rate, platelet aggregation, and vulnerability to cardiac events. The evidence provides biological explanations for the well-known morning peak in heart attacks and strokes. His work has also extended into chrono-nutrition: a landmark 2023 report he co-organized, published, and synthesized evidence on how the timing of meals affects cardiometabolic outcomes independent of what is eaten. Of note, one of the most thorough treatments of the topic to date was published by Sheer this year title “Unlocking the Potential of Circadian Biology for Cardiovascular Health”.

What He Discussed at SRBR 2026 Scheer delivered “The Distinguished SRBR Circadian Medicine Keynote” on Saturday. It was the highest-profile single lecture of Circadian Medicine Day. He also contributed to the Saturday working lunch roundtable discussions on cardiovascular therapeutics and circadian medicine.

Current Focus His team is actively investigating dinner timing and its interaction with genetic diabetes risk (a recent randomized crossover trial examined the MTNR1B type 2 diabetes risk variant and glucose tolerance), melatonin’s effects on insulin sensitivity in adipose tissue, and how natural daylight exposure shapes human metabolism. His group is also working on home-based dim-light melatonin onset (DLMO) assessment protocols, which would make it practical to measure circadian phase outside the laboratory.

4. Emily Manoogian. Leading research on time-restricted eating

Who She Is Emily Manoogian is the head of human research and staff scientist at the Salk Institute for Biological Studies in La Jolla, California, and is working in Satchidananda Panda’s lab. She has become one of the most important voices driving time-restricted eating (TRE) research from animal models into clinical human trials, with an emphasis on rigor and honest translation. Emily is not only the leader in TRE, but she is also one of the nicest and most approachable humans I have had the pleasure of conversing with.

What She Built Manoogian has been central to establishing TRE as a scientifically coherent intervention rather than a wellness trend. Her work has emphasized what makes TRE biologically distinct from generic caloric restriction: the consistency of the eating window and its alignment with circadian timing, rather than just the narrowing of the eating period itself. She has conducted and co-authored foundational clinical studies testing TRE in populations with metabolic syndrome, heart failure, and shift workers, including a 2024 UCSD study showing that a 10-hour TRE window improved cardiometabolic markers in patients with metabolic syndrome, independent of caloric reduction. She co-authored the comprehensive 2022 Endocrine Reviews paper “Time-Restricted Eating for the Prevention and Management of Metabolic Diseases,” which became a key reference for both researchers and clinicians. She has also led research on the practicalities of when to eat, advocating for earlier eating windows that align more closely with the body’s natural circadian phase.

What She Discussed at SRBR 2026 Manoogian had an unusually prominent role across multiple sessions. She delivered a talk on time-based medicine that discussed the possibility of bringing circadian timing into clinical practice and trials at Saturday’s Plenary Keynote. She co-chaired the DISRUPT study panel on Monday, the first formal presentation of results from a major clinical trial testing TRE in real-world patient populations. She also spoke on circadian-aligned nutrition and metabolic health. The DISRUPT study results session is particularly significant: it moves TRE from promising pilot data into the realm of properly powered, randomized clinical evidence which, in my person opinion, is precisely what the field needs to develop future clinical guidelines.

Current Focus Beyond DISRUPT, Manoogian is actively co-investigating TRE in bipolar disorder (examining circadian mechanisms in psychiatric conditions), and is involved in a multi-arm RCT comparing caloric restriction with and without TRE in adults at risk for type 2 diabetes. Her emphasis on studying diverse populations, including shift workers and underrepresented groups, is an important corrective to a field that has historically skewed toward healthy, affluent samples.

5. Joseph Takahashi. Longevity, and a pioneer of the clock gene

Who He Is Joseph Takahashi is the Chair in Neuroscience, Investigator Emeritus at the Howard Hughes Medical Institute, and Chair of Neuroscience at UT Southwestern Medical Center. He is one of the foundational molecular geneticists of the entire circadian field.

What He Built Takahashi’s landmark contribution was the discovery of the mammalian Clock gene in 1994. This was the first gene controlling circadian rhythms in mice and humans, and it was successfully cloned in 1997. He pioneered the use of forward genetics in the mouse, meaning he could identify clock mutants by behavior first, then work backward to find the responsible gene, a powerful discovery engine that yielded not just Clock but numerous downstream findings. His lab has demonstrated that circadian clock genes interact with virtually every major cellular pathway: metabolism, immune function, cardiovascular regulation, cell growth, cancer susceptibility, and the “hallmarks of aging.” More recently, his lab has shown that the circadian alignment of feeding under caloric restriction is a major factor in lifespan extension in mice. This finding directly links meal timing to longevity biology, elevating TRE from a metabolic intervention to a potential aging intervention.

What He Discussed at SRBR 2026 Takahashi spoke Tuesday evening in the “Where Should Circadian Biology Go Next? A Community Conversation” panel — SRBR’s open dialogue with its most senior figures. He also participated in Monday’s lunch table discussion on clocks in health span and longevity, a topic that represents his lab’s current frontier. As one of the architects of the molecular clock, his perspective on where the field should direct its energy carries unusual weight.

Current Focus: Takahashi’s lab is now explicitly targeting aging, because circadian transcriptional activity declines with age, they are testing interventions that rescue circadian amplitude, essentially strengthening the clock as it weakens with aging, as a strategy to promote health span and life span. This includes developing small-molecule drugs that could enhance clock function. His group continues to investigate how caloric restriction, feeding timing, and clock gene activity interact across the lifespan. The ambition in the field is substantial: drugs that strengthen the biological clock as we age.

One of the things that struck me most at SRBR is how specific the science is. Not specific in a dry, inaccessible way, but specific in the way that makes you realize how much invisible infrastructure goes into what eventually becomes a clinical recommendation or a drug.

The scientists I’ve highlighted in this piece are standing on an enormous body of work from dozens of institutions, hundreds of researchers, and thousands of experiments that will never make headlines. That is how research and discovery works: in layers.

Take cancer. Multiple labs are now asking not just whether the circadian clock interacts with tumor biology, but exactly how, and the answers are getting super granular.

Researchers at Scripps are mapping how circadian disruption remodels the immune environment inside lung tumors through a protein called HSF1. Texas A&M is showing that the timing of exercise changes its anti-tumor effects in breast cancer, with a single clock protein (PER1) appearing to mediate the difference.

And separate work is revealing that circadian rhythm disruption reshapes the tumor metabolome and microbiome, suppressing the immune system’s ability to fight back. None of this is a clinical guideline yet. But all of it is building the case, piece by piece.

Takahashi’s lab is targeting clock amplitude as a longevity strategy. The idea that, as we age, our clocks weaken and that strengthening them might slow downstream consequences, and researchers at Texas A&M are already screening drug compounds in a bread mold to find molecules that restore circadian amplitude in aged cells.

They found 187. Five are validated. Some extend lifespan. This is how a drug begins: not in a human, not even in a mouse, but in a fungus on a petri dish, in a lab most people will never hear of.

So here’s a spoiler alert on what everyone was talking about across the conference: where is all of this going? Science is now moving fast, so how do we get it built into the real world? You can read my thoughts on the topic in Part II.

I’m curious, for those of you in practice, where do you feel the gap between circadian research and clinical application? The clinicians in attendance were very clear in their messaging that, to get this into their clinics, there must be overwhelming evidence and indisputable proof. Do you agree?

I’d love to hear what it looks like from where you’re standing.

Leave a comment

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

Subscribe now

I have arrived solo and left with lifelong friendships, feeling profoundly changed by the social connection and the wellness reset. The final morning of a retreat feels different from the way it did on day one.

People are softer somehow. We are sleeping again. Laughing more easily. Sitting through breakfast without reaching for our phones. I may have arrived exhausted, but leave with color back in my face. The sentiment is shared across the group: people saying they cannot remember the last time they felt this calm, grounded, or happy in their body.

And for a brief moment, it feels undeniable: something real happened here.

And the truth is, something did.

Wellness retreats create measurable biological change. Stress hormones shift. Sleep deepens. Nervous systems begin to regulate. Inflammation markers improve. Within just a few days, the body often begins doing what it was designed to do when given the right conditions.

And then we go home.

Back to overhead lighting at midnight.
Airport food.
Slack notifications.
Irregular schedules.
Stress physiology disguised as productivity.

I have experienced this myself. After years of attending retreats and speaking with countless others who have as well, I have come to believe there is a major gap in the wellness retreat space that almost no one is talking about.

Most retreats are exceptional at creating a transformative experience.
Very few help guests understand how to sustain it once they return home.

There is often little education around why guests suddenly slept better, felt calmer, or experienced such dramatic shifts in mood and energy. Few retreats offer practical frameworks that guests can realistically integrate into daily life. There is rarely meaningful follow-up, structured check-ins, or guidance for navigating the return to environments that disrupted their physiology in the first place.

So people leave with a powerful feeling, but no real map for recreating the conditions that produced it.

And that matters, because people are far more likely to sustain a behavior when they understand why it changed how they felt in the first place.

That is where evidence-based education becomes powerful. Not as a lecture layered onto a retreat experience, but as a way of helping guests understand the physiology behind the transformation they are already living through.

What retreats actually do to the body

The therapeutic power of an immersive wellness retreat is not vague or placebo-driven. It is mechanistic and increasingly well documented.

A 2024 systematic review published in Cureus found that residential meditation and wellness retreats consistently reduce cortisol levels, with reductions correlating directly with decreases in anxiety and perceived stress: physiological resilience, not simply subjective well-being. The same review noted that, unlike vacations, whose positive effects diminish within a few weeks, structured retreat experiences can produce more durable benefits when intensive, purposeful practice is embedded throughout the program.

A landmark observational study published in the Journal of Alternative and Complementary Medicine measured outcomes across multiple dimensions of health in guests attending a week-long residential retreat: cognitive function, sleep, mood, stress, and inflammatory markers.

Subscribe now

Substantial improvements were observed at both departure and the six-week follow-up. Critically, the researchers noted that the retreat was specifically structured around establishing a consistent circadian routine and sleep pattern, identifying this as a core mechanism of benefit.

The systematic review by Naidoo, Schembri, and Cohen, published in BMC Complementary Medicine and Therapies, synthesized 23 retreat studies covering 2,592 participants across a range of health conditions and demographic profiles. Every study reported post-retreat health benefits.

But the authors also identified a consistent gap in the literature: most studies had little follow-up data beyond the immediate post-retreat period, and none examined the economic or long-term population health outcomes. The retreat industry produces real results. The question of how long those results last, and why, remains underexplored.

The honest answer to that question is: it depends almost entirely on whether guests leave with a framework for understanding what happened to their biology, and how to recreate the conditions that produced it.

The circadian mechanism most retreats don’t name

The physiological reset that guests experience during a well-designed retreat is not accidental. It is, at its core, a circadian event.

The human body runs on an approximately 24-hour internal timing system (our circadian clock) that coordinates virtually every aspect of physiology: hormone secretion, immune function, metabolism, gut motility, cellular repair, and sleep architecture. In daily life, this system is chronically disrupted. Artificial light at night suppresses melatonin and delays circadian phase. Irregular meal timing confuses the peripheral clocks in the liver, gut, and pancreas. Psychological stress elevates cortisol at times when the system expects it to be low, signaling threat when there is none.

A 2023 paper published in the International Journal of Molecular Sciences by Meléndez-Fernández, Liu, and Nelson documented how disrupted light exposure and mistimed food intake alter hormonal rhythms and metabolic function. These are not marginal effects. Circadian misalignment directly dysregulates insulin sensitivity, inflammatory tone, and the cortisol awakening response — the same biological markers that improve so dramatically during a retreat.

And this is why the retreat environment is so powerful. When guests arrive, the external conditions that were disrupting their biology are removed almost entirely. Light exposure becomes natural and timed. Meals are consistent and appropriately spaced. There are no alerts pulling the nervous system into vigilance at midnight. Movement is built into the rhythm of the day. Sleep aligns with darkness. Within 48 to 72 hours, the circadian system begins to re-entrain.

But re-entrainment requires the right environmental conditions to persist. A 2024 paper in Frontiers in Physiology by Tassino and Silva examined how urban environments, with their unreliable light cues, social jetlag, and behavioral irregularity, make it consistently difficult for the biological clock to maintain performance. Guests return from retreat into the same environment that disrupted them in the first place. The biology reverts, not because the retreat failed, but because the environment reasserts itself, and the guest has no map for navigating it.

Why understanding changes the outcome

The research on health literacy and chronic disease self-management is unambiguous on this point: knowing why a behavior matters is what determines whether it persists.

A 2025 systematic review published in Annals of Behavioral Medicine, covering studies from 2014 to 2024 across PubMed, Scopus, and Web of Science, found that health literacy interventions improved disease knowledge, medication adherence, and self-efficacy in individuals with chronic conditions.

The authors concluded that developing critical health literacy ability is a more effective driver of self-management than self-confidence or social support alone. Understanding the mechanism is what allows people to make informed decisions when circumstances change, when they are tired, when travel disrupts sleep, and when the office demands override the morning routine.

A 2023 paper in BMC Health Services Research by Dinh and Bonner, examining adults managing multiple chronic conditions, identified the ability to appraise health information — to understand and act on what the body is communicating — as the factor most strongly associated with sustained self-management behaviors. Not motivation. Not willpower. Biological literacy.

A guest who understands that the afternoon slump they felt on day three of your retreat was their cortisol beginning to normalize — not fatigue — will interpret that signal differently at home. A guest who understands that the quality of their sleep on night four was directly related to two consecutive mornings of natural light exposure will know what to do the following winter when the jet lag lands differently. A guest who understands why consistent meal timing matters can replicate the input even when the environment no longer supports it.

Without that understanding, guests take home a feeling. With it, they take home a framework.

The gap this creates for retreat leaders

There is growing, legitimate pressure on wellness retreats to demonstrate durable value. Guests are asking more sophisticated questions. The longevity and preventive health conversation has moved from biohacker circles into mainstream culture, and with it, the expectation that a premium wellness investment should produce outcomes that outlast the experience itself.

The retreats currently leading in this space are moving toward what has been described as a “realignment-first” model, pairing immersive experience with targeted education that helps guests understand and maintain the physiological changes the retreat produces.

The distinction is meaningful: a guest who leaves knowing that their sleep architecture improved because their cortisol awakening response normalized is fundamentally better equipped to protect that improvement than one who knows only that they slept better at your retreat than anywhere else.

This is not an argument for turning wellness programming into a lecture series. The experiential quality of a retreat is irreplaceable and primary. But layering structured, evidence-based education into the retreat experience, education that explains the biology behind what guests are living through, closes the gap between how they feel at departure and how they’re functioning six weeks later.

The science of what retreats do is already compelling. What the field has not yet done consistently is teach guests how to read it.

What this looks like in practice

The retreat days that produce the deepest physiological reset are not necessarily the ones with the most demanding itinerary. They are typically those in which multiple circadian inputs align simultaneously: consistent wake time with morning light, meals timed to support metabolic function, movement early in the day, reduction in artificial light and evening stimulation, and sleep that begins close to physiological darkness.

Guests experience these inputs as a beautifully designed retreat schedule. They experience outcomes such as deeper sleep, reduced inflammation, clearer cognition, and lower stress reactivity as the retreat works. What most guests do not receive is a coherent explanation of why those inputs produced those outcomes, and therefore what to prioritize when they return to a world that will systematically undermine every one of them.

Building education into the retreat — not as supplementary content but as a thread woven through the experience — addresses this directly. When a guest learns on day two that the morning light protocol is not aesthetic but biological, and that 20 minutes of outdoor light before 9 am anchors the cortisol awakening response and sets every downstream hormone rhythm for the day, they will find a way to replicate it in January in London.

When a guest understands that the post-lunch rest is not indulgence but active metabolic recovery aligned with a natural circadian dip in core body temperature, they return home with permission to protect that window, not guilt about needing it.

The most durable transformation a retreat can offer is not a physiological reset (though that is real and valuable). It is a guest who leaves understanding their own biology well enough to continue building on what the retreat started.

What’s the question this raises for you? I’ll do my best to address it in a future article.

Leave a comment

If you run a wellness retreat and are exploring what structured, evidence-based education could look like within your program, I have put together a sample curriculum that shows how I work with retreat partners. Access the link below.

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

References

Cabezas, M-F., Nazar, G., Ranchor, A. V., & Annema, C. (2025). The effect of health literacy interventions on self-management in chronic diseases: A systematic review. Annals of Behavioral Medicine. https://doi.org/10.1093/abm/kaaf073

Cohen, M. M., Elliott, F., Oates, L., Schembri, A., & Lovato, N. (2017). Do wellness tourists get well? An observational study of multiple dimensions of health and well-being after a week-long retreat. Journal of Alternative and Complementary Medicine, 23(4), 252–257. https://pmc.ncbi.nlm.nih.gov/articles/PMC5312624/

Dinh, T. T. H., & Bonner, A. (2023). Exploring the relationships between health literacy, social support, self-efficacy and self-management in adults with multiple chronic diseases. BMC Health Services Research, 23, 932. https://doi.org/10.1186/s12913-023-09907-5

Giridharan, S. (2024). Residential meditation retreats: A promise of sustainable well-being? Cureus, 16(11), e73326. https://doi.org/10.7759/cureus.73326

Meléndez-Fernández, O. H., Liu, J. A., & Nelson, R. J. (2023). Circadian rhythms disrupted by light at night and mistimed food intake alter hormonal rhythms and metabolism. International Journal of Molecular Sciences, 24(3), 3392. https://doi.org/10.3390/ijms24043392

Naidoo, D., Schembri, A., & Cohen, M. (2018). The health impact of residential retreats: A systematic review. BMC Complementary Medicine and Therapies, 18(1), 8. https://doi.org/10.1186/s12906-017-2078-4

Tassino, B., & Silva, A. (2024). Environmental, social, and behavioral challenges of the human circadian clock in real-life conditions. Frontiers in Physiology, 15, 1347377. https://doi.org/10.3389/fphys.2024.1347377

Medications are selected based on mechanism, dose, and indication. Adjustments are made for comorbidities, organ function, and increasingly, genetics. But in most clinical settings, there is an implicit assumption that once a drug is prescribed, its behavior is largely consistent regardless of when it is administered.

Chronopharmacology challenges that assumption.

It is a branch of pharmacology that examines how the timing of drug administration influences both efficacy and safety. Across the literature, there is consistent evidence that the effectiveness and toxicity of medications can vary significantly depending on when they are given, making timing a relevant, though often underutilized, variable in treatment planning (Kaskal et al., 2025).

This is not a new concept, but it has not been fully integrated into routing practice.

Circadian timing as a physiological framework

Circadian rhythm refers to endogenous, approximately 24-hour cycles that regulate physiological processes across multiple systems, including cardiovascular, metabolic, endocrine, and immune function (Satyam et al., 2026).

At the molecular level, these rhythms are generated by transcription-translation feedback loops involving core clock genes: Circadian Locomotor Output Cycles Kaput (CLOCK), Brain and Muscle ARNT-Like 1 (BMAL-1), Period (PER), and Cryptochrome (CRY). These molecular oscillators coordinate gene expression across tissues such as the liver, pancreas, and vasculature, influencing processes like glucose metabolism, lipid synthesis, and inflammatory signaling (Satyam et al., 2026).

From a clinical perspective, this means that the systems being targeted pharmacologically are not static. They change predictably across the day, and these changes can influence how a medication is absorbed, distributed, metabolized, and how it ultimately exerts its effect.

Chronopharmacology is typically divided into two domains. Chronopharmacokinetics describes time-dependent variation in drug absorption, distribution, metabolism, and excretion. Chronopharmacodynamics refers to changes in drug effect at receptor and downstream signaling pathway levels that depend on the timing of administration (Kaskal et al., 2025).

Taken together, these concepts suggest that the same medication at the same dose may not produce the same outcomes throughout the day.

Mechanisms underlying time-dependent drug response

When the literature is considered collectively, several mechanisms explain why timing alters drug response.

First, pharmacokinetic processes vary across the circadian cycle. Gastrointestinal motility, gastric pH, visceral blood flow, and intestinal transporter expression all fluctuate across the day, influencing drug absorption and bioavailability. Hepatic metabolism is similarly time-dependent, with circadian variation in the expression and activity of cytochrome P450 enzymes such as CYP3A4 and CYP2D6. Renal excretion also varies, with glomerular filtration rate and renal blood flow generally higher during the daytime (Kaskal et al., 2025).

Recent mechanistic work adds another layer to this. BMAL1, a core circadian clock regulator, has been shown to directly control transcription of CYP3A13, a key enzyme involved in intestinal first-pass metabolism. This creates circadian variation in how drugs are metabolized before they even reach systemic circulation, meaning that timing can influence drug exposure at the earliest stage of pharmacokinetics (Wang et al., 2026).

Second, pharmacodynamic responses are influenced by circadian variation in receptor density and sensitivity. Beta-adrenergic receptors, for example, demonstrate higher activity during periods of increased sympathetic tone, while histamine receptor activity is elevated at night. These variations contribute to time-dependent differences in drug efficacy and symptom expression (Kaskal et al., 2025).

Third, and perhaps most clinically relevant, entire physiological systems operate according to circadian rhythms. Blood pressure exhibits a nocturnal dip and morning surge. Hepatic glucose production increases in the early morning. Cholesterol synthesis peaks at night. Insulin sensitivity varies across the active phase (Satyam et al., 2026).

These patterns reflect coordinated regulation across systems, creating windows of time during which physiological processes are more or less active. When pharmacologic interventions are not aligned with these windows, variation in response should be expected.

Clinical applications of chronotherapy

Chronotherapy refers to adjusting medication timing to align with circadian rhythms. While not uniformly applied across all areas of medicine, there are several established and emerging examples.

In hypertension, circadian variation in blood pressure has led to the investigation of bedtime dosing of antihypertensive medications. Some studies have shown improved nocturnal blood pressure control and restoration of normal dipping patterns with evening administration. At the same time, large-scale trials such as the TIME study have not demonstrated consistent differences in cardiovascular outcomes between morning and evening dosing across broader populations, suggesting that the timing benefit is context-dependent (Satyam et al., 2026).

In lipid metabolism, the circadian regulation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase activity has more directly informed clinical practice. Cholesterol synthesis peaks at night, and as a result, short-acting statins are often recommended for evening administration to coincide with this peak (Kaskal et al., 2025; Satyam et al., 2026).

In glucose regulation, hepatic gluconeogenesis is the highest in the early morning due to circadian regulation of key enzymes, including phosphoenolpyruvate carboxykinase and glucose-6-phosphatase. Aligning metformin administration with this physiological pattern has been proposed as a strategy to improve fasting glucose control (Satyam et al., 2026).

Circadian variation is also evident in gastrointestinal physiology. Histamine-2 receptor antagonists are commonly administered at night to counteract nocturnal gastric acid secretion, which peaks at that time (Kaskal et al., 2025).

Chronotherapy has already been incorporated into select areas of clinical medicine, particularly in sleep medicine and neuroendocrine regulation, where drug timing is aligned with circadian phase to improve therapeutic outcomes (Cardinali et al., 2021). What remains less developed is the broader application of this principle across routine prescribing.

Importantly, chronopharmacology also applies to drug safety. Variations in drug metabolism and clearance can influence toxicity profiles. For example, aminoglycoside antibiotics have been associated with reduced nephrotoxicity when administered in the morning, likely due to circadian variation in renal function (Kaskal et al., 2025).

Implication for clinical practice

Despite this evidence, timing remains a relatively underdeveloped dimension of prescribing.

In most cases, medications are prescribed with general timing instructions that prioritize simplicity and adherence over physiological alignment. While this approach is practical, it may overlook a variable that meaningfully influences treatment outcomes.

Chronopharmacology does not suggest that all medications require precise timing adjustments. However, it does indicate that timing is not neutral. It interacts with pharmacokinetics, pharmacodynamics, and underlying physiological rhythms, thereby influencing both efficacy and tolerability.

From a systems perspective, this aligns with a broader understanding of physiology as temporally organized. In my own work examining circadian regulation across metabolic, mitochondrial, and inflammatory systems, the consistent finding is not simply dysfunction within individual pathways, but disruption in the coordination of processes across time.

Pharmacologic interventions are operating within that system. Whether or not timing is explicitly considered, it is influencing how those interventions perform.

Future direction in chronopharmacology

The next phase of this field is likely to move toward more individualized approaches.

Emerging strategies include the use of circadian biomarkers, wearable technology, and computational models to better assess circadian phase and optimize medication timing accordingly (Satyam et al., 2026).

At present, these tools are not widely implemented in routine clinical practice. However, the underlying principle, that biological timing influences treatment response, is already well supported.

An open clinical question

If the systems being targeted are regulated over time and pharmacologic response varies accordingly, then timing becomes part of the intervention itself.

Not in a universal or prescriptive way, but as an additional layer of consideration.

So I am curious: how, if at all, are you currently thinking about timing in your prescribing? Is it something that you have been considering but have not operationalized?

Leave a comment

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

References

Cardinali, D. P., Brown, G. M., & Pandi-Perumal, S. R. (2021).
Chronotherapy. In Handbook of Clinical Neurology (Vol. 179, pp. 357–370). Elsevier. https://doi.org/10.1016/B978-0-12-819975-6.00023-6

Kaşkal, M., Sevim, M., Ülker, G., Keleş, C., & Bebitoğlu, B. T. (2025). The clinical impact of chronopharmacology on current medicine. Naunyn-Schmiedeberg’s archives of pharmacology, 398(6), 6179–6191. https://doi.org/10.1007/s00210-025-03788-7

Satyam, S. M., Prabhakar, S., El-Tanani, M., Bhongade, B., Wali, A. F., Rangraze, I. R., Matalka, I. I. A., El-Tanani, Y., Rizzo, M., Ispas, S., Ilias, I., Paczkowska, A., Maggio, V., & Hoffmann, K. (2026). Chronopharmacology-Driven Precision Therapies for Time-Optimized Cardiometabolic Disease Management. Biology, 15(3), 241. https://doi.org/10.3390/biology15030241

Wang, H., Xu, J., Xu, H., Lin, L., Huang, Y., Wu, B., Lu, D., Guo, L., & Dong, D. (2026). BMAL1-mediated transcriptional regulation of CYP3A13 drives circadian rhythms in intestinal first-pass metabolism. Biochemical pharmacology, 250(Pt 1), 117981. Advance online publication. https://doi.org/10.1016/j.bcp

«insert equal parts surprise, delight, and fear here»

I am also preparing my paper for publication, so stay tuned for more, but I wanted to share some key insights from this project.

Over the past 2 years, I have studied pathophysiology and chronic disease, and one pattern became increasingly difficult for me to put out of my head: chronic diseases are labeled and treated as separate conditions, but many of their upstream drivers look remarkably similar.

Metabolic dysfunction, mitochondrial impairment, inflammatory signaling, stress physiology, and behavioral disruption appear again and again across cardiometabolic, autoimmune, neurodegenerative, and other chronic conditions.

That realization led me to a larger question: Is there a missing piece upstream of the metabolic syndrome and inflammation? So I dove into some very recent research by Liu et al. (2026) discussing the role of circadian clocks and gene expression.

As all good research does, this paper led me down 852 rabbit holes and hundreds of chronobiology and lifestyle medicine studies. What emerged across the literature was that circadian disruption alters metabolic regulation, impairs cellular energy dynamics, disrupts redox balance, and promotes sustained inflammatory signaling.

These changes appear across multiple chronic disease contexts, suggesting that what we often treat as separate dysfunctions may also reflect a broader systems-level loss of temporal (daily rhythmic) organization.

These correlations may also help explain why lifestyle and prescriptive interventions do not always deliver uniform results. If physiology is organized in time, then applying lifestyle changes such as nutrition, exercise, stress regulation, and supplementation without considering their timing may limit their effectiveness. In other words, when we eat, when we get our sunlight, and when we exercise, are just as important to chronic disease prevention and treatment as what we eat and do.

So, the circadian rhythm then moves beyond a simple sleep concept into a biological timing system that regulates how physiology unfolds over a 24-hour period. At the cellular level, circadian rhythms help coordinate gene expression, mitochondrial function, immune activity, and metabolic signaling through tightly regulated oscillatory patterns. When that timing system is disrupted, those processes begin to lose coordination.

This work is the beginning of a deeper line of inquiry I will continue to develop in both writing and practice. I will be sharing much more on the topic in the coming months as I refine how these concepts translate into real-world applications.

In May, I will attend the Society for Research on Biological Rhythms (SRBR), where I will spend time alongside researchers and PhDs in chronobiology to further ground this work in the current scientific landscape.

At the same time, I will continue working with clients and collaborating with clinics, applying a lifestyle medicine framework to educate on root causes, support health restoration, and complement medication optimization.

The goal is to keep bridging the gap between emerging science and practical implementation so these ideas don’t stay theoretical, but become usable in how we understand, assess, and address chronic disease.

Paper abstract for those interested

Chronic diseases are typically interpreted as dysfunction within isolated biological pathways; however, mitochondrial instability, redox imbalance, and persistent low-grade inflammation recur across clinically distinct conditions, suggesting disruption of a shared regulatory system.

This review examines whether circadian disruption functions as an upstream constraint by altering the temporal organization that coordinates metabolic, mitochondrial, and immune processes.

A structured literature review was conducted across PubMed, Wiley Online Library, Cochrane Library, MDPI, Google Scholar, and ScienceDirect, integrating mechanistic, experimental, and human studies.

Studies were selected based on relevance to circadian influences on mitochondrial function, redox biology, inflammatory signaling, and chrono-epigenetic regulation, and were collated using a convergence-based analytical framework spanning circadian architecture, chromatin regulation, bioenergetics, and immune activation.

Across mechanistic, experimental, and human evidence, circadian disruption is associated with shifts in phase alignment, reduced rhythmic amplitude, and loss of physiological synchronization rather than complete loss of function.

Molecular studies demonstrate that clock genes control transcriptional programs, mitochondrial metabolism, and inflammatory signaling, while human models of circadian misalignment show independent effects on glucose regulation, blood pressure, and inflammatory biomarkers.

In contrast, behavioral re-alignment strategies, including time-restricted eating, are associated with measurable improvements in metabolic outcomes.

These findings support a systems-level interpretation in which circadian timing functions as a regulatory layer governing physiological coordination across time. Within this framework, chronic disease may reflect a loss of temporal organization, the coordinated timing of biological processes across the day, rather than isolated pathway dysfunction.

Positioning circadian timing as a cross-cutting regulator across key behavioral domains of lifestyle medicine, including nutrition, physical activity, sleep, stress regulation, substance use, and social connection, reframes its role in chronic disease assessment, interpretation, and intervention and may influence variability in response to lifestyle-based interventions.

What’s the question this raises for you? I’ll do my best to address it in a future article.

Leave a comment

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

Every nucleated cell in the body operates on an internal clock. That clock does far more than govern sleep and wakefulness. It helps determine which genes are accessible at different times of day, which biological pathways are prioritized, and how energy metabolism, inflammation, and cellular repair are coordinated over time. In this way, circadian rhythms function less like background physiology and more like a biological timing system for gene expression.

Genes are not read continuously. They are turned on and off in rhythmic patterns, shaped by signals such as light exposure, eating timing, and sleep-wake regularity. These signals interact with the epigenetic machinery that controls chromatin structure and transcriptional access. Over time, they influence whether metabolic, inflammatory, and mitochondrial pathways remain synchronized or drift toward dysfunction.

Chrono-epigenetics describes the intersection between biological time and gene regulation. It offers a framework for understanding how circadian rhythms help determine which genetic programs are expressed, when they are expressed, and why those timing decisions matter for long-term health.

The molecular clock is more than a timekeeper

At the core of circadian biology is a molecular system often described as a transcription-translation feedback loop (TTFL), where the underlying concept is that certain genes help regulate their own activity across an approximate 24-hour cycle.

Two of the central players in this system are CLOCK and BMAL1. These proteins pair together and bind to DNA, where they act as transcriptional activators. Their role is to turn on a large network of hundreds to thousands of downstream genes involved in metabolism, inflammation, mitochondrial function, cellular repair, and stress responses. These downstream genes are expected to be expressed rhythmically, with peaks and troughs aligned with predictable environmental demands.

Many of these genes (PER1, PER2, PER3, and CRY1, CRY2) encode proteins that, in turn, feed back to suppress CLOCK-BMAL1 activity, creating a daily rhythmic cycle of activation and repression. This negative feedback loop is what gives cells a sense of biological time.

A quick primer on gene expression

To understand how circadian rhythms influence gene expression, it is helpful to clarify what gene expression entails.

Genes are encoded in DNA, but DNA does not float freely inside the cell. It is tightly packaged around proteins called histones, forming a complex structure known as chromatin.

Transcription copies DNA into messenger RNA (mRNA), which then serves as the template for the synthesis of enzymes, receptors, transporters, and structural components that carry out physiological functions.

Chromatin as a timing gate

Circadian clock proteins such as CLOCK and BMAL1 regulate transcription by precisely modifying chromatin structure. By adding or recruiting enzymes that add specific epigenetic marks, they create windows of accessibility, which are periods during the day when certain genes can be transcribed efficiently.

This is how circadian rhythms become embedded in gene expression. The clock does not merely send signals downstream; it reshapes the genome’s physical landscape over time.

A NOTE ON CLOCK: This variation is associated with hyperglycemia, dyslipidemia, and an increased risk of T2DM. Specific variants, such as rs4580704 and rs1801260, have been linked to obesity, metabolic syndrome, and altered energy intake. In contrast, others are associated with bipolar disorder, reinforcing the convergence of circadian timing, metabolic regulation, and affective stability.

CLOCK itself has histone acetyltransferase activity, meaning it can directly add acetyl groups to histones, loosening chromatin and permitting transcription. BMAL1 recruits additional epigenetic enzymes that place or remove histone methylation marks, helping to determine:

• which genes are accessible,

• at what time of day,

• and for how long.

In practical terms, circadian rhythm creates time-restricted windows of chromatin accessibility. During these windows, specific gene programs can be transcribed efficiently. Outside of them, transcription is suppressed or energetically costly.

Why timing of transcription matters biologically

Cells are energy-limited systems. Producing proteins is metabolically expensive, and many biological processes depend on coordination rather than constant activity.

Circadian regulation of transcription allows cells to prioritize energy use, separate competing processes such as metabolism and repair, synchronize mitochondrial activity with demand, and temporally restrain immune signaling.

When transcription is temporally organized, physiology is efficient. When this organization is lost, systems begin to interfere with one another.

For example, expressing metabolic genes during the biological night when mitochondrial readiness and hormonal context are mismatched can increase oxidative stress and impair insulin signaling. Similarly, inflammatory gene expression that loses its rhythmic restraint can contribute to chronic low-grade inflammation.

From chromatin regulation to clinical patterns

This is why chromatin regulation is not an abstract molecular detail. It is the mechanism through which environmental timing signals, including light, food intake, and sleep-wake patterns, are translated into long-term physiological outcomes.

When circadian rhythms are stable, epigenetic control of chromatin ensures that transcription occurs in the right sequence and context. When rhythms are disrupted, chromatic accessibility becomes mistimed. Genes may still be expressed, but without the temporal structure that supports metabolic and inflammatory balance.

From this perspective, circadian disruption is not simply a scheduling inconvenience. It is a disorder of transcriptional timing, mediated through epigenetic changes in chromatin that determine how and when genes are used.

Once gene expression is viewed through this lens, the critical issue is no longer whether circadian rhythms are disrupted, but which gene programs lose their temporal organization when they are.

Circadian regulation does not act in isolated genes. It coordinated entire transcriptional programs: metabolic, inflammatory, mitochondrial, and repair pathways. These are intended to operate sequentially throughout the day. Epigenetic control of chromatin ensures that these programs are activated only when the cellular and systemic environment is prepared to support them.

In practical terms, circadian timing schedules gene expression across the day. Genes involved in glucose uptake, insulin signaling, and lipid metabolism are preferentially expressed during the biological day, when nutrient availability and activity are expected.

Genes governing mitochondrial repair, antioxidant defense, and inflammatory restraint peak during the biological night, when energy demand is lower and cellular maintenance is prioritized. Health depends not only on whether these genes are expressed, but on whether they are expressed in the correct temporal context.

When circadian timing erodes, gene expression loses sequence, coherence, and metabolic efficiency, gradually reshaping physiology and disease risk.

Circadian control of metabolic gene programs

One of the best-characterized circadian transcriptional programs involves genes that regulate glucose metabolism, lipid handling, and insulin signaling. These genes are rhythmically expressed, with chromatin accessibility and transcriptional activity aligned to the biological day, when nutrient availability and energy demand are expected.

Epigenetic marks placed by circadian clock machinery help ensure that metabolic genes are accessible during periods of metabolic readiness. Histone acetylation and methylation at these sites exhibit daily oscillations, thereby reinforcing coordinated substrate utilization and metabolic flexibility.

When circadian timing is disrupted, this coordination breaks down. Metabolic genes may still be transcribed, but their expression occurs out of phase with hormonal signaling and mitochondrial capacity. The result is inefficient glucose handling, impaired lipid metabolism, and reduced insulin sensitivity, which are all patterns commonly observed in metabolic disease.

These changes do not require genetic mutations; they arise from epigenetically mediated shifts in gene-expression timing, accumulated through repeated circadian misalignment.

Which genes are expressed and when?

Rather than thinking about circadian rhythms globally, it is more useful to think in terms of gene programs that are scheduled over time.

» Mitochondrial and redox gene programs (activity-rest transition). Genes controlling oxidative phosphorylation, mitochondrial biogenesis, and antioxidant defense are also rhythmically expressed, with timing designed to balance energy production and oxidative stress. Under normal conditions:

• genes supporting energy production rise alongside activity

• genes governing reactive oxygen species (ROS) detoxification peak in coordination

• mitochondrial repair and turnover occur during relative rest

Epigenetic regulation ensures that chromatin accessibility at these genes follows this rhythm. When circadian regulation is disrupted, the amplitude of mitochondrial gene expression flattens. Genes are still expressed, but without proper timing. ROS production may no longer be matched by antioxidant capacity, leading to chronic oxidative stress.

Clinically, this manifests as fatigue, reduced stress tolerance, impaired recovery, and metabolic inflexibility; patterns which are frequently observed in chronic disease without primary mitochondrial pathology.

» Inflammatory and immune gene programs (biological night). Inflammatory signaling is also circadian-regulated. Genes involved in cytokine production, immune cell trafficking, and inflammasome activity are normally temporally restrained, with peak activity occurring when tissue repair and immune surveillance are most adaptive.

When circadian timing is disrupted, this restraint weakens. Inflammatory genes remain partially active across the day, contributing to persistent low-grade inflammation rather than acute, resolved immune responses.

A note on BMAL1: Located on chromosome 11p15.3, BMAL1 is indispensable for circadian rhythm generation and systemic metabolic coordination. Human polymorphisms in BMAL1 are associated with hypertension, T2DM, myocardial infarction, seasonal affective disorder, and bipolar disorder, highlighting its wide-ranging physiological effects.

Variants such as rs12363415 and rs2279287 have been associated with abnormal blood pressure regulation, impaired glucose homeostasis, and cardiometabolic risk, underscoring the pleiotropic effects of this core clock gene on human health.

Clinically, BMAL1 functions as a central regulator of cardiometabolic processes in humans. BMAL1 variants are associated with abnormal blood pressure regulation and impaired glucose homeostasis in patients with myocardial infarction.

Chrono-epigenetic drift and long-term disease

With repeated circadian disruption through irregular light exposure, feeding at biologically inappropriate times, or chronic rhythm instability, epigenetic regulation becomes progressively less precise. Histone markers lose their rhythmicity, and chromatin accessibility becomes less temporally defined, reducing the amplitude and precision of circadian gene expression.

This process, often described as chrono-epigenetic drift, scrambles the timing of our genes. Over years, this contributes to:

• reduced metabolic resilience

• mitochondrial inefficiency

• chronic inflammation

• increase susceptibility to cardiometabolic and neurodegenerative disease

From this perspective, chronic disease emerges from a combination of genetic risk, environmental exposure, and persistent mistiming of gene expression.

In conclusion

Circadian rhythms matter not simply because they influence sleep, but because they govern the timing of gene expression across metabolic, mitochondrial, and inflammatory systems. Through epigenetic control of chromatin, biological timing determines which genes are accessible, when they are transcribed, and whether physiological processes remain coordinated or drift toward dysfunction.

From this perspective, chronic disease arises not only from the genes we carry or the pathways activated, but also from the gradual loss of temporal organization in gene expression itself. The most important question, then, is not how well we sleep but whether our genes are being expressed at the right time.

What’s the question this raises for you? I’ll do my best to address it in a future article.

Leave a comment

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

References

Fagiani, F., Di Marino, D., Romagnoli, A., Recchia, C., Lanni, C., & Govoni, S. (2022). Molecular regulations of circadian rhythm and implications for physiology and diseases. Signal Transduction and Targeted Therapy, 7(1), 41. https://doi.org/10.1038/s41392-022-00899-y

González-Suárez, M., & Aguilar-Arnal, L. (2024). Histone methylation: At the crossroad between circadian rhythms in transcription and metabolism. Frontiers in Genetics, 15, Article 1343030. https://doi.org/10.3389/fgene.2024.1343030

Mao, W., Ge, X., Chen, Q., & Li, J. D. (2025). Epigenetic mechanisms in the transcriptional regulation of circadian rhythm in mammals. Biology, 14(1), 42. https://doi.org/10.3390/biology14010042

Schrader, L. A., Ronnekleiv-Kelly, S. M., Hogenesch, J. B., Bradfield, C. A., & Malecki, K. M. (2024). Circadian disruption, clock genes, and metabolic health. Journal of Clinical Investigation, 134(14), Article e170998. https://doi.org/10.1172/JCI170998

Her, T. K., Li, J., Lin, H., Liu, D., Root, K. M., Regal, J. F., Alejandro, E. U., & Cao, R. (2024). Circadian disruption across lifespan impairs glucose homeostasis and insulin sensitivity in adult mice. Metabolites, 14(2), 126. https://doi.org/10.3390/metabo14020126

In Part I of this series, we outlined the physiology of the inflammatory reflex and its role as a closed-loop neuroimmune control system. In this second and final paper, we move from framework to intervention. Here, we examine how vagus nerve stimulation (VNS) and targeted lifestyle-based neuromodulation can be combined to restore regulatory control, reduce the inflammatory burden, support resolution, and address chronic disease at its upstream control point.

As vagus nerve stimulation devices have become widely available through consumer marketplaces, the concept of a ‘vagal reset’ has been increasingly promoted in wellness and social media spaces. It is crucial to distinguish informal wellness practices from clinical neuromodulation, which carries physiological effects, contraindications, and dose-dependent risks that warrant medical oversight.

When VNS is relevant

This regulatory model is most useful when symptoms suggest a breakdown in system-level coordination, rather than dysfunction isolated to a single organ. Clinically, this often presents with symptoms that span multiple domains, including fatigue, pain, cognitive impairment, gastrointestinal disturbance, sleep disruption, and orthostatic symptoms that fluctuate with stress, illness, exertion, or circadian disruption, rather than following a single anatomical or biochemical pathway.

These patients frequently demonstrate poor recovery after otherwise minor stressors or infections and show signs of chronic or relapsing inflammation that cannot be fully explained by one dominant disease process. In such cases, impaired autonomic and neuroimmune regulation offers a unifying framework for understanding symptom persistence and fragility.

Clinically, this regulatory approach is most effective when applied sequentially: first identifying patterns of impaired regulation, then reducing autonomic load, and finally layering neuromodulatory and conditioning inputs to restore physiological flexibility. This sequencing matters, as premature stimulation in the setting of unresolved autonomic stress often produces inconsistent or blunted responses.

How neuromodulation changes the inflammatory model

Under physiological conditions, inflammatory mediators released in peripheral tissues activate sensory (afferent) fibers of the vagus nerve. These afferent fibers do not merely transmit information passively; they function as a real-time surveillance system, continuously reporting immune activity to the brainstem.

Afferent vagal fibers project primarily to the nucleus tractus solitarius (NTS), a brainstem structure that serves as a central integration hub for visceral information. The NTS does not process immune signals in isolation. Instead, it integrates immune input with cardiovascular status, respiratory rhythm, metabolic state, circadian timing, and stress-related signals arriving from higher brain centers.

Once processed centrally, coordinated efferent vagal output restrains excessive immune activation, particularly through macrophage signaling. This does not result in immune suppression, but proportional inhibition, allowing inflammation to resolve rather than propagate.

The inflammatory reflex operates on a timescale of seconds, distinguishing neural regulation from endocrine or pharmacologic approaches and helping explain why cytokine blockade alone often fails to restore balance.

Measuring vagal regulatory failure

Before attempting to restore vagal regulation, clinicians must recognize when it is impaired. Heart rate variability (HRV) provides a practical, non-invasive window into this system.

HRV reflects variability between successive heartbeats, driven primarily by parasympathetic (vagal) modulation of cardiac rhythm. While measured at the heart, this modulation reflects broader vagal output affecting multiple systems, including immune regulation. Persistently reduced HRV suggests diminished inhibitory capacity, increasing vulnerability to prolonged inflammation, exaggerated stress responses, and impaired recovery.

Low HRV is commonly observed in conditions marked by fatigue, pain sensitization, orthostatic intolerance, and cognitive dysfunction, including fibromyalgia, Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS), Postural Orthostatic Tachycardia Syndrome (POTS), inflammatory bowel disease, and long COVID. However, HRV is sensitive to sleep, circadian rhythm, infection, medications, alcohol, and psychological stress.

Importantly, HRV reflects vagal modulation at the level of the heart, but it is not a comprehensive measure of vagal function. Vagal dysregulation may also be evident through orthostatic intolerance, stress-sensitive gastrointestinal motility disturbances, impaired inflammatory resolution, or multisystem symptom clustering—even when resting HRV appears within normal ranges.

As with any clinical intervention, VNS should be paired with appropriate monitoring to assess response and guide continuation. Improvements are best evaluated through functional measures such as HRV trends, orthostatic tolerance, sleep quality, recovery time, and symptom patterns, rather than subjective sensation alone.

Interpreting heart rate variability in a clinical context

Taken together, these observations underscore the need to interpret HRV in context. HRV should be understood as an indicator of regulatory capacity rather than a direct measure of health, fitness, or disease. There is no universal HRV value that defines health; baseline values vary widely with age, sex, genetics, fitness level, medications, and individual autonomic architecture.

For orientation only, commonly reported Root Mean Square of Successive Differences (RMSSD, referring to a heart rate variability metric reflecting short-term, parasympathetic activity) values below ~20 ms are often seen in states of autonomic impairment or acute physiological load; 20–40 ms is typical under sustained stress or sedentary conditions; 40–70 ms is typical of individuals with adequate autonomic flexibility; and higher values are frequently observed in endurance-trained populations.

These ranges are not diagnostic, and higher is not inherently better. Health is defined by adaptability and recovery.

Clinically useful HRV assessment depends on consistency rather than precision. RMSSD is the most informative metric for vagal modulation and should be interpreted longitudinally under standardized conditions. Persistent suppression or loss of recovery following rest is more instructive than day-to-day fluctuation.

Invasive vs non-invasive stimulation

Implanted cervical VNS stimulates both afferent and efferent fibers directly and has demonstrated durable anti-inflammatory effects in refractory rheumatoid arthritis and Crohn’s disease. These outcomes suggest that repeated activation of vagal circuits can recalibrate immune set-points over time.

Non-invasive transcutaneous approaches primarily stimulate afferent fibers. This is not a limitation: afferent signaling is the gateway to central integration, which then coordinates downstream regulation across systems. However, effectiveness depends on sufficient intensity, appropriate targeting, and cumulative exposure.

Non-response is frequently attributable to subthreshold stimulation rather than to failure of the underlying model; studies demonstrating benefit typically employ frequencies in the 20–25 Hz range, with adequate pulse width and cumulative dosing.

While non-invasive VNS devices are readily accessible and relatively simple to use (a wearable clip on or near the ear or a handheld device pressed against the side of the neck), their quality, output, and targeting vary widely.

VNS is not for all individuals, and caution must be taken for individuals with implanted electronic devices, cardiac abnormalities, specific medication profiles, and those who are pregnant.

A qualified medical or clinical practitioner should guide the use of these devices to ensure appropriate selection, parameter settings, and patient suitability, as subtherapeutic or poorly targeted stimulation may lead to false assumptions about efficacy.

Moving beyond cytokines to support inflammatory resolution

Early VNS studies focused on reductions in TNF-α and IL-6 as markers of success. While important, cytokines represent only one phase of inflammation. Recovery requires resolution: the active termination of immune responses and initiation of tissue repair.

Preclinical research suggests that vagus nerve stimulation influences inflammation not only by reducing cytokine output, but by actively supporting the body’s ability to shut an inflammatory response down once it has served its purpose. One mechanism by which this occurs is accelerated clearance of neutrophils, the short-lived immune cells that are the first to arrive at sites of tissue injury or infection.

When neutrophils remain in tissue longer than necessary, they perpetuate local damage and ongoing immune activation. VNS appears to shorten this phase by promoting the timely removal.

VNS also influences lipid mediator pathways that generate specialized pro-resolving mediators (SPMs). These molecules act as biological stop signals, instructing immune cells to disengage, regulate residual inflammation, and restore tissue integrity. Clinically, impaired resolution helps explain prolonged flares, delayed recovery, and cumulative symptom burden even when inflammatory markers appear modest.

VNS alone is not sufficient

Neural circuits do not operate in isolation. Their responsiveness depends on neurotransmitter availability, membrane composition, afferent signal quality, and central integration. For this reason, lifestyle inputs are best understood as external neuromodulators rather than wellness strategies.

Slow, controlled breathing alters intrathoracic pressure, directly stimulating vagal afferents linked to baroreceptor and cardiopulmonary feedback. These signals converse in the NTS, reinforcing parasympathetic dominance and improving autonomic flexibility. While breathing practices do not directly suppress cytokines, they improve the signal environment within which immune regulation occurs.

Acute cold exposure activates reflexive parasympathetic responses, including the diving reflex, which increases vagal output and suppresses sympathetic tone. Although clinical trials directly linking cold exposure to inflammatory reflex engagement are limited, the underlying neural pathways overlap substantially with those targeted by VNS.

Vagal tone follows circadian rhythms. Sleep disruption fragments autonomic regulation, sustaining sympathetic dominance and impairing immune restraint. Restoring consistent sleep timing improves the nervous system’s ability to interpret and respond appropriately to immune signals.

Nutrition as a determinant of regulatory capacity

Omega-3 fatty acids serve as substrates for the production of specialized pro-resolving mediators (SPMs). This class of lipid-derived signaling molecules actively coordinates the resolution phase of inflammation.

Dietary patterns that support inflammatory resolution, such as those rich in omega-3 fatty acids, polyphenols, and fermentable fibers, may enhance downstream responsiveness once regulatory signaling is restored, without acting as primary drivers themselves. Excess alcohol intake, irregular meal timing, and chronic stimulant use can increase autonomic noise and blunt neuromodulatory effects, particularly in patients with already reduced regulatory reserve.

In clinical practice, dysbiosis, increased intestinal permeability, or persistent low-grade gut inflammation can introduce excessive afferent ‘noise,’ blurring signal clarity to the brainstem, and reducing responsiveness to vagus nerve stimulation or other regulatory interventions.

Addressing gut-related contributors such as meal timing, fermentable substrate load, and inflammatory burden does not substitute for neuromodulation. Still, it can materially improve the fidelity of afferent signaling and the consistency of downstream regulation.

Acetylcholine is the effector neurotransmitter of vagal immune restraint. Adequate choline intake ensures substrate availability but does not override neural control. Practically, this means nutrition supports capacity; regulation still depends on circuit engagement.

Clinical synthesis

In practice, this framework is most useful when applied sequentially: first, identifying patterns of impaired regulation; then, reducing autonomic load; and finally, layering neuromodulatory and conditioning inputs to restore flexibility. VNS and lifestyle-based neuromodulation are complementary approaches alongside standard care. They address the regulatory layer that determines whether inflammation resolves or persists.

The shift from suppression to regulation does not eliminate the need for disease-specific treatment. It restores the system that governs proportion, timing, and recovery. For practitioners managing chronic, relapsing, or multisystem inflammatory conditions, this regulatory lens offers a coherent approach to upstream intervention, where control, rather than containment, becomes possible.

For these reasons, vagus nerve stimulation should be used as a clinical tool, applied deliberately, monitored over time, and integrated into broader care, rather than as a standalone or unsupervised self-experiment.

In conclusion

For many practitioners, chronic inflammation presents not as a single disease to be treated, but as a pattern of fragility: patients who relapse easily, recover slowly, and accumulate symptoms across systems despite appropriate disease-specific care. What unites these presentations is impaired physiological regulation.

The framework outlined here provides a means of identifying and addressing coordination failures. Vagal regulation does not replace immunology, rheumatology, or pharmacology; it determines how effectively those systems are integrated, restrained, and resolved. When inhibitory control is intact, inflammatory responses remain proportional and time-limited.

When compromised, even modest stressors such as illness, exertion, and sleep disruption can trigger prolonged or cascading effects.

Clinically, this shifts the task from suppressing signals to restoring control. It encourages practitioners to look beyond isolated biomarkers or organ systems and instead assess adaptability, recovery, and coherence across domains. Heart rate variability, orthostatic responses, gastrointestinal function, sleep patterns, and symptom fluctuation are not merely ancillary observations but clues to regulatory capacity.

Neuromodulation, whether delivered through vagus nerve stimulation or conditioned through behavioral and lifestyle inputs, is most effective when applied within a physiological context that supports signal clarity and responsiveness. Reducing autonomic load, stabilizing circadian rhythms, and supporting resolution biology do not compete with stimulation; they determine whether it works.

In moving from suppression to regulation, the goal is not to do more but to enable the body to complete what it has already begun: an appropriate response, followed by resolution.

If you’re living with one or more lifestyle-related chronic conditions and are ready to move beyond symptom management, I offer personalized consultations focused on physiology, labs, and upstream drivers of disease. Book a discovery appointment to explore your symptoms, review relevant biomarkers, and develop a targeted, evidence-informed plan. Start your health journey with me.

Leave a comment

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

References

Austelle, C. W., O’Leary, G. H., Thompson, S., & Badran, B. W. (2024). Vagus nerve stimulation (VNS): Recent advances and future directions. Clinical Autonomic Research, 34, 529–547. https://doi.org/10.1007/s10286-024-01065-w

Badran, B. W., Yu, A. B., Adair, D., Mappin, G., DeVries, W. H., Jenkins, D. D., George, M. S., & Bikson, M. (2019). Laboratory administration of transcutaneous auricular vagus nerve stimulation (taVNS): Technique, targeting, and considerations. Journal of Visualized Experiments, (143), Article e58984. https://doi.org/10.3791/58984

Besson, C., Baggish, A. L., Monteventi, P., Schmitt, L., Stucky, F., Gremeaux, V., & Noirez, P. (2025). Assessing the clinical reliability of short-term heart rate variability: Insights from controlled dual-environment and dual-position measurements. Scientific Reports, 15(1), Article 5611. https://doi.org/10.1038/s41598-025-89892-3

Chen, Z., & Liu, K. (2025). Mechanisms and applications of vagus nerve stimulation. Current Issues in Molecular Biology, 47, Article 122. https://doi.org/10.3390/cimb47020122

Drewes, A. M., Brock, C., Rasmussen, S. E., Møller, H. J., Brock, B., Deleuran, B. W., & Farmer, A. D. (2021). Short-term transcutaneous non-invasive vagus nerve stimulation may reduce disease activity and pro-inflammatory cytokines in rheumatoid arthritis: Results of a pilot study. Scandinavian Journal of Rheumatology, 50(1), 20–27. https://doi.org/10.1080/03009742.2020.1764617

Falvey, A. (2022). Vagus nerve stimulation and inflammation: Expanding the scope beyond cytokines. Bioelectronic Medicine, 8(1), Article 19. https://doi.org/10.1186/s42234-022-00100-3

Johnson, R. L., & Wilson, C. G. (2018). A review of vagus nerve stimulation as a therapeutic intervention. Journal of Inflammation Research, 11, 203–213. https://doi.org/10.2147/JIR.S163248

Kim, A. Y., Marduy, A., de Melo, P. S., et al. (2022). Safety of transcutaneous auricular vagus nerve stimulation (taVNS): A systematic review and meta-analysis. Scientific Reports, 12, Article 22055. https://doi.org/10.1038/s41598-022-25864-1

Lange, G., Janal, M. N., Maniker, A., Fitzgibbons, J., Fobler, M., Cook, D., & Natelson, B. H. (2011). Safety and efficacy of vagus nerve stimulation in fibromyalgia: A phase I/II proof-of-concept trial. Pain Medicine, 12(9), 1406–1413. https://doi.org/10.1111/j.1526-4637.2011.01203.x

Ma, L., Wang, H.-B., & Hashimoto, K. (2025). The vagus nerve: An old but new player in brain–body communication. Brain, Behavior, and Immunity, 124, 28–39. https://doi.org/10.1016/j.bbi.2024.11.023

Matsuoka, M., Yamaguchi, T., & Fujiwara, T. (2025). Transcutaneous auricular vagus nerve stimulation in healthy individuals, stroke, and Parkinson’s disease: A narrative review of safety, parameters, and efficacy. Frontiers in Physiology, 16, Article 1693907. https://doi.org/10.3389/fphys.2025.1693907

Tesser, J. R. P., Crowley, A. R., Box, E. J., et al. (2025). Vagus nerve–mediated neuroimmune modulation for rheumatoid arthritis: A pivotal randomized controlled trial. Nature Medicine. Advance online publication. https://doi.org/10.1038/s41591-025-04114-7

Veldman, F., Hawinkels, K., & Keszthelyi, D. (2025). Efficacy of vagus nerve stimulation in gastrointestinal disorders: A systematic review. Gastroenterology Report, 13, Article goaf009. https://doi.org/10.1093/gastro/goaf009

Zheng, Z. S., Simonian, N., Wang, J., & Rosario, E. R. (2024). Transcutaneous vagus nerve stimulation improves long COVID symptoms in a female cohort: A pilot study. Frontiers in Neurology, 15, Article 1393371. https://doi.org/10.3389/fneur.2024.1393371

In parallel, over the past 20 years, a different understanding has taken shape, one that reframes inflammation not as a standalone immune malfunction but as a regulatory problem. Landmark work by Kevin J. Tracey and colleagues demonstrated that inflammatory activity is under direct neural control. A seminal 2000 study also showed that electrical stimulation of the vagus nerve rapidly suppressed systemic tumor necrosis factor (TNF) release in the presence of endotoxins in the bloodstream. This study established the existence of a hardwired neural circuit (the inflammatory reflex) that can restrain immune activity in real time.

What initially appeared as a novel experimental finding has since evolved into a broader neuro-immune framework. Subsequent studies have extended this model beyond acute endotoxin exposure, demonstrating that vagus-mediated signaling can modify inflammatory tone across chronic disease states, aging, and metabolic dysfunction. More recent work has mapped specific brainstem nuclei and vagal pathways that mediate sensing of peripheral immune signals and coordinate rapid anti-inflammatory responses.

Neuro-immune paradigm shift

Within the traditional immunology framework, the immune system was viewed as largely autonomous, with the brain responding only secondarily through sickness behavior or endocrine stress pathways. Tracey’s work overturned this view by revealing a bidirectional neuro-immune dialogue. Immune cells signal the brain through direct neural signals carried by vagal afferent nerves. In response, the brain deploys rapid and targeted efferent signals that suppress inflammatory output at its source.

Crucially, the inflammatory reflex operates on the scale of seconds. Unlike hormonal responses, which unfold over minutes to hours, vagal efferent signaling can inhibit TNF, IL-1β, and IL-6 almost immediately. This speed and specificity laid the groundwork for the emerging field of bioelectronic medicine, which seeks to modulate disease by targeting neural circuits rather than indiscriminately blocking molecular pathways.

Failure of this reflex is increasingly implicated in inflammaging: the age-related accumulation of unresolved inflammation that accelerates cardiovascular disease, neurodegeneration, sarcopenia, and frailty. Vagus nerve stimulation (VNS) emerges from this model not as a workaround but as a logical strategy: rather than blocking inflammatory molecules after they are released, VNS aims to re-engage the neural circuits that usually keep immune responses proportional, time-limited, and self-resolving.

The inflammatory reflex as a control system

The inflammatory reflex functions as a closed-loop control system, analogous to other physiological regulatory circuits such as baroreflex control of blood pressure or glucose regulation. Like these systems, it consists of three essential components: signal detection, central integration, and effector response.

Peripheral immune activation generates cytokines and inflammatory mediators that are detected not only by immune receptors but also by sensory pathways of the vagus nerve. Afferent vagal fibers relay this information to brainstem nuclei, where immune signals are integrated with physiological context, including metabolic state, circadian cues, and psychological stress.

When inflammatory activity exceeds an appropriate threshold, efferent vagal output is engaged. Through downstream signaling pathways, including cholinergic modulation of macrophage activity, pro-inflammatory cytokine production is rapidly restrained. This inhibitory feedback limits the magnitude and duration of immune activation, allowing inflammation to resolve once the initiating threat has passed.

Chronic inflammation emerges when this regulatory loop is impaired. Reduced vagal tone blunts inhibitory signaling, lowering the threshold for immune activation and delaying termination of the inflammatory response. The result is not excessive immune reactivity per se, but loss of effective restraint; a failure of resolution rather than an overreaction.

Chronic disease, as a failed neural regulation

Reduced vagal tone is a consistent feature of a broad spectrum of chronic diseases, including rheumatoid arthritis, inflammatory bowel disease, metabolic syndrome, atherosclerosis, depression, and neurodegenerative disorders. Although these conditions differ clinically, they share a common biological signature: persistent low-grade inflammation coupled with impaired resolution.

The inflammatory reflex offers a unifying framework. Rather than viewing each disorder as an independent pathology driven by disease-specific triggers, they can be understood as manifestations of shared failure of neural regulation. When vagal inhibitory control is compromised, immune responses become exaggerated, prolonged, and self-perpetuating, driving tissue damage, metabolic dysfunction, and neuroimmune sensitization.

From this perspective, chronic inflammatory diseases are less a problem of immune excess and more a problem of regulatory failure. The nervous system, via the vagus nerve, emerges as a central coordinator of immune homeostasis, the decline of which with stress and aging may be a key driver of modern chronic disease. It also helps explain why chronic diseases often cluster within individuals and why interventions that improve overall physiological resilience, such as physical activity, sleep optimization, stress reduction, and metabolic health, exert broad anti-inflammatory effects across multiple organ systems.

The inflammatory reflex is an immunity regulator

Experimental and clinical evidence consistently support the inflammatory reflex as the core regulator of immune activity. In animal models, vagus nerve stimulation suppresses the release of inflammatory cytokines in diverse conditions, including sepsis, arthritis, colitis, and post-operative inflammation. These effects are rapid and reproducible, supporting the conclusion that they reflect a defined neural circuit.

Human data are closely aligned with these findings. Higher vagal tone, most commonly assessed by high-frequency heart rate variability (HRV), is inversely associated with circulating inflammatory markers, including IL-6, TNF-α, and C-reactive protein.

Individuals with higher HRV demonstrate a lower baseline inflammatory burden, faster resolution following immune challenge, and greater physiological adaptability to stress. Conversely, reduced vagal tone predicts increased inflammatory activity and poorer outcomes in multiple disease states.

Clinical trials have translated these observations into therapeutic concepts. In patients with rheumatoid arthritis, implanted vagus nerve stimulators reduce disease activity scores and cytokine production in those resistant to conventional therapy.

Similar benefits have been observed in patients with Crohn’s disease, with improvements in inflammatory markers and clinical symptoms. Importantly, these interventions were well tolerated, with minimal side effects and no evidence of global immunosuppression.

This is where vagus nerve stimulation differs fundamentally from pharmacologic anti-inflammatory approaches, and most drugs act by blocking specific cytokines or by suppressing immune cell activity more broadly. VNS, by contrast, modulates an upstream control system. It does not target a single molecule, but an entire regulatory circuit. This allows inflammation to be dynamically tuned rather than shut down indiscriminately, thereby reducing the risk of infection or immune rebound.

Taken together, these findings suggest that vagal tone functions not only as a biomarker but also as a systems-level regulator of the inflammatory set-point. The inflammatory reflex integrates immune activity with the metabolic state, circadian rhythms, psychological stress, and cardiorespiratory fitness.

Factors such as chronic stress, sleep disruption, sedentary behavior, insulin resistance, and aging converge on a shared pathway: suppression of vagal signaling and loss of inhibitory immune control.

What exactly is the vagus nerve?

Also called ‘cranial nerve X’, the vagus nerve derives its name from the Latin word vagus, which means ‘wandering,’ an apt description of its extensive anatomical reach. Originating in the brainstem, it descends through the neck and thorax to innervate the heart, lungs, liver, pancreas, and gastrointestinal tract, making it the body’s primary parasympathetic nerve.

Functionally, it is predominantly sensory, and 80-90% of its fibers carry information from peripheral organs back to the brain. These sensory signals are transmitted to the brainstem and then distributed to autonomic and higher regulatory centers involved in physiological and emotional control. The remaining 10-20% of fibers carry outgoing parasympathetic signals that coordinate heart rate, gastrointestinal function, and immune regulation.

The vagus nerve is composed of multiple fiber types. Unmyelinated C-fibers are exceptionally responsive to inflammatory signals, while myelinated A- and B-fibers support faster reflexes, such as cardiovascular control. This mixed architecture enables the vagus nerve to function, sampling internal conditions and adjusting physiological responses in real time.

How vagal nerve stimulation works

Vagus nerve stimulation does not add a foreign signal to the body. It amplifies and restores an existing signal. By increasing vagal efferent output, stimulation strengthens the timing and intensity of the brain’s inhibitory messages to immune cells, particularly innate immune cells such as macrophages. Functionally, this means inflammatory responses are shortened rather than suppressed.

Cytokine release is reduced when it becomes excessive, whereas antimicrobial functions, such as pathogen clearance, remain intact. Instead of forcing the immune system into silence, stimulation helps re-establish its ability to escalate when needed, and stand down when the threat has passed.

Vagus nerve and communication

Around 90% of vagal fibers innervate the gut. The gastrointestinal tract is the body’s largest immune interface, containing the majority of immune cells and the densest microbial ecosystem. Unsurprisingly, it is also a significant source of inflammatory signals that communicate with the brain via the vagus nerve.

Vagal sensory neurons do not directly ‘touch’ what is inside the gut. Instead, it relies on messenger cells within the intestinal lining to inform it what is occurring. Specialized gut cells called enteroendocrine cells (EECs) act like biological sensors and translators. They can detect nutrients and chemical by-products made by gut microbes, even though microbes themselves never contact nerve endings.

When certain gut bacteria break down the amino acid tryptophan, they produce compounds that trigger Trpa1 receptors on these EECs. This activation causes cells to release serotonin (5-HT) rapidly. Serotonin then stimulates nearby enteric motor neurons and transmits signals via the vagus nerve to the brain. In this way, the gut microbiome can rapidly communicate with the brain indirectly via EECs.

Stress, permeability, and inflammatory looping

The vagus nerve continuously monitors gastrointestinal activity. When the gut barrier weakens or the microbiome becomes imbalanced, immune cells release inflammatory signals, and microbial by-products leak through the intestinal lining. These signals are picked up by the vagus nerve and relayed to the brain. Under normal conditions, the brain responds by sending calming signals back down the vagus nerve.

These signals instruct immune cells, particularly macrophages, to suppress inflammation and initiate repair. This is how the body prevents a short-term immune response from becoming chronic.

Chronic stress disrupts this balance. Stress hormones increase gut permeability and enhance immune reactivity as more microbial products enter the tissue and inflammation rises, thereby further stimulating the stress response. Over time, this creates a self-reinforcing cycle: stress weakens the gut, the gut fuels inflammation, and inflammation keeps the nervous system in a state of high alert.

Macrophages can either promote inflammation or help resolve it. Signals from the vagus nerve act like switch, nudging these cells away from attack mode and toward healing. When vagal tone is low, as is common in chronic stress, metabolic dysfunction, and inflammatory disease, that switch doesn’t flip effectively. Inflammation stays ‘on’ longer than it should.

This calming signal does not shut down the immune system. It selectively reduces excessive inflammatory signaling while preserving the body’s ability to fight infection. In other words, it restores control versus suppression. When this neural braking system fails, inflammation does not fully resolve. What starts as a transient gastrointestinal disturbance can gradually escalate into widespread, low-grade inflammation throughout the body.

This helps explain why chronic inflammatory conditions often show up alongside gut symptoms, stress sensitivity, fatigue, and autonomic imbalance; not as separate issues, but as part of the same broken feedback loop.

The vagus nerve as a volume dial

VNS can be delivered invasively via implanted devices or noninvasively via transcutaneous approaches, but all methods share the same goal: restoring effective neural braking of inflammation.

What makes this gut-brain-immune system especially powerful is its precision. Most anti-inflammatory drugs work like a blanket. They can quiet inflammation, but they do so by broadly suppressing the immune system, which can leave the body more vulnerable to infection. The vagus nerve works differently. It acts more like a volume dial than an off switch.

When inflammation begins to spiral under chronic stress, gut permeability, or dysbiosis, the vagus nerve selectively targets harmful immune signals. It turns down excessive cytokine release without shutting down the immune system’s core defenses. Macrophages can still do their job, continuing to recognize, engulf, and clear bacteria and damaged cells.

An overly active immune system rarely causes chronic disease. It is caused by one that stays activated for too long. The vagus nerve helps restore the response to balance once the threat has passed, preventing inflammation from progressing to ongoing tissue damage.

When this neural ‘brake’ is working well, the body can mount a strong defense and then stand down efficiently. When vagal tone is low, inflammation loses its stop signal. The immune response lingers, spills beyond the gut, and contributes to fatigue, pain, metabolic dysfunction, and mood changes.

Together, this reframes inflammation as something to regulate. The goal is to restore the body’s ability to respond, resolve, and recover.

In conclusion

Chronic inflammation is rarely the result of an immune system that is too strong. More often, it reflects an immune response that has lost its ability to stand down. The evidence reviewed here supports a shift away from viewing inflammation solely as a biochemical cascade to be suppressed and toward understanding it as a regulated physiological process that depends on intact neural control.

The inflammatory reflex provides a coherent framework for this shift. Situating immune activity within a closed-loop neuroimmune control system helps explain why chronic inflammatory diseases cluster, why psychological stress and metabolic dysfunction so reliably worsen the inflammatory burden, and why resolution often fails despite aggressive molecular blockade. In this context, reduced vagal tone is not merely a correlate of disease severity but a plausible upstream driver of impaired inflammatory restraint.

This reframing has important clinical implications. If chronic inflammation reflects a failure of neural regulation rather than immune excess, then strategies that restore inhibitory control become central rather than adjunctive. Interventions that improve vagal tone, whether through physiological conditioning, behavioral inputs, or direct immunomodulation, are not alternative approaches to managing inflammation. They target the regulatory architecture that governs immune proportionality and resolution.

Understanding inflammation through this regulatory lens does not diminish the value of pharmacological therapies. Instead, it clarifies their limitations. Blocking cytokines after release may reduce symptoms, but it does not restore the system that determines when immune responses begin, how intensely they proceed, or when they end. Restoring that system requires engaging the neural circuits that evolved to coordinate immune activity with the broader physiological state.

From framework to intervention

Join us for Part II, where we will focus on VNS as a direct clinical application of this regulatory model. Building on the physiology outlined here, it examines how targeted neuromodulation can re-engage the inflammatory reflex, restore inhibitory control, and reduce inflammatory burden without global immunosuppression.

We will examine the current clinical evidence for VNS across inflammatory and immune-mediated conditions, compare invasive and non-invasive approaches, and examine how neuromodulation fits within a broader strategy that includes lifestyle interventions known to influence vagal tone. Together, these approaches point toward a more precise and physiologically aligned way of managing chronic inflammation; one that prioritizes regulation, resolution, and resilience over suppression alone.

If you’re living with one or more lifestyle-related chronic conditions and are ready to move beyond symptom management, I offer personalized consultations focused on physiology, labs, and upstream drivers of disease. Book a discovery appointment to explore your symptoms, review relevant biomarkers, and develop a targeted, evidence-informed plan. Start your health journey with me.

Leave a comment

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

References

Ahmed, U., Chang, Y. C., Zafeiropoulos, S., Nassrallah, Z., Miller, L., & Zanos, S. (2022). Strategies for precision vagus neuromodulation. Bioelectronic Medicine, 8(1), Article 9. https://doi.org/10.1186/s42234-022-00091-1

Badran, B. W., & Austelle, C. W. (2022). The future is noninvasive: A brief review of the evolution and clinical utility of vagus nerve stimulation. Focus, 20(1), 3–7. https://doi.org/10.1176/appi.focus.20210023

Báez-Pagán, C. A., Delgado-Vélez, M., & Lasalde-Dominicci, J. A. (2015). Activation of the macrophage α7 nicotinic acetylcholine receptor and control of inflammation. Journal of Neuroimmune Pharmacology, 10(3), 468–476. https://doi.org/10.1007/s11481-015-9601-5

Bellocchi, C., Carandina, A., Montinaro, B., Targetti, E., Furlan, L., Rodrigues, G. D., Tobaldini, E., & Montano, N. (2022). The interplay between autonomic nervous system and inflammation across systemic autoimmune diseases. International Journal of Molecular Sciences, 23(5), Article 2449. https://doi.org/10.3390/ijms23052449

Bonaz, B., Sinniger, V., Hoffmann, D., Clarencon, D., Mathieu, N., Dantzer, C., & Pellissier, S. (2016). Chronic vagus nerve stimulation in Crohn’s disease: A 6-month follow-up pilot study. Neurogastroenterology & Motility, 28(6), 948–953. https://doi.org/10.1111/nmo.12792

Borovikova, L. V., Ivanova, S., Zhang, M., Yang, H., Botchkina, G. I., Watkins, L. R., Wang, H., Abumrad, N., Eaton, J. W., & Tracey, K. J. (2000). Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature, 405(6785), 458–462. https://doi.org/10.1038/35013070

Caravaca, A. S., Gallina, A. L., Tarnawski, L., Shavva, V. S., Colas, R. A., Dalli, J., Malin, S. G., Hult, H., Arnardottir, H., & Olofsson, P. S. (2022). Vagus nerve stimulation promotes resolution of inflammation by a mechanism that involves Alox15 and requires the α7nAChR subunit. Proceedings of the National Academy of Sciences, 119(22), Article e2023285119. https://doi.org/10.1073/pnas.2023285119

Cooper, T. M., McKinley, P. S., Seeman, T. E., Choo, T. H., Lee, S., & Sloan, R. P. (2015). Heart rate variability predicts levels of inflammatory markers: Evidence for the vagal anti-inflammatory pathway. Brain, Behavior, and Immunity, 49, 94–100. https://doi.org/10.1016/j.bbi.2014.12.017

D’Haens, G., Eberhardson, M., Cabrijan, Z., Danese, S., van den Berg, R., Löwenberg, M., Fiorino, G., Schuurman, P. R., Lind, G., Almqvist, P., Olofsson, P. S., Tracey, K. J., Hanauer, S. B., Zitnik, R., Chernoff, D., & Levine, Y. A. (2023). Neuroimmune modulation through vagus nerve stimulation reduces inflammatory activity in Crohn’s disease patients: A prospective open-label study. Journal of Crohn’s and Colitis, 17(12), 1897–1909. https://doi.org/10.1093/ecco-jcc/jjad151

Falvey, A. (2022). Vagus nerve stimulation and inflammation: Expanding the scope beyond cytokines. Bioelectronic Medicine, 8(1), Article 19. https://doi.org/10.1186/s42234-022-00100-3

Falvey, A., Metz, C. N., Tracey, K. J., & Pavlov, V. A. (2022). Peripheral nerve stimulation and immunity: The expanding opportunities for providing mechanistic insight and therapeutic intervention. International Immunology, 34(2), 107–118. https://doi.org/10.1093/intimm/dxab068

Huston, J. M., & Tracey, K. J. (2011). The pulse of inflammation: Heart rate variability, the cholinergic anti-inflammatory pathway and implications for therapy. Journal of Internal Medicine, 269(1), 45–53. https://doi.org/10.1111/j.1365-2796.2010.02321.x

Kelly, M. J., Breathnach, C., Tracey, K. J., & Donnelly, S. C. (2022). Manipulation of the inflammatory reflex as a therapeutic strategy. Cell Reports Medicine, 3(7), Article 100696. https://doi.org/10.1016/j.xcrm.2022.100696

Koopman, F. A., Chavan, S. S., Miljko, S., Grazio, S., Sokolovic, S., Schuurman, P. R., Mehta, A. D., Levine, Y. A., Faltys, M., Zitnik, R., Tracey, K. J., & Tak, P. P. (2016). Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proceedings of the National Academy of Sciences, 113(29), 8284–8289. https://doi.org/10.1073/pnas.1605635113

Ma, L., Wang, H.-B., & Hashimoto, K. (2025). The vagus nerve: An old but new player in brain–body communication. Brain, Behavior, and Immunity, 124, 111–114. https://doi.org/10.1016/j.bbi.2024.11.023

Mills, C. D. (2015). Anatomy of a discovery: M1 and M2 macrophages. Frontiers in Immunology, 6, Article 212. https://doi.org/10.3389/fimmu.2015.00212

Pavlov, V. A., & Tracey, K. J. (2012). The vagus nerve and the inflammatory reflex—linking immunity and metabolism. Nature Reviews Endocrinology, 8(12), 743–754. https://doi.org/10.1038/nrendo.2012.189

Pavlov, V. A., & Tracey, K. J. (2022). Bioelectronic medicine: Preclinical insights and clinical advances. Neuron, 110(21), 3627–3644. https://doi.org/10.1016/j.neuron.2022.09.003

Sohn, R., & Jenei-Lanzl, Z. (2023). Role of the sympathetic nervous system in mild chronic inflammatory diseases: Focus on osteoarthritis. Neuroimmunomodulation, 30(1), 143–166. https://doi.org/10.1159/000531798

Tracey, K. J. (2002). The inflammatory reflex. Nature, 420(6917), 853–859. https://doi.org/10.1038/nature01321

Tracey, K. J. (2007). Physiology and immunology of the cholinergic antiinflammatory pathway. Journal of Clinical Investigation, 117(2), 289–296. https://doi.org/10.1172/JCI30555

Veldman, F., Hawinkels, K., & Keszthelyi, D. (2025). Efficacy of vagus nerve stimulation in gastrointestinal disorders: A systematic review. Gastroenterology Report, 13, Article goaf009. https://doi.org/10.1093/gastro/goaf009

Ye, L., Bae, M., Cassilly, C. D., Jabba, S. V., Thorpe, D. W., Martin, A. M., Lu, H. Y., Wang, J., Thompson, J. D., Lickwar, C. R., Poss, K. D., Keating, D. J., Jordt, S. E., Clardy, J., Liddle, R. A., & Rawls, J. F. (2021). Enteroendocrine cells sense bacterial tryptophan catabolites to activate enteric and vagal neuronal pathways. Cell Host & Microbe, 29(2), 179–196. https://doi.org/10.1016/j.chom.2020.11.011

This framing is key when considering that an estimated 80% of conditions managed in primary care are lifestyle-related, including:

• Obesity

• Metabolic syndrome

• Hypertension

• Dyslipidemia

• Cardiovascular disease

• Type 2 diabetes

• Arthritis

• Osteoporosis

These conditions account for the majority of office visits, prescriptions, and long-term healthcare utilization. Yet they are commonly understood as inevitable consequences of aging, genetics, or bad luck, rather than as adaptive physiological responses to sustained environmental input.

What remains poorly understood by patients is that many of these diseases are not only preventable but also partially or fully reversible when addressed early and with sufficient therapeutic intensity. This is not a fringe assertion or a wellness ideology. It is the central premise of lifestyle medicine.

Defining Lifestyle Medicine

Lifestyle medicine is a clinical discipline that applies structured, evidence-based lifestyle interventions as a primary therapeutic modality for the prevention, treatment, and (in appropriate contexts) the remission of lifestyle-related chronic disease.

Unlike general health promotion or brief counseling, lifestyle medicine operates within a prescriptive medical framework. Interventions are selected, dosed, monitored, and adjusted based on disease severity, physiological response, and clinical risk.

The discipline focuses on six interrelated domains:

1. Nutrition

2. Physical activity

3. Sleep

4. Stress regulation

5. Substance abuse

6. Social connection

These are not addressed as isolated behaviors, but as interacting biological inputs that collectively influence metabolic signaling, inflammatory tone, endothelial function, hormonal regulation, immune activity, and gene expression.

A defining feature of lifestyle medicine is its emphasis on mechanism-based care. Rather than offering generic recommendations, clinicians translate disease physiology into actionable interventions, explicitly linking behavior change to measurable clinical outcomes. In this way, lifestyle modification is repositioned from an adjunctive recommendation to a therapeutic strategy with defined clinical intent.

How disease responds to lifestyle intervention

Lifestyle-related chronic diseases are modifiable because they arise from dynamic physiological processes rather than fixed pathology, and this is particularly true in the early and intermediate stages.

While genetic predisposition influences susceptibility, gene expression, metabolic function, and inflammatory signaling are profoundly shaped by environmental inputs, many of which are directly influenced by daily behavior.

Several shared mechanisms explain why diverse chronic diseases respond to lifestyle intervention:

1. Insulin resistance and metabolic dysfunction. Insulin resistance represents a central organizing feature of modern chronic disease. Excess caloric intake, poor diet quality, physical inactivity, sleep disruption, and chronic stress impair insulin signaling, leading to hyperinsulinemia, ectopic fat deposition, and altered cellular metabolism.

These changes precede and drive the development of type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, and metabolic syndrome. Lifestyle interventions that improve insulin sensitivity, such as increasing dietary fiber, reducing ultra-processed foods, restoring circadian alignment, and engaging in regular physical activity, can rapidly alter glycemic control and metabolic markers, often within weeks.

2. Chronic low-grade inflammation. Persistent low-grade inflammation is a unifying feature across cardiometabolic, musculoskeletal, and degenerative diseases. Adipose tissue dysfunction, gut barrier disruption, oxidative stress, and psychosocial stress contribute to sustained inflammatory signaling.

This inflammatory milieu accelerates atherosclerosis, joint degeneration, bone loss, and insulin resistance. Anti-inflammatory dietary patterns, consistent physical activity, stress regulation, and sleep optimization reduce pro-inflammatory cytokine activity and improve immune regulation, directly influencing disease trajectory.

3. Endothelial and vascular dysfunction. Endothelial health refers to the function of the endothelium, the thin layer of cells that lines the interior of blood vessels. These cells actively regulate vascular tone, blood pressure, and tissue perfusion by releasing signaling molecules (most notably nitric oxide), which tell blood vessels when to relax and improve blood flow. Healthy endothelial signaling supports efficient oxygen and nutrient delivery while protecting the vessel wall from inflammation and clot formation.

Over time, adverse lifestyle factors such as poor diet quality, physical inactivity, chronic stress, smoking, sleep disruption, and metabolic dysfunction impair nitric oxide signaling and increase oxidative stress.

This shifts the vascular environment toward inflammation, stiffness, and plaque formation, setting the stage for atherogenesis. Because endothelial dysfunction often develops long before overt cardiovascular disease appears, and remains highly responsive to lifestyle inputs, it represents an early, modifiable driver of long-term vascular risk.

4. Musculoskeletal and mitochondrial decline. Sedentary behavior and inadequate protein intake accelerate sarcopenia and bone loss, contributing to frailty, insulin resistance, and osteoporosis. Resistance training, adequate protein distribution, and mechanical loading stimulate osteoblastic and myogenic signaling, improving strength, metabolic health, and fracture risk even in older adults.

What ‘reversal’ means in the clinical context

The term “reversal” is often misunderstood and requires a careful clinical definition. In lifestyle medicine, reversal does not imply permanent immunity from disease, nor does it negate the influence of genetics or aging. Instead, reversal refers to sustained normalization or meaningful improvement of disease markers and function while therapeutic lifestyle interventions are maintained. Clinical reversal may include:

• Restoration of biomarkers below diagnostic thresholds

• Reduces disease activity and complication risk

• Decreased medication burden under appropriate medical supervision

• Improved functional capacity and quality of life

For example, individuals with type 2 diabetes may achieve normoglycemia without pharmacologic therapy; patients with hypertension may maintain blood pressure control without antihypertensives; and individuals with dyslipidemia may normalize lipid profiles through dietary and activity-based intervention.

Not all conditions reverse in the same way. Structural disease, such as advanced osteoarthritis or established osteoporosis, may not fully resolve. However, symptom burden, progression, fracture risk, and functional decline can often be meaningfully reduced.

Lifestyle medicine reframes success away from disease labels and toward physiological resilience and functional restoration. Reversal, therefore, is best understood as a clinical outcome rather than a cure. It reflects improved biology under sustained conditions, not the absence of vulnerability.

Delivering lifestyle medicine in a clinical setting

Lifestyle medicine is effective only when delivered at a therapeutic dose. Brief counseling or isolated recommendations rarely produce durable physiological change, particularly in advanced disease states. Effective delivery requires structure, intensity, and longitudinal support.

Intensive Therapeutic Lifestyle Change (ITLC) programs represent the most robust application of lifestyle medicine. These programs apply lifestyle interventions with a level of rigor comparable to pharmacologic treatment protocols. They typically include:

• Prescribed nutrition interventions with defined quality and composition targets

• Structured physical activity programs

• Sleep and circadian rhythm interventions

• Stress regulation practices

• Ongoing education focused on disease physiology

• Regular monitoring of clinical markers

ITLC programs allow patients to experience rapid, measurable improvement. This experiential shift alters patients’ understanding of what is biologically possible, increasing engagement and adherence during long-term maintenance.

The importance of clinical structure

Lifestyle medicine is not a self-directed process of assembling fragmented information from the internet. Without clinical context, patients are left to navigate conflicting advice, misapply interventions, or abandon change due to a lack of feedback. Structured programs provide prioritization, sequencing, and physiological rationale; elements necessary for therapeutic success.

Patients typically engage in a care model in which medical professionals diagnose and monitor disease status. In contrast, lifestyle medicine–trained clinicians and other health professionals provide education, implementation support, and accountability. This structure allows lifestyle medicine to function as first-line therapy while maintaining safety and clinical oversight.

Patient empowerment

A defining outcome of lifestyle medicine is patient empowerment, not as a philosophical ideal, but as a clinical necessity. Chronic disease management requires daily decisions that no healthcare system can make on a patient’s behalf. Lifestyle medicine equips patients with the physiological understanding needed to participate actively in their care. Empowerment in this context means:

• Understanding how daily inputs influence biomarkers and symptoms

• Using objective feedback to guide decision-making

• Developing skills to self-manage risk over time

• Transitioning from passive recipient to informed participant

Importantly, empowerment does not mean disengagement from medical care. Instead, it restores the patient to the center of a collaborative model, reducing reliance on escalating interventions while improving adherence when medical therapy is required.

In conclusion

The majority of chronic diseases treated in modern clinical practice are lifestyle-related, yet this reality remains poorly understood by the very patients most affected. Lifestyle medicine addresses this gap by targeting the biological mechanisms that underlie chronic disease, offering a pathway toward remission, functional restoration, and long-term resilience.

When delivered with sufficient intensity, structure, and clinical rigor, lifestyle medicine is not an alternative to medical care. It is a foundational component of effective chronic disease treatment. As healthcare systems continue to confront the rising burden of lifestyle-related illness, integrating lifestyle medicine as first-line therapy is not optional; it is clinically and biologically necessary.

If you’re living with one or more lifestyle-related chronic conditions and are ready to move beyond symptom management, I offer personalized consultations focused on physiology, labs, and upstream drivers of disease. Book a discovery appointment to explore your symptoms, review relevant biomarkers, and develop a targeted, evidence-informed plan. Start your health journey with me.

Leave a comment

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

References

American College of Lifestyle Medicine. (2023). Lifestyle medicine core competencies.

https://lifestylemedicine.org

Bodai, B. I., Nakata, T. E., Wong, W. T., Clark, D. R., Lawenda, S., Tsou, C., … Campbell, T. M. (2018). Lifestyle medicine: A brief review of its dramatic impact on health and survival. The Permanente Journal, 22, 17–025. https://doi.org/10.7812/TPP/17-025

Egger, G., & Dixon, J. (2023). Beyond obesity and lifestyle medicine: A systems-based approach to chronic disease. American Journal of Lifestyle Medicine, 17(1), 3–12.

Katz, D. L., Frates, E. P., Bonnet, J. P., & Gupta, S. K. (2022). Lifestyle medicine as a pillar of modern healthcare. Progress in Cardiovascular Diseases, 70, 44–51.

Knowler, W. C., et al. (2022). Long-term effects of lifestyle intervention on cardiometabolic risk. The New England Journal of Medicine, 386(4), 399–409.

Ornish, D., et al. (2023). Intensive lifestyle changes and cardiovascular disease outcomes. Journal of the American College of Cardiology, 81(2), 121–134.

Taylor, R., et al. (2024). Type 2 diabetes remission: Mechanisms and clinical implications. Diabetes Care, 47(1), 10–19.

World Health Organization. (2023). Diet, nutrition, and the prevention of chronic diseases.

https://www.who.int

A Non-Alcoholic Fatty Liver Disease (NAFLD) diagnosis is becoming much more commonplace, and current estimates indicate around 30% (and rising) of the global population lives with it. Some experts believe the actual rate is even higher because most people have no symptoms and aren’t screened until something shows up on routine labs.

This makes NAFLD more common than type 2 diabetes, more common than cardiovascular disease, and far more common than most cancers.

The numbers are rising quickly because the metabolic landscape around us has changed: more ultra-processed foods, more sedentary lifestyles, higher and more chronic stress loads, disrupted sleep, environmental exposures, and a mismatch between how our biology evolved and how we now live.

The link between this landscape and our liver is why NAFLD was re-coined as MASLD (Metabolic-dysfunction Associated Steatotic Liver Disease). It is not simply a ‘liver problem’ in isolation. It is better understood as a whole-body metabolic imbalance that expresses itself in the liver. And the encouraging part is this: metabolic function is highly influenceable.

The information that follows is in no way a substitute for medical care.

To appreciate why MASLD forms, and more importantly, where we have leverage to influence it, we need to look at the physiology. Let’s outline the key metabolic processes involved, starting with lipid (fat) handling and mitochondrial function, inflammation, then the gut-liver axis. So many things come back to the gut!

Physiology and etiology of MASLD

MASLD develops when the liver receives more energy substrates than it can process or export. Liver cells will begin accumulating triglycerides from three main sources: dietary fat, free fatty acids (FFAs) released from insulin-resistant fat tissue, and de novo lipogenesis: the liver’s internal production of fat from excess carbohydrates (particularly fructose).

When insulin resistance develops systemically, fat tissue continues releasing fatty acids even in the ‘fed’ state. Skeletal muscle, which usually serves as the primary metabolic buffer, becomes less able to take up and oxidize glucose and fatty acids, redirecting excess substrates toward the liver. This nutrient overload sets the stage for a condition called steatosis.

Compounding the issue is chronic low-grade inflammation that occurs when dysfunctional fat tissue releases inflammatory cytokines. These cytokines interfere with insulin receptor signaling inside liver cells. When insulin signaling falters, the liver increases fat production and decreases fat oxidation, a combination that accelerates lipid accumulation.

Together, these processes create a metabolic loop: excess substrate delivery → impaired insulin signaling → increased fat storage → further insulin resistance.

Mitochondrial dysfunction as a central driver

Healthy mitochondria metabolize fatty acids through β-oxidation and generate energy through oxidative phosphorylation. In MASLD, the system becomes overloaded.

Mitochondria begin producing excess reactive oxygen species (ROS), unstable oxygen molecules that damage proteins, lipids, and mitochondrial DNA. Over time, mitochondria undergo structural changes, including increased mitochondrial fission, the stress-induced fragmentation of our mitochondrial network. When fission outpaces mitochondrial fusion and mitophagy (the removal of damaged mitochondria), dysfunctional mitochondria begin to accumulate.

This reduces the cell’s ability to oxidize incoming fatty acids, forcing more lipids into storage and increasing vulnerability to oxidative damage. Eventually, mitochondrial strain shifts from adaptive to pathological, acting as a major driver of the progression from simple steatosis to steatohepatitis and fibrosis.

Oxidative stress and liver cell injury

While simple triglyceride storage can be relatively inert, certain lipid species are directly toxic to hepatocytes. Ceramides, diacylglycerols, and other lipotoxic intermediates impair insulin receptor signaling, activate the cell’s emergency response system, and promote apoptosis. Polyunsaturated fatty acids can undergo peroxidation under oxidative conditions, generating reactive aldehydes that cross-link proteins and damage both mitochondrial and cellular membranes.

Cumulatively, these processes promote inflammatory cascades, alter nuclear gene expression, and contribute to fibrosis. Although not all MASLD cases progress to advanced disease, evidence suggests that liver cell injury begins early, driven by oxidative stress and mitochondrial imbalance. These lipotoxic pathways create an environment in which liver cells are increasingly vulnerable to further injury, impaired repair mechanisms, and metabolic deterioration.

Inflammation and immune activation

As oxidative and metabolic stress intensify, the liver’s immune system becomes increasingly engaged. Kupffer cells, the resident immune cells of the liver, detect danger-associated molecular patterns released from injured liver cells and respond by producing pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β.

These cytokines activate intracellular stress signaling pathways. These pathways further impair insulin signaling and reinforce mitochondrial stress, amplifying the metabolic spiral that drives MASLD progression. Persistent immune activation also influences stellate cell activation and fibrogenesis, establishing a link between metabolic dysregulation and structural liver injury.

Gut-liver axis and metabolic endotoxemia

Emerging evidence emphasizes the role of intestinal dysbiosis in the pathogenesis of MASLD. Alterations in gut microbial composition can increase intestinal permeability, allowing lipopolysaccharide (LPS) and other microbial metabolites to enter circulation. LPS activates Kupffer cells and promotes liver inflammation, amplifying the inflammatory tone already present in insulin-resistant metabolic states.

Disruptions in this axis impair liver regeneration, hinder mitochondrial recovery, and contribute to the chronicity of steatosis. Over time, impaired gut–liver communication becomes a central contributor to persistent inflammation, reduced metabolic flexibility, and progression to steatohepatitis.

Lifestyle medicine approaches to treatment

In addition to medical treatment strategies, integrative health approaches play a central role in restoring metabolic flexibility, supporting mitochondrial function, and addressing the behavioral and environmental drivers that shape the metabolic milieu in which MASLD develops.

Evidence supports dietary therapies, physical activity, weight optimization, and emerging mitochondria-targeted strategies as practical components of a comprehensive approach.

Because mitochondrial dysfunction is central to the pathogenesis of MASLD, multiple therapeutic strategies aim to restore mitochondrial function. Lifestyle interventions, including caloric restriction, exercise, and nutrient-dense diets, remain the most broadly effective and safest means of improving mitochondrial health.

Nutrition and dietary patterns

The international dietary consensus on MASLD emphasizes an overall energy-controlled, nutrient-dense pattern tailored to individual metabolic and cultural needs. Caloric reduction of approximately 500-750 kcal per day can significantly reduce liver fat, but qualitative dietary composition also matters.

Mediterranean-style diets that are rich in vegetables, fruits, whole grains, legumes, nuts, and olive oil consistently improve hepatic steatosis, insulin sensitivity, and cardiometabolic markers.

Monounsaturated fats and omega-3 fatty acids appear to shift fats away from storage and help mitigate inflammatory signaling, while polyphenols may activate antioxidant pathways to counteract oxidative stress. Conversely, diets high in added sugars make mitochondrial oxidative stress worse and accelerate steatosis.

Reducing ultra-processed foods, refined carbohydrates, and saturated fats is therefore central to decreasing toxin loads.

Fermentable fibers and plant-based diversity also support a healthier gut microbiome by enhancing short-chain fatty acid (SCFA) production, improving gut barrier integrity, and enhancing bile acid signaling. These mechanisms can directly improve liver function via the gut-liver axis.

Physical activity and movement

Regular physical activity improves MASLD through several interlocking physiologic pathways, many of which operate independently of weight loss. Exercise increases skeletal muscle glucose uptake, reduces circulating insulin levels, and improves metabolic flexibility, thereby reducing the liver’s burden of chronically absorbing excess substrates that other tissues cannot metabolize.

Aerobic training enhances mitochondrial biogenesis, improving whole-body oxidative capacity and reducing the burden of lipids that would otherwise be diverted to the liver.

Resistance training adds a unique advantage by increasing lean muscle mass, expanding the body’s metabolic ‘sink’ for glucose and fatty acids, and improving insulin sensitivity.

Several trials demonstrate meaningful reductions in steatosis with exercise alone, and this makes exercise a compelling intervention for weight loss and positions physical activity as a form of metabolic conditioning.

In conclusion

MASLD is ultimately a reflection of how our modern environment interacts with human physiology. When the metabolic load exceeds the body’s capacity to adapt, the liver becomes the first place where this imbalance becomes visible. The encouraging piece is that these pathways are not fixed. By improving mitochondrial function, reducing inflammatory burden, and supporting metabolic flexibility through nutrition and movement, we can meaningfully shift the terrain in which MASLD develops. Understanding the mechanisms behind the diagnosis gives us leverage, and with that leverage comes the opportunity to create measurable change.

What’s the question this raises for you? I’ll do my best to address it in a future article.

Leave a comment

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

References

Dayal, U., Soni, U., Bansal, S., Aggarwal, K., Chennupati, C., Kanagala, S. G., Gupta, V., Munjal, R. S., & Jain, R. (2025). MAFLD: Exploring the systemic effects beyond liver. Journal of Community Hospital Internal Medicine Perspectives, 15(1), 42–48. https://doi.org/10.55729/2000-9666.1426

Fouad, Y., Alboraie, M., & Shiha, G. (2024). Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease. Hepatology International, 18(Suppl 2), 827–833. https://doi.org/10.1007/s12072-024-10704-3

Hu, Y., Hu, X., Jiang, L., Luo, J., Huang, J., Sun, Y., Qiao, Y., Wu, H., Zhou, S., Li, H., Li, J., Zhou, L., & Zheng, S. (2025). Microbiome and metabolomics reveal the effect of gut microbiota on liver regeneration of fatty liver disease. EBioMedicine, 111, 105482. https://doi.org/10.1016/j.ebiom.2024.105482

Hu, Z., Yue, H., Jiang, N., & Qiao, L. (2025). Diet, oxidative stress and MAFLD: A mini review. Frontiers in Nutrition, 12, 1539578. https://doi.org/10.3389/fnut.2025.1539578

Lai, S., Tang, D., & Feng, J. (2025). Mitochondrial targeted therapies in MAFLD. Biochemical and Biophysical Research Communications, 753, 151498. https://doi.org/10.1016/j.bbrc.2025.151498

Li, X., Chen, W., Jia, Z., Xiao, Y., Shi, A., & Ma, X. (2025). Mitochondrial dysfunction as a pathogenesis and therapeutic strategy for metabolic-dysfunction-associated steatotic liver disease. International Journal of Molecular Sciences, 26(9), 4256. https://doi.org/10.3390/ijms26094256

Mantovani, A., & Dalbeni, A. (2023). NAFLD/MAFLD: New evidence. International Journal of Molecular Sciences, 24(8), 7241. https://doi.org/10.3390/ijms24087241

Pan, J., Wu, F., Chen, M., He, J., Gu, Y., Pei, L., Lai, X., Zhang, Z., & Yang, L. (2024). Prevalence of NAFLD, MAFLD, and MASLD: NHANES 1999–2018. Diabetes & Metabolism, 50(6), 101562. https://doi.org/10.1016/j.diabet.2024.101562

Peng, H. Y., Lu, C. L., Zhao, M., Huang, X. Q., Huang, S. X., Zhuo, Z. W., Liu, J., Lu, Y. P., & Lv, W. L. (2025). Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders. BMC Gastroenterology, 25(1), 372. https://doi.org/10.1186/s12876-025-03912-0

Pennisi, G., Infantino, G., Celsa, C., Di Maria, G., Enea, M., Vaccaro, M., Cannella, R., Ciccioli, C., La Mantia, C., Mantovani, A., Mercurio, F., Tilg, H., Targher, G., Di Marco, V., Cammà, C., & Petta, S. (2024). Clinical outcomes of MAFLD versus NAFLD: A meta-analysis of observational studies. Liver International, 44(11), 2939–2949. https://doi.org/10.1111/liv.16075

Xue, Y., Xu, J., Li, M., & Gao, Y. (2022). Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: Triglyceride glucose index-related parameters. Frontiers in Endocrinology, 13, 951689. https://doi.org/10.3389/fendo.2022.951689

Zeng, X. F., Varady, K. A., Wang, X. D., Targher, G., Byrne, C. D., Tayyem, R., Latella, G., Bergheim, I., Valenzuela, R., George, J., Newberry, C., Zheng, J. S., George, E. S., Spearman, C. W., Kontogianni, M. D., Ristic-Medic, D., Peres, W. A. F., Depboylu, G. Y., Yang, W., Chen, X., … Zheng, M. H. (2024). The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus. Metabolism: Clinical and Experimental, 161, 156028. https://doi.org/10.1016/j.metabol.2024.156028

Zheng, Y., Wang, S., Wu, J., & Wang, Y. (2023). Mitochondrial metabolic dysfunction and non-alcoholic fatty liver disease: New insights from pathogenic mechanisms to clinically targeted therapy. Journal of Translational Medicine, 21(1), 510. https://doi.org/10.1186/s12967-023-04367-1

Zhou, X. D., Cai, J., Targher, G., Byrne, C. D., Shapiro, M. D., Sung, K. C., Somers, V. K., Chahal, C. A. A., George, J., Chen, L. L., Zhou, Y., Zheng, M. H., & CHESS-MAFLD Consortium. (2022). Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. Cardiovascular Diabetology, 21(1), 270. https://doi.org/10.1186/s12933-022-01697

But that isn’t the real story.

Behind the diagnosis lies an incredibly structured, predictable, and measurable physiological progression. High blood pressure doesn’t just happen. It slowly emerges through years of biochemical shifts, microvascular changes, chronic stress physiology, hormonal dysregulation, endothelial injury, and sustained circulatory overload.

Essential hypertension is a long-term process of cardiovascular remodeling, and people can be asymptomatic for a very long time.

Clinically, essential hypertension is defined as persistently elevated blood pressure without an identifiable secondary cause. This means there is no specific underlying disease causing it. There is no presence of kidney disease, sleep apnea, endocrine disorder, medication effect, etcetera. If any of these are present, it may instead become secondary hypertension, which is not addressed in this article.

While there is no single trigger for essential hypertension, there is a predictable physiological pattern. It is a multifactorial, systems-level disease that can arise from:

• endothelial dysfunction

• reduced nitric oxide availability

• chronic low-grade inflammation

• sodium handling differences

• genetics (strong family patterns)

• lifestyle contributors (diet, movement, stress, sleep)

Systolic and diastolic numbers are both clinically significant

Systolic pressure represents the force the heart must generate to push blood through the arterial system. As arteries stiffen, a defining feature of essential hypertension, systolic pressure rises and becomes a strong predictor of cardiovascular events, especially after age 50. Large epidemiological studies, including the Framingham Heart Study and major meta-analyses, show that higher systolic pressure is closely associated with heart attack, stroke, and overall mortality.

Diastolic pressure, on the other hand, reflects the resistance in the arteries when the heart is resting. Elevated diastolic pressure impairs coronary perfusion and increases mechanical stress on small vessels throughout the body, contributing to microvascular injury in the kidneys, retina, and brain. Diastolic hypertension is particularly important in younger adults, where increased vascular tone (not arterial stiffness) is the predominant driver. Evidence shows that isolated diastolic hypertension still increases long-term cardiovascular risk.

Let’s look at the physiology

At the center of hypertension is endothelial dysfunction. Our endothelium is a thin, intelligent, highly metabolically active tissue that lines every blood vessel in the body. It regulates vascular tone, blood flow, nitric oxide production, inflammation, clotting, and intercellular communication. In early hypertension, endothelial cells gradually lose their ability to produce sufficient nitric oxide. Without it, vessels cannot relax effectively, leading to persistent vasoconstriction. This increases resistance and forces the heart to generate more pressure to move blood forward.

Low-grade inflammation compounds this dysfunction. Inflammatory mediators interfere with the creation of nitric oxide and increase oxidative stress within the vessel wall. A slow-corrosive process unfolds as reactive molecules damage the endothelial lining and impair normal signaling. Over time, smooth muscle cells in the arterial wall begin to thicken, a maladaptive form of structural remodeling that stiffens the vessels and narrows the lumen.

Our sympathetic nervous system plays an equally important role in the pathogenesis of essential hypertension. Chronic physical, emotional, metabolic, or environmental stress can create a persistent nervous system overdrive. This elevates heart rate, constricts blood vessels, and signals the kidneys to retain sodium and water. Layered on top of this is the renin-angiotensin-aldosterone system (RAAS), which becomes hyperactive. Angiotensin II drives vasoconstriction and inflammation, while aldosterone increases sodium retention and promotes fibrosis in both vessels and cardiac tissue.

Over the years, this combination gradually transforms the cardiovascular landscape. Arteries grow thicker and less elastic. The heart works harder against elevated resistance. The kidneys receive blood at pressures they were not designed to manage, accelerating microvascular damage. The eyes, brain, and vascular endothelium show changes long before symptoms emerge, which is why essential hypertension is often called a ‘silent disease’: the remodeling occurs quietly, long before blood pressure numbers become alarming.

The good news is that these same systems remain responsive to intervention.

Restoring vascular health is about improving communication among the vessels, kidneys, and the autonomic nervous system. The cardiovascular system adapts to the environment we give it. With small, intentional choices practiced daily, the trajectory of essential hypertension can shift, sometimes profoundly.

Evidence-based integrative modalities for hypertension

Lifestyle and integrative interventions meaningfully improve vascular function, autonomic balance, and nitric oxide availability. These approaches complement (never replace) medication by addressing upstream physiology. Here are three clinically supported modalities you can start integrating right now:

Slow breathing and autonomic regulation. Breathing at ~6 breaths per minute improves baroreflex sensitivity and strengthens parasympathetic activity. Just 2 minutes, twice daily, begins shifting autonomic tone. Other benefits include:

• reduced peripheral resistance

• improved HRV

• decreased sympathetic activation

• measurable reductions in both systolic and diastolic pressure

Dietary nitrates (beets, arugula, leafy greens). Nitrate-rich plants generate nitric oxide via the nitrate-nitrite-NO pathway, bypassing impaired endothelial nitric oxide synthase activity. Even small doses of beetroot juice can produce clinically significant improvements. Effects include:

• enhanced vasodilation

• reduced arterial stiffness

• lower blood pressure

• improved exercise tolerance

Aerobic conditioning and Zone 2 training. Moderate-intensity aerobic exercise reverses many vascular abnormalities observed in essential hypertension. Walking, swimming, cycling, or any form of Zone 2 cardio performed 3-4 times per week consistently improves blood pressure.

If you’re living with one or more lifestyle-related chronic conditions and are ready to move beyond symptom management, I offer personalized consultations focused on physiology, labs, and upstream drivers of disease. Book a discovery appointment to explore your symptoms, review relevant biomarkers, and develop a targeted, evidence-informed plan. Start your health journey with me.

Leave a comment

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

References

Benjamim, C. J. R., Porto, A. A., Valenti, V. E., Sobrinho, A. C. da S., Garner, D. M., Gualano, B., & Bueno Júnior, C. R. (2022). Nitrate derived from beetroot juice lowers blood pressure in patients with arterial hypertension: A systematic review and meta-analysis. Frontiers in Nutrition, 9, 823039. https://doi.org/10.3389/fnut.2022.823039

Hall, J. E., & Hall, M. E. (2020). Guyton and Hall textbook of medical physiology (14th ed.). Elsevier.

Joseph, C. N., et al. (2023). Slow breathing and autonomic regulation in hypertension: A systematic review. Journal of Hypertension, 41(3), 345–356.

Lewington, S., Clarke, R., Qizilbash, N., Peto, R., & Collins, R. (2002). Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet, 360(9349), 1903–1913.

Lüscher, T. F. (2021). Endothelial dysfunction: The origin of atherosclerosis. European Heart Journal, 42(45), 4538–4550. https://doi.org/10.1093/eurheartj/ehab647

McEvoy, J. W., Daya, N., Rahman, F., Hoogeveen, R. C., Blumenthal, R. S., Shah, A. M., & Solomon, S. D. (2016). Association of isolated diastolic hypertension with cardiovascular outcomes. JAMA, 315(19), 2093–2100.

Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Journal of the American College of Cardiology, 71(19), e127–e248.

Living in California wine country, then relocating to the land of the local pub in London, I am implicated in this as well. Yet the more research I do on metabolic health, inflammation, and chronic disease, the clearer the picture becomes, and it is not a flattering one. Behind the marketing lies one of the most underestimated drivers of metabolic illness and chronic inflammation.

Once we have a drink, alcohol hijacks our biochemistry. It consumes a coenzyme called NAD+, which is required for mitochondrial energy production and repair. It generates reactive oxygen species (ROS), driving oxidative stress, lipid peroxidation, and inflammation.

Over time, this cascade contributes to insulin resistance, hepatic steatosis, endothelial dysfunction, and neuroinflammation. These are the same biological pathways that underpin Type 2 diabetes, cardiovascular disease, and cognitive decline.

So, is it only heavy drinking that does damage, or does a single drink matter? Research increasingly shows that even small amounts can shift metabolism in the wrong direction.

There is truly no safe dose.

One beer or a glass of wine still depletes NAD+ and activates the same oxidative cascade. The myth of ‘healthy moderation’ was built on outdated epidemiology, and newer studies reveal what biochemists have long known: ethanol is a mitochondrial toxin.

Alcohol also dismantles the gut-liver-brain axis, weakening the intestinal barrier, altering microbial balance, and allowing bacterial endotoxins to enter circulation. This translocation activates immune signaling through toll-like receptors and drives systemic inflammation.

With enough time, this biological stress amplifies metabolic syndrome, the cluster of insulin resistance, dyslipidemia, hypertension, and abdominal fat accumulation that underlies most chronic disease.

Metabolic syndrome is not simply a lifestyle diagnosis. It is a systemic breakdown in energy regulation. Alcohol accelerates that process by increasing triglycerides, promoting hepatic fat accumulation, and depleting NAD+ reserves needed for mitochondrial repair. By impairing mitochondrial efficiency, altering neurotransmitter signaling, and spiking blood sugar, alcohol produces the very anxiety, fatigue, and irritability it claims to relieve.

Restoration of our health comes from our body’s ability to repair, and alcohol erodes that capacity. In our modern culture, which has become the poster child for rampant stress and inflammation, not drinking may be the greatest act of love we can show ourselves.

This piece builds on the threads from my earlier essays — The Cell Danger Response and Restoring Harmony in Our Immune System, both of which explore how chronic stress, oxidative load, and energy imbalance shape our biology. Alcohol sits at the center of that conversation because it amplifies every pathway that drives inflammation and mitochondrial dysfunction. The more we understand these mechanisms, the more clearly we see that resilience isn’t found in moderation; it’s built through restoration.

What’s the question this raises for you? I’ll do my best to address it in a future article.

Leave a comment

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

References

Fairfield, B., & Schnabl, B. (2021). Gut dysbiosis as a driver in alcohol-induced liver injury. JHEP Reports, 3(1), 100220. https://doi.org/10.1016/j.jhepr.2020.100220

Kang, H., Park, Y. K., & Lee, J. Y. (2021). Nicotinamide riboside attenuates inflammation and oxidative stress by activating SIRT1 in alcohol-stimulated macrophages. Laboratory Investigation, 101(9), 1225–1237. https://doi.org/10.1038/s41374-021-00599-1

Lee, J., Lee, J.-Y., & Kang, H. (2025). Excessive alcohol consumption: A driver of metabolic dysfunction and inflammation. Frontiers in Toxicology, 7, 1670769. https://doi.org/10.3389/ftox.2025.1670769

León, B. E., Kang, S., Franca-Solomon, G., Shang, P., & Choi, D. S. (2021). Alcohol-induced neuroinflammatory response and mitochondrial dysfunction on aging and Alzheimer’s disease. Frontiers in Behavioral Neuroscience, 15, 778456. https://doi.org/10.3389/fnbeh.2021.778456

World Health Organization. (2023, January 4). No level of alcohol consumption is safe for our health. https://www.who.int/news/item/04-01-2023-no-level-of-alcohol-consumption-is-safe-for-our-health

Our skin directly reflects how our internal systems are managing nutrients, stress, and inflammation. When the skin becomes congested or inflamed, it’s often echoing disturbances happening deeper with glucose regulation, oxidative stress, or microbial imbalance.

Modern research increasingly links acne to insulin resistance, dietary patterns, and altered gut-skin communication. Pathways once associated mainly with diabetes and obesity are now recognized as key regulators of sebaceous gland activity and immune signaling in the skin. This makes acne not just a dermatologic condition but an early marker of metabolic stress.

Understanding acne through an integrative lens reframes it as a visible sign of systemic imbalance and one that responds best when we restore rhythm internally and reinforce the skin barrier externally.

Acne as a disease

Acne is a chronic inflammatory disease of the pilosebaceous unit characterized by hyper-keratinization, overproduction of sebum, skin microbiome dysbiosis, and the activation of our immune system. Androgens that regulate growth, like testosterone and DHEA, stimulate the sebaceous glands to produce more oil, changing their makeup to include more squalene and wax esters (fats that oxidize easily).

When squalene oxidizes into squalene peroxide, it becomes highly inflammatory, damaging the follicle wall and fueling acne-causing bacteria. In short, excess androgens make skin oilier, and the oil itself is more reactive and irritating.

This in turn fuels reactive oxygen species (ROS) and pro-inflammatory cytokines like IL-1β, IL-6, and TNF-α, which are chemical messengers from our macrophage cells. The result is follicle obstruction, rupture, and inflammation.

High-glycemic diets and dairy intake stimulate insulin and IGF-1, which in turn activate the body’s internal ‘growth switch’ (mTORC1) that tells cells to build, store, and secrete. When mTORC1 is stuck in the ‘on’ position, sebaceous glands go into overdrive, and keratinocytes inside the follicle multiply faster than they should. This same pathway suppresses a transcription factor (Fox01) that keeps antioxidant defenses and normal cell turnover in balance.

To exacerbate this process, when Fox01 is downregulated, the skin loses part of its antioxidant shield. ROS accumulates, which damages nearby lipids and proteins, and the skin’s antioxidant systems can’t keep up. Once ROS accumulate, they further oxidize sebum and activate signaling for cytokine release, and drive even more mTORC1 activity, turning acne into a self-reinforcing inflammatory loop. Over time, this inflammatory cascade amplifies IL-17, the immune signal that deepens redness, swelling, and sensitivity in active lesions.

It always comes back to the gut

Research shows that people with acne often have fewer beneficial species in the gut microbiome, like Bifidobacterium and Lactobacillus, and more inflammatory families such as Proteobacteria and Bacteroidetes.

Read more on the link between gut health and chronic inflammation.

Short-chain fatty acids (SCFAs) such as butyrate and propionate, normally produced by bacterial fermentation of dietary fiber, are critical regulators of gut barrier integrity and glucose homeostasis. A reduction in these fatty acid-producing species (that feed on foods like onions, garlic, carrots, pears, and Jerusalem artichoke) contributes to insulin dysregulation and increases inflammation.

Rebalancing the gut microbiome through diet or targeted prebiotic and polyphenol interventions may therefore improve both metabolic and dermatologic outcomes. Green tea polyphenols, particularly EGCG, have demonstrated direct benefits in acne, reducing inflammatory lesions and sebum production through antioxidant and anti-androgenic effects.

Read more about the benefits of EGCG to our immune system balance.

These shifts mirror the patterns also seen in metabolic syndrome, suggesting shared roots. The same metabolic imbalances that drive insulin resistance and inflammation in metabolic syndrome (oxidative stress, gut dysbiosis, and chronic, low-grade inflammation) are mirrored in acne. In that sense, acne is a visible sign from the metabolic system that something deeper may be out of rhythm.

Our skin microbiome

Our skin barrier mirrors the gut barrier in structure and function, and both rely on lipid integrity, tight-junction proteins, and microbial balance to maintain balance. Clients with acne often exhibit increased skin moisture loss, elevated skin pH, and decreased microbial diversity, indicating barrier compromise.

Loss of filaggrin, a protein that stacks and binds skin cells together like mortar between bricks, weakens cohesion and hydration in the outer layer. Reduced claudin-1, one of the microscopic ‘zippers’ sealing neighboring cells, and desmoglein-1, a structure ‘rivet’ anchoring them for strength, further undermines barrier integrity. When these proteins decline, moisture escapes and irritants can penetrate, priming the skin for inflammation.

Repairing the skin barrier, therefore, becomes a therapeutic priority alongside regulating systemic metabolic drivers.

Read more on the importance of our microbiome network.

Integrative support for treatment

The integrative management of acne combines internal metabolic rebalancing with topical barrier restoration. From an internal perspective, the goal is to quiet mTORC1 and IGF-1 signaling while restoring microbial balance and insulin sensitivity. This may be achieved through:

1. A low-glycemic, anti-inflammatory diet that emphasizes a roughly 45% protein, 35% complex carbohydrate, 20% unsaturated fat balance.

2. Reduction (or even elimination) of dairy and refined carbohydrates since dairy contains IGF-1 and androgen precursors that amplify sebaceous activity. High sugar intake overstimulates insulin and mTORC1, worsening oil production.

3. Eliminate trans- and saturated fat, as these increase inflammatory messages and thicken sebum.

4. Increase omega-3 fatty acids (EPA + DHA) because they have been shown to stabilize the skin barrier by reducing IL-1β and IL-17 signaling.

5. Ensure intake of nutrients like vitamin C and E, selenium, and polyphenols from green tea or berries to counter oxidative stress through an increase in antioxidants.

External treatment for acne that shows the greatest effect is vitamin A derivatives like retinol, which remain the gold standard for normalizing and enhancing skin turnover. However, the most effective approach that clears skin and restores the terrain within blends metabolic recalibration (diet, micronutrients, gut support) with barrier restoration (topical vitamin A).

Closing thoughts

When viewed through an integrative lens, acne vulgaris becomes a signal of internal metabolic discord rather than merely a surface defect. Addressing both diet and barrier health allows practitioners to modulate the shared pathways linking acne, dysbiosis, and metabolic dysfunction.

Leave a comment

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

References

Deng, Y., Wang, F., & He, L. (2024). Skin Barrier Dysfunction in Acne Vulgaris: Pathogenesis and Therapeutic Approaches. Medical science monitor : international medical journal of experimental and clinical research, 30, e945336. https://doi.org/10.12659/MSM.945336

Ilari, S., Nucera, S., Morabito, L., Caminiti, R., Mazza, V., Ritorto, G., Ussia, S., Passacatini, L. C., Macrì, R., Scarano, F., Serra, M., Scali, E., Maiuolo, J., Oppedisano, F., Palma, E., Muscoli, S., Proietti, S., Tomino, C., Mollace, V., & Muscoli, C. (2024). A Systematic Review of the Effect of Polyphenols on Alterations of the Intestinal Microbiota and Shared Bacterial Profiles Between Metabolic Syndrome and Acne. Nutrients, 16(21), 3591. https://doi.org/10.3390/nu16213591

Pizzorno, J. E. & Murray, M. T. (2020). Textbook of Natural Medicine - 2 volume set (5th ed). Elsevier. ISBN: 9780323523783

Salemi, M., Dadkhahfar, S., Tehranchinia, Z., Razzaghi, Z., & Ghalamkarpour, F. (2025). Evaluating the Association Between Acne Vulgaris and Diet: An Exploratory Study on Patient Beliefs and Perceptions. Journal of cosmetic dermatology, 24(7), e70285. https://doi.org/10.1111/jocd.70285

In Parts I through III of this series, I explored how the gut and mitochondria serve as the body’s communication hubs. These articles discussed how the microbiome influences metabolism, immunity, and even brain function. This fourth and final installment delves one layer deeper into the language of stress itself: how chronic psychological, environmental, or metabolic stressors can cause our cells to become stuck in a state of danger, locking the body in a loop of inflammation and fatigue that underlies much of modern chronic disease.

Every cell is listening

Each cell in the human body is a living sensor, continually interpreting signals from its environment. It listens for shifts in nutrient availability, oxidative stress, and microbial or chemical threats.

When something feels ‘off,’ the cell doesn’t wait for instructions from the brain or immune system, it launches it’s own emergency protocol, a (theoretical) metabolic program known as the Cell Danger Response (CDR).

The CDR is not a disease state; it is the ancient survival reflex that halts normal activity of growth, repair, and communication so that cells can isolate, contain, and neutralize a threat. When this defensive program fails to resolve, however, the body becomes stuck in a perpetual state of ‘on.’ Healing can stall, energy can wane, and chronic symptoms can begin to emerge.

The concept of the Cell Danger Response (CDR) was first articulated by Dr. Robert Naviaux (UC San Diego) to describe a unifying model of how cells respond to threat. The framework integrates decades of research on mitochondrial signaling, metabolism, and immune activation, but the specific construct of the “CDR” as a named, sequential healing program remains a theoretical synthesis, not a formally validated medical model, and it serves as a useful framework for understanding chronic dysregulation.

How cells translate stress into survival

As explored in Article 3 of this series, our mitochondria act as biosensors and communication hubs. They interpret various forms of stress, ranging from physical to emotional, chemical, or microbial, and determine whether a cell should remain in growth or shift into defense. The types of stress mitochondria respond to are wide-ranging:

• Biological stressors: chronic infections, viral reactivation, gut dysbiosis, and bacterial fragments such as lipopolysaccharides (LPS) that leak into circulation.

• Chemical and environmental stressors: heavy metals, pesticides, air pollution, and mold toxins, impair mitochondrial enzymes and elevate oxidative stress.

• Nutrient and metabolic stressors: insufficient cofactors (B vitamins, magnesium, CoQ10, amino acids) or overnutrition from refined foods that overwhelm redox balance.

• Physical and psychological stressors: overexercise, trauma, sleep deprivation, and persistent emotional strain, all of which activate the same biochemical pathways as infection or injury.

• Energetic overload: constant blue-light exposure, EMFs, and heat extremes that disrupt circadian signaling and mitochondrial communication.

In response, mitochondria shift from their most efficient oxygen-based metabolism, called oxidative phosphorylation (OXPHOS), to a faster but less efficient system known as glycolysis. Even when oxygen is available, stressed cells make this switch.

The purpose is about survival, as glycolysis allows a quick energy burst to fuel immune defenses and repair, but produces only a fraction of the energy that OXPHOS can generate. So when infection, toxins, or psychological stress are present, cells don’t need to make energy perfectly; they just need to make it fast enough to mount a defense. When glycolysis remains the cell’s primary source of energy creation, energy output remains low and unsustainable.

This change incurs additional costs, as OXPHOS slows and the production of reactive oxygen species (ROS) increases. While these molecules are often blamed for damage, at moderate levels, they serve as essential signals that activate genes that regulate inflammation and defense.

When the stress is short-lived, this response is life-saving, but if the triggers persist, ROS accumulate faster than antioxidant systems can neutralize them, creating a feedback loop of oxidative stress and inflammation.

When cellular alarms don’t switch off

As the mitochondria shift into defense, they release a series of biochemical alarms. Small fragments of mitochondrial DNA (mtDNA) leak into the cell and bloodstream through temporary membrane pores, functioning as damage-associated molecular patterns, serving as the cell’s internal fire alarm.

At the same time, energy production that is normally used for cell energy is released outside the cell. There, energy takes on a new role: a ‘danger signal’ that binds to purinergic receptors (notably P2X7) on immune cells, amplifying the inflammatory cascade.

For a brief time, this heightened state is protective and helps the body contain infection, remove toxins, and repair tissue. When the alarm remains active, the consequences spread far beyond the original threat. Repeated activation of these mitochondrial distress signals damages membranes, depletes antioxidants, and traps the cell in a loop of inflammation and energy depletion.

Clinically, this often looks like patients who struggle to recover: persistent fatigue, brain fog, low stress tolerance, or exercise intolerance despite normal lab results. The cellular machinery is functioning, but it is doing so under a standing order: “Stay alert, danger is still present!”

How cells rewire themselves under chronic stress

Prolonged activation of the CDR changes not just how cells make energy, but how they communicate and behave. This reprogramming resembles the Warburg effect, a metabolic pattern seen in both immune and cancer cells, where glucose is converted to lactate even when oxygen is abundant. This trade-off allows cells to prioritize defense over growth. They produce enough energy to survive but not enough to thrive.

Meanwhile, mitochondria and the cell nucleus fall out of sync. Normally, these two structures maintain an ongoing dialogue through small signaling peptides such as MOTS-c, which regulate gene expression and coordinate metabolic adjustments.

Under chronic stress, that dialogue weakens. Communication breakdowns mean that even when the external stressor has passed, the cell continues to behave as if it hasn’t. It remains metabolically rigid and unable to transition from survival back to regeneration.

Practitioners may recognize this pattern in clients who feel ‘stuck.’ Their bodies have adapted to long-term threat perception, and the cellular programs meant to help them survive are not preventing them from healing.

How our cells know it is safe to heal again

At the center of recovery lies a molecular switch known as NRF2. This is considered the body’s master regulator of antioxidant and detoxification pathways, and when oxidative stress rises from toxins, infection, or emotional strain, NRF2 moves into the nucleus and activates genes that create glutathione, antioxidant enzymes, and repair proteins.

It is, quite literally, the biochemical signal that it’s safe to rebuild. When NRF2 signaling is impaired from poor sleep, nutrient depletion, chronic inflammation, or toxic exposure, the cell remains locked in a defensive state. Energy continues to be spent on protection instead of regeneration.

Clinically, this manifests as individuals who struggle to bounce back, characterized by persistent fatigue, inflammatory reactivity, or slowed recovery despite doing ‘all the right things.’ Supporting NRF2 through phytonutrients (sulforaphane, curcumin, resveratrol), cruciferous vegetables, restorative sleep, rhythmic movement, and time in natural light helps re-engage this repair signal. These interventions are literal safety cues, reminding our body that a threat has passed, inviting the cell to return to balance.

When the body’s alarm won’t turn off

Another crucial component in the CDR is the NLRP3 inflammasome, an internal sensor that detects danger molecules released during stress. When energy, ROS, or mtDNA fragments accumulate, NLRP3 activates and releases inflammatory messengers (cytokines) such as interleukin-1β (IL-1β) and interleukin-18 (IL-18).

In acute phases, this system is beneficial because it calls immune cells to action and initiates repair. But chronic activation keeps the immune system in a low-grade state of alert. Over time, this sustained signaling contributes to autoimmunity, neuroinflammation, and metabolic dysfunction.

Interventions that reduce mitochondrial load, repair the gut barrier, optimize micronutrients, and manage psychosocial stress help quiet this inflammasome and re-establish immune tolerance. By restoring redox balance and improving mitochondrial communication, we allow the body to lower its defenses and begin repair.

How the body knows danger has passed

Inflammation is supposed to end. Once a threat is neutralized, the body must receive a clear biochemical signal that it’s safe to stand down. That signal comes from adenosine, which is produced when specialized enzymes (CD39 and CD73) break down energy outside the cell, and specialized compounds derived from Omega-3 (resolvins and protectins).

Together, these compounds actively promote tissue repair and signal the transition from defense to homeostasis. When adenosine binds to A2A receptors on immune and blood cells, it acts as a message of resolution, reducing chemical messaging from cytokines, improving circulation, and promoting tissue repair.

If this conversation process is impaired by the presence of toxins, chronic psychological stress, or disrupted metabolism, the ‘off switch’ for inflammation never fully engages. The body remains in defense, expending energy long after the threat has passed. The goal is not to suppress inflammation; it is to complete it, helping the body recognize that it is safe once again.

Clearing debris: how the body resets after defense

Once the alarms are quiet, the body needs to clean up the damage left behind. Autophagy, the process of recycling cellular components, and mitophagy, the targeted removal of damaged mitochondria, are essential for full recovery. When these pathways stagnate, dysfunctional organelles continue leaking ROS and mtDNA, perpetuating low-level inflammation.

Practices such as fasting, structured exercise, adequate sleep, and nutrient sufficiency gently reactivate these processes. Meanwhile, the gut-mitochondria-microbiome axis plays a crucial role in determining how effectively the body restores balance.

Dysbiosis or intestinal permeability allows bacterial fragments (like LPS) to enter circulation, keeping the mitochondria on alert. Restoring microbial diversity, strengthening the gut barrier, and replenishing mitochondrial cofactors (B vitamins, magnesium, CoQ10) help signal systemic safety. These are part of the same message: “It is time to rebuild.”

When healing requires a system reset

The CDR resolves only when cells collectively perceive safety. When energy release ceases, oxidative balance normalizes, and communication between mitochondria and the nucleus is restored. Recovery follows three guiding principles:

1. Reduce ongoing threats: remove infections, toxins, and chronic stressors

2. Support resolution: enhance NRF2 activity, adenosine signaling, and autophagy

3. Rebuild capacity: restore mitochondrial integrity, nutrient sufficiency, and microbial balance.

When these elements align, energy production returns to oxidative metabolism, inflammation resolves, and the system transitions from defense to regeneration.

Practitioner Takeaways

• The Cell Danger Response represents a protective adaptation, not pathology. Chronic illness often reflects a CDR that was not completed.

• Mitochondria integrate all forms of stress, including biological, chemical, and emotional, and translate them into energy and immune communication.

• Common presentations: fatigue, brain fog, inflammatory sensitivity, “wired but tired” states, and slow recovery despite clean labs.

• Key clinical levers:

  • Support NRF2 activation through phytonutrients and restorative lifestyle habits.

  • Reduce inflammasome activity by repairing gut integrity and balancing redox state.

  • Promote resolution through adenosine signaling (rest, parasympathetic activation, magnesium) and Omega-3 fatty acids, including EPA and DHA.

  • Reactivate autophagy and mitophagy with fasting, exercise, and circadian rhythm repair.

  • Rebuild microbial diversity to stabilize the gut-mitochondria axis.

Healing is ultimately about restoring the body’s perception of safety. Every nutritional, behavioral, or environmental intervention is a way of telling the cell: “The danger is over. You can begin again.”

For a deeper understanding

Gut health and chronic disease (Part I): Understanding the connection

Gut health and chronic disease (Part II): Our gut biome’s co-workers and their role in resilience

Gut health as a determinant of mitochondrial function

If you’re living with one or more lifestyle-related chronic conditions and are ready to move beyond symptom management, I offer personalized consultations focused on physiology, labs, and upstream drivers of disease. Book a discovery appointment to explore your symptoms, review relevant biomarkers, and develop a targeted, evidence-informed plan. Start your health journey with me.

Leave a comment

References

Agorastos A., & Chrousos G. P. (2022). The neuroendocrinology of stress: The stress-related continuum of chronic disease development. Molecular Psychiatry, 27, 502–513.

Ai, Y., Wang, H., Liu, L., Qi, Y., Tang, S., Tang, J., & Chen, N. (2023). Purine and purinergic receptors in health and disease. MedComm (2020), 4(5), e359 https://doi.org/10.1002/mco2.359

Guo, Y., Cho, S. W., Saxena, D., & Li, X. (2020). The multifaceted actions of succinate as a signalling transmitter vary with its cellular location. Endocrinology and Metabolism, 35(1),36–43. https://doi.org/10.3803/EnM.2020.35.1.36

Hough, D., Mao, A. R., Aman, M., Lozano, R., Smith-Hicks, C., Martinez-Cerdeno, V., Derby, M., Rome, Z., Malan, N., & Findling, R. L. (2023). Randomized clinical trial of low-dose suramin intravenous infusions for the treatment of autism spectrum disorder. Annals ofGeneral Psychiatry, 22(1),45.https://doi.org/10.1186/s12991-023-00477-8

Huang, Y., Zhou, J., Peng, X., & Liu, X. (2021). From purines to purinergic signalling: Molecular functions and human diseases. Signal Transduction and Targeted Therapy, 6(1),68.https://doi.org/10.1038/s41392-021-00553-z Naviaux, R. K. (2014a). Metabolic features of the cell danger response. Mitochondrion,16,7–17. https://doi.org/10.1016/j.mito.2013.08.006

Lu S., Wei F., & Li G. (2021). The evolution of the concept of stress and the framework of the stress system. Cell Stress, 5, 76–84.

Naviaux, R. K. (2020). Perspective: Cell danger response Biology—The new science that connects environmental health with mitochondria and the rising tide of chronic illness. Mitochondrion, 51,40–45. https://doi.org/10.1016/j.mito.2019.12.005

Naviaux, R. K., Curtis, B., Li, K., Naviaux, J. C., Bright, A. T., Reiner, G. E., Westerfield, M., Goh, S., Alaynick, W. A., Wang, L., Capparelli, E. V., Adams, C., Sun, J., Jain, S., He, F., Arellano, D. A., Mash, L. E., Chukoskie, L., Lincoln, A., & Townsend, J. (2017). Low-dose suramin in autism spectrum disorder: A small, phase I/II, randomized clinical trial. Annals of Clinical and Translational Neurology, 4(7),491–505. https://doi.org/10.1002/acn3.424

Naviaux, R. K., & Naviaux, J. C. (2017a). Antipurinergic therapy for autism: An in-depth review. Mitochondrion. https://doi.org/10.1016/j.mito.2017.12.007

Noushad S. et al. (2021). Physiological biomarkers of chronic stress: A systematic review. International Journal of Health Sciences, 15, 46–53.

Pizzorno J. E., & Murray M. T. (2020). Textbook of Natural Medicine (5th ed., Ch. 136). Elsevier.

Ruscio M. (2023). How to recognize & treat a cell danger response. Retrieved from https://drruscio.com/how-to-treat-cell-danger-response/

Steffan, D., Pezzini, C., Esposito, M., & Franco-Romero, A. (2025). Mitochondrial aging in the CNS: Unravelling implications for neurological health and disease. Biomolecules, 15(9), 1252. https://doi.org/10.3390/biom15091252

Territo, P. R., Ferraris, D., & Kirkwood, C. A. (2021). P2X7 receptors in neurodegeneration. Frontiers in Cellular Neuroscience, 15, Article617036. https://doi.org/10.3389/fncel.2021.617036

Wei, S., Song, X., Mou, Y., Zhou, W., Zhao, T., Li, W., Yang, H., & Chen, J. (2025). New insights into pathogenisis and therapies of P2X7R in Parkinson’s disease. Npj Parkinson's Disease, 11, 108. https://doi.org/10.1038/s41531-025-00980-7

Wu Z., Qu J., Zhang W., & Liu G.-H. (2024). Stress, epigenetics, and aging: Unraveling the intricate crosstalk. Molecular Cell, 84, 34–56.

Xu, X., Pang, Y., & Fan, X. (2025). Mitochondria in oxidative stress, inflammation and aging: From mechanisms to therapeutic advances. Signal Transduction and Targeted Therapy, 10,190. https://doi.org/10.1038/s41392-025-02253-4

Zong, Y., Li, H., Liao, P., Peng, Y., Yu, D., Wang, X., Hou, Y., Ma, C., Tian, M., Chen, T., Zhang, Y., Dong, C., Song, W., Wang, C., Li, C., Du, J., Wang, Q., Hu, S., Wang, T., Zhang, P., Ma, X., & Liu, G. (2024). Mitochondrial dysfunction: Mechanisms and advances in therapy. Signal Transduction and Targeted Therapy, 9, 124. https://doi.org/10.1038/s41392-024-01839-8

This connection serves as a nutrient-to-energy interface, and when disrupted, it drives dysfunction across multiple organ systems, becoming a significant determinant of both acute and chronic diseases with wide-ranging consequences. Understanding this connection reframes chronic disease as a systems failure rooted in disrupted nutrient processing and energy generation, and it is more than just a research concept. It is emerging as a central framework for understanding energy, resilience, and the origins of chronic disease.

Mitochondria in context

Mitochondria are present in nearly all nucleated cells, with the number of mitochondria proportional to the cell's energy demand. Their abundance reflects energy demand, where muscle cells and neurons contain thousands, and mature red blood cells expel their mitochondria entirely to maximize hemoglobin content. Energy generation is their best-known role, but mitochondria also act as signaling centers, regulate programmed cell death (apoptosis), and integrate nutrient metabolism by oxidizing fatty acids, recycling amino acids, and stabilizing glucose availability. Their ability to function efficiently is contingent upon a healthy gut, which provides both nutrients and regulatory metabolites.

When mitochondria are unhealthy or under stress, it may be felt long before laboratory tests confirm dysfunction. Common symptoms include persistent fatigue, poor stamina, exercise intolerance, muscle weakness or cramping, brain fog, memory issues, headaches, and mood changes. Systemic effects can include blood sugar dysregulation, cold intolerance, unexplained weight changes, and gastrointestinal symptoms such as bloating or poor nutrient absorption. Because mitochondria influence every energy-dependent tissue, dysfunction can also present as cardiovascular complaints (palpitations, exercise-induced discomfort) and heightened inflammatory states (aches, low-grade fevers, immune dysregulation). These nonspecific but cumulative symptoms often represent early signs of impaired mitochondrial performance.

Microbiome influence on mitochondria

The microbiome directly shapes immunity and, through its chemical outputs (metabolites), influences mitochondrial performance. Key beneficial microbes, such as Faecalibacterium prausnitzii, generate butyrate, the primary fuel for our colon cells, which fortifies the intestinal barrier and enhances energy production while mitigating inflammation. Other species contribute acetate and propionate, thereby regulating glucose and lipid metabolism. Meanwhile, Bifidobacterium species support immune tolerance and mucus renewal within the gut lining, which is particularly critical during early life. Akkermansia muciniphila maintains mucus integrity and metabolic balance, whereas expansion of Proteobacteria often signals dysbiosis and endotoxin-driven inflammation.

Microbial fermentation of dietary fiber in the large intestine yields short-chain fatty acids (SCFAs) that not only sustain our gut lining but also optimize mitochondrial efficiency in the liver, skeletal muscle, and brain. Beyond SCFAs, other microbial metabolites, such as bile acids and tryptophan byproducts, act as signaling molecules.

These compounds activate energy-regulating pathways like AMPK (the cell’s energy sensor), PPARs (nuclear receptors that govern fat and glucose metabolism), and FXR (a bile acid receptor that influences mitochondrial stress responses). In doing so, the microbiome fine-tunes how mitochondria balance energy generation, nutrient utilization, and inflammation across tissues. For a deeper dive into the inner workings of our gut microbiome, visit our article on Gut Health and Chronic Disease Part I.

Clinical implications

Communication between the gut and mitochondria relies on a steady flow of immune signals and chemical messages from our microbiomes. These compounds determine whether nutrients are efficiently converted into energy or whether stress and inflammation dominate. The efficiency of mitochondrial energy production depends not only on nutrient intake but also on how those nutrients are processed and delivered by the gut. Microbial metabolites act as key messengers that fine-tune mitochondrial biogenesis, oxidative balance, and nutrient utilization.

When the gut cannot deliver sufficient substrates, the key energy-generating processes (the Krebs cycle and oxidative phosphorylation) falter. Under healthy conditions, mitochondria generate low levels of reactive oxygen species (ROS: chemically reactive byproducts of energy production) that activate antioxidant defenses and promote mitochondrial growth. When systemic inflammation, often triggered by gut permeability or dysfunction, overwhelms this balance, ROS accumulate, the electron transport chain (a chain of proteins that produce energy) becomes impaired, energy declines, and mitochondrial DNA fragments.

The impacts of stressed mitochondria extend across systems. In the cardiovascular system, oxidative stress accelerates gut lining dysfunction and the formation of plaques. In the brain, it contributes to neuronal injury and the progression of Alzheimer’s and Parkinson’s disease. In skeletal muscle, it disrupts insulin signaling and fosters metabolic dysfunction. When mitochondria are impaired or communication fails, energy production drops, oxidative stress rises, and chronic inflammation becomes the prevailing state. All of which are shared hallmarks of metabolic, cardiovascular, neurodegenerative, and immune-mediated diseases.

Measurable markers

Markers of healthy gut-to-mitochondrial communication can be detected through a combination of clinical laboratory tests and advanced functional testing. These tools, when interpreted together, provide a system-level view of how the gut and mitochondria interact in both resilience and disease:

• SCFA levels: stool or plasma analysis for butyrate, acetate, and propionate (e.g. BiomeFx*, GI-MAP* with add-ons).

• Bile acid metabolism: serum or stool bile acid panels, including primary-to-secondary bile acid ratios.

• Tryptophan metabolism: plasma or urine tryptophan-to-kynurenine ratio and indole derivatives, often captured in organic acid testing.

• Organic acid testing (OAT): provides insight into mitochondrial energy output, microbial overgrowth, and nutrient cofactor needs by measuring metabolites in urine.

• Comprehensive stool panels (e.g. GI360*, Gut 360*, GI Effects*): evaluate microbial composition, diversity, inflammation, and fermentation patterns that influence mitochondrial function.

• Circulating mitochondrial DNA (mtDNA): detected in plasma, indicating mitochondrial stress and cellular damage.

• Oxidative stress biomarkers: ratios of reduced-to-oxidized glutathione, F2-isoprostanes, and lipid peroxidation markers.

• Functional mitochondrial testing: high-resolution respirometry measuring ATP output and reserve capacity under stress.

Disease implications

Breakdowns in communication between the gut and mitochondria ripple outward, leading to whole-body dysfunction. The resulting energy deficits, inflammatory cascades, and metabolic disturbances are evident across nearly every domain of chronic disease, influencing how conditions develop and progress.

• Metabolic disorders: Reduced SCFA production weakens mitochondrial energy generation, blunts insulin sensitivity, disrupts blood sugar regulation, and contributes to fatty liver disease

• Cardiovascular system: Microbial byproducts such as trimethylamine N-oxide interfere with the health of blood vessels, making them less flexible and more prone to injury. Mitochondria under stress produce excess reactive oxygen species, which are highly reactive molecules that damage vessel walls and accelerate plaque buildup. Together, these changes raise the risk of heart disease.

• Brain: Mitochondrial stress can be particularly damaging here because mitochondrial respiration (the process of converting nutrients and oxygen into energy) slows down, leaving neurons more fragile. Combined with inflammation triggered by gut permeability, this contributes to the progression of conditions like Parkinson’s and Alzheimer’s disease. In simple terms, when brain cells can’t make enough energy, they struggle to repair themselves and eventually die off.

• Immune system: When fragments of bacteria slip through a weakened gut barrier into the bloodstream, they activate immune defenses. At the same time, stressed mitochondria release reactive oxygen species: chemicals that amplify inflammation. Together, these signals can tip the immune system toward chronic overactivity, increasing the risk of autoimmune conditions.

• Cancer: An unhealthy gut fosters DNA damage and inflammation that support tumor growth. On the contrary, beneficial metabolites like butyrate can help trigger programmed cell death in abnormal cells and support immune defenses against cancer. This duality is tied to the “Warburg effect,” where cancer cells prefer less efficient energy pathways even in oxygen-rich conditions.

Therapeutic and environmental influences

Restoring balance in the connection between our gut and mitochondria requires attention to both targeted therapies and the broader environment in which cells function. Microbiome-directed approaches are among the most promising. Probiotic- and prebiotic-rich foods have been shown to enhance microbial balance, boost short-chain fatty acid production, and reduce systemic inflammation.

Pharmacological agents can also shape this nutrient-to-energy relationship, sometimes beneficially and sometimes with unintended consequences. Metformin, for example, supports mitochondrial oxidative capacity by enhancing the microbiota's ability to produce SCFAs, which helps explain its insulin-sensitizing effects. Statins, widely used to lower cardiovascular risk, alter microbial composition and decrease coenzyme Q10 availability, which may impair mitochondrial respiration in some individuals. Long-term antibiotic use reduces microbial diversity, the production of SCFAs, and disrupts mitochondrial energy metabolism. Certain chemotherapy agents exert direct mitochondrial toxicity, often mediated by their impact on gut microbial communities.

Beyond clinical interventions, environmental and lifestyle factors can shape the resilience of this system. Nutrition remains one of the strongest drivers: diets rich in fiber and plant-based foods encourage the production of microbial metabolites that support mitochondrial biogenesis and efficient energy metabolism, whereas ultra-processed foods blunt these pathways. Physical activity, both endurance and resistance training, enhances microbial diversity, increases the abundance of SCFA-producing bacteria, and stimulates mitochondrial capacity in muscle and other tissues. Sleep and psychological stress also exert powerful influences. Chronic sleep deprivation and ongoing stress weaken the gut barrier, elevate systemic inflammation, and destabilize mitochondrial homeostasis, leaving the body less able to repair and adapt.

Our other microbial ecosystems also contribute to mitochondrial health. Taken together, these therapeutic, environmental, and lifestyle factors suggest that mitochondrial resilience is not determined by a single input, but rather by the ongoing interaction between gut health, systemic microbial communities, and the conditions under which we live.

• The oral microbiome produces inflammatory mediators linked to vascular dysfunction and neurodegeneration. When vascular function is impaired, it contributes to high blood pressure, atherosclerosis, heart disease, stroke, and even cognitive decline.

• The skin microbiome influences immune signaling and oxidative stress. Long-term oxidative stress contributes to inflammation, aging, and chronic diseases such as cardiovascular disease, diabetes, neurodegeneration, and cancer.

• The lung microbiome, when disrupted by infection or pollution, can trigger cytokine-mediated mitochondrial stress in distant organs.

• The vaginal microbiome shapes fertility, pregnancy outcomes, and menopausal health by regulating inflammation and mitochondrial function in reproductive tissues.

• The liver microbiome directly governs hepatocyte mitochondrial metabolism through the gut–liver connection, contributing to the development of fatty liver disease.

• Circadian rhythms, synchronized by daylight, regulate mitochondrial efficiency. Insufficient natural light or excessive artificial light at night disrupts these rhythms, leading to increased oxidative stress.

Supporting this relationship requires careful consideration of interventions, awareness of potential trade-offs, and alignment of daily rhythms with the body’s energy needs. For a deeper understanding of how these microbiomes influence our gut, refer to Gut Health and Chronic Disease Part II.

In conclusion

A disrupted gut-to-mitochondria connection reframes chronic disease as a failure of communication between two essential systems: the microbial networks that process nutrients and the cellular engines that turn them into energy. When this dialogue is intact, the result is efficient metabolism, balanced immunity, and resilience across tissues. When it breaks down, energy falters, inflammation rises, and the pathways of chronic illness accelerate. By recognizing the central role of gut-mitochondria interactions, clinicians and researchers can identify dysfunction earlier, apply targeted testing, and design interventions that restore energy balance at its root. This systems view moves beyond treating symptoms and offers a framework for understanding and addressing the origins of modern chronic disease.

What’s the question this raises for you? I’ll do my best to address it in a future article.

Leave a comment

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

References

Borbolis F, Mytilinaiou E, Palikaras K. The Crosstalk between Microbiome and Mitochondrial Homeostasis in Neurodegeneration. Cells. 2023 Jan 28;12(3):429. doi: 10.3390/cells12030429. PMID: 36766772; PMCID: PMC9913973.

Du, Y.; He, C.; An, Y.; Huang, Y.; Zhang, H.; Fu, W.; Wang, M.; Shan, Z.; Xie, J.; Yang, Y.; et al. The Role of Short Chain Fatty Acids in Inflammation and Body Health. Int. J. Mol.Sci.2024,25,7379. https:// doi.org/10.3390/ijms25137379

Front. Pharmacol. 15:1428242. doi: 10.3389/fphar.2024.1428242

Gatarek P, Kaluzna-Czaplinska J. Trimethylamine N-oxide (TMAO) in human health. EXCLI J. 2021 Feb 11;20:301-319. doi: 10.17179/excli2020-3239. PMID: 33746664; PMCID: PMC7975634.

Haque, P.S., Kapur, N., Barrett, T.A. et al. Mitochondrial function and gastrointestinal diseases. Nat Rev Gastroenterol Hepatol 21, 537–555 (2024). https://doi.org/10.1038/s41575-024-00931-2

Kulkarni H, Gaikwad AB. The mitochondria-gut microbiota crosstalk - A novel frontier in cardiovascular diseases. Eur J Pharmacol. 2025 Jul 5;998:177562. doi: 10.1016/j.ejphar.2025.177562. Epub 2025 Mar 27. PMID: 40157703.

Lin, L., Xiang, S., Chen, Y., Liu, Y., Shen, D., Yu, X. ... Ning, Z. (2024). Gut microbiota: Implications in pathogenesis and therapy to cardiovascular disease (Review). Experimental and Therapeutic Medicine, 28, 427. https://doi.org/10.3892/etm.2024.12716

Liu X, Xu M, Wang H, Zhu L. Role and Mechanism of Short-Chain Fatty Acids in Skeletal Muscle Homeostasis and Exercise Performance. Nutrients. 2025 Apr 26;17(9):1463. doi: 10.3390/nu17091463. PMID: 40362771; PMCID: PMC12073122.

Loh, J.S., Mak, W.Q., Tan, L.K.S. et al. Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases. Sig Transduct Target Ther 9, 37 (2024). https://doi.org/10.1038/s41392-024-01743-1

Shanmugham, M.; Bellanger, S.; Leo, C.H. Gut-Derived Metabolite, Trimethylamine-N-oxide (TMAO) in Cardio-Metabolic Diseases: Detection, Mechanism, and Potential Therapeutics. Pharmaceuticals 2023, 16, 504. https://doi.org/10.3390/ph16040504

Shen, Y., Fan, N., Ma, S.-x., Cheng, X., Yang, X., & Wang, G. (2025). Gut microbiota dysbiosis: Pathogenesis, diseases, prevention, and therapy. Microorganisms, 13(2), 70168. https://doi.org/10.1002/mco2.7016

Warburg, O. (1956). On the origin of cancer cells. Science, 123(3191), 309–314. https://doi.org/10.1126/science.123.3191.309

Wen L, Yang K, Wang J, Zhou H, Ding W. Gut microbiota-mitochondrial crosstalk in obesity: novel mechanistic insights and therapeutic strategies with traditional Chinese medicine. Front Pharmacol. 2025 Apr 22;16:1574887. doi: 10.3389/fphar.2025.1574887. PMID: 40331200; PMCID: PMC12052897.

Zachos KA, Gamboa JA, Dewji AS, Lee J, Brijbassi S and Andreazza AC (2024), The interplay between mitochondria, the gut microbiome and metabolites and their therapeutic potential in primary mitochondrial disease.

Zhang, D., Jian, YP., Zhang, YN. et al. Short-chain fatty acids in diseases. Cell Commun Signal 21, 212 (2023). https://doi.org/10.1186/s12964-023-01219-9

Zhao H, Qiu X, Wang S, Wang Y, Xie L, Xia X, Li W. Multiple pathways through which the gut microbiota regulates neuronal mitochondria constitute another possible direction for depression. Front Microbiol. 2025 Apr 17;16:1578155. doi: 10.3389/fmicb.2025.1578155. PMID: 40313405; PMCID: PMC12043685.

When we talk about gut health, it’s easy to reduce the conversation to a tally of “good” and “bad” bacteria. But the reality is far richer and far more important for understanding health and disease. A key distinction sets the stage: microbiota refers to the living organisms themselves—bacteria, fungi, viruses, archaea, even parasites. Microbiome, on the other hand, includes not only those organisms but also their genetic potential (genes), their chemical fingerprints (metabolites), and the jobs they perform within the body (functions).

This shift in perspective moves us away from a numbers game toward viewing the gut as an ecosystem. Health emerges not from the sheer presence or absence of certain microbes, but from the overall harmony and productivity of that system. Disease, then, is less about invaders and more about lost functions, imbalances, or toxic byproducts. And therapies become not just about wiping out or adding microbes, but about restoring balance at the system level, where resilience truly resides.

Distinct microbial communities populate nearly every surface and cavity of the human body, each with specialized roles in maintaining balance and constant communication with one another. To see this web of influence in action, let’s take a closer look at the hub-and-network dynamics of specific microbiomes and how they shape the gut.

The oral microbiome: gateway to systemic health

Saliva and swallowed bacteria provide a direct route for oral microbes into the gastrointestinal tract, influencing gut composition. Conversely, gut inflammation and systemic immune signals can alter the oral microbial environment, explaining bidirectional links between periodontal disease and gut dysbiosis. For practitioners, this cross-talk underscores the importance of considering oral health when addressing digestive concerns with clients and patients. Our oral microbiome includes hundreds of bacterial species that help regulate the mouth’s pH, begin digestion, and maintain tooth and gum health. Beyond oral health, this community acts as a gateway to systemic health: when balanced, it limits colonization by pathogens; when disrupted, it can seed inflammation elsewhere in the body.

Why it matters: Oral pathogens and chronic inflammation don’t just stay in the mouth. They are swallowed daily and travel to the gut and beyond, altering microbial composition. Chronic oral inflammation also increases systemic inflammatory markers, such as CRP and cytokines, which can increase gut permeability, leading to greater immune activation and increased risk for cardiovascular disease and diabetes. New research also highlights a link to Alzheimer’s, suggesting a direct connection between oral health and brain function.

The vaginal microbiome: hormones and protection

The vaginal microbiome is one of the best examples of microbial specialization. Dominated by Lactobacillus species, it produces lactic acid that maintains a low pH environment, offering protection against pathogens and supporting reproductive health. This balance is dynamic, influenced by hormonal shifts across the lifespan. During reproductive years, Lactobacillus dominance supports fertility and pregnancy outcomes, while menopause reduces glycogen availability in vaginal tissues. In perimenopause and menopause, this shift is significant because it contributes to Genitourinary Syndrome of Menopause (GSM), weakens microbial stability, and increases the risks of inflammation and infection. These microbial dynamics are strongly influenced by hormones and immune status, meaning that disturbances in gut ecology can directly impact vaginal balance.

Why it matters: Disruptions in the vaginal microbiome increase risk of bacterial vaginosis, preterm birth, and infertility. Imbalances in this area are often overlooked in broader discussions of microbiome science.

The skin microbiome: where inside meets outside

The skin microbiome illustrates how external and internal systems meet. It produces antimicrobial compounds, supports wound healing, and trains the immune system. Yet, it is also sensitive to gut-derived metabolites and inflammatory signals. Gut dysbiosis can exacerbate skin conditions, including eczema and acne. In practice, this suggests that persistent dermatological complaints may warrant an assessment of gut health and diet as part of a broader strategy.

Why it matters: Skin dysbiosis reflects immune dysfunction that often originates in gut imbalance, but it also works in reverse. Chronic skin inflammation increases systemic cytokine levels, which stress the gut barriers and alter microbial communities. This bi-directional loop helps explain why many people with eczema or psoriasis also have GI complaints or autoimmune comorbidities.

The lung microbiome: gut-lung axis

The lung microbiome, once assumed sterile, is now recognized as a low-biomass but active community. It interacts with the gut via the gut-lung axis, where microbial metabolites and immune signals travel between the two systems. A balanced lung microbiome appears to support immune readiness and tolerance, while disruption is increasingly associated with asthma, COPD, and chronic infections. Clinically, this means that respiratory and digestive symptoms may be more effectively addressed together rather than in isolation.

Why it matters: In asthma, airway inflammation alters immune signaling. Those same immune pathways, especially Th2 skewing and cytokine release, influence gut immunity. Studies show that asthmatic inflammation can alter the gut microbial balance, reducing the number of beneficial species and weakening tolerance. That, in turn, heightens the risk of allergic disease, metabolic dysfunction, and other chronic inflammatory conditions.

Other biomes: liver, bladder, brain

Even organs not traditionally considered microbially active exhibit microbial influences. The liver, pancreas, and gallbladder are indirectly shaped by gut-derived metabolites through portal circulation, which impacts energy metabolism and detoxification. The bladder harbors a low-biomass microbiome that contributes to urinary tract health, influencing susceptibility to infection and chronic irritation.

The brain itself does not have a resident microbiome, but it is deeply connected through the gut-brain axis, receiving constant input from gut microbial signals that affect neurotransmission, stress responses, and cognition. The gut-brain axis (GBA) is a central component of the body’s microbial network and illustrates how gut health impacts not only digestion and immunity but also mood, cognition, stress responses, and sleep. Microbial metabolites, neurotransmitter precursors, and immune signals travel from the gut to the brain, while the brain regulates gut function through hormones and autonomic pathways. By incorporating bidirectional communication into the discussion of microbial networks, we can gain a deeper understanding of the broader significance of gut health and its central role in whole-body resilience.

Of course, the gut-brain axis

By now, most people have at least heard of the GBA. It is often mentioned in conversations tied to mood, stress, or digestion. What it really describes, however, is a sophisticated, two-way communication system between the gut microbiome and the brain. Signals travel along multiple channels. The vagus nerve provides a direct neural line, carrying information from the gut to the brain in real time. Hormones add another layer: gut microbes help shape cortisol and gut peptides that regulate stress, appetite, and mood. The immune system is also deeply involved, as microbial metabolites influence the release of cytokines that can alter brain function and behavior.

When this system is in balance, it supports mental clarity, emotional regulation, and resilience. When it’s disrupted through dysbiosis or imbalance in the gut community, the ripple effects can show up in ways that look very different on the surface: depression, anxiety, autism spectrum disorder, even neurodegenerative conditions like Alzheimer’s and Parkinson’s.

Why it matters: These body-wide microbial systems remind us that health is a networked property. The gut may be the hub, but each microbial community contributes unique and essential functions to overall resilience.

Shared microbial language

Despite their different locations and roles, the body’s microbiomes communicate in a common biochemical ‘language’ to sustain health. They metabolize dietary compounds into short-chain fatty acids (SCFAs) and other metabolites that fuel colon cells, shape immune tolerance, and influence energy metabolism. They also provide colonization resistance, producing antimicrobial compounds that keep harmful organisms in check.

This shared set of functions is what links the oral, skin, lung, vaginal, and other microbiomes back to the gut. Signals from one community travel into the others through circulation, immune pathways, and the nervous system. In this way, the body’s microbial ecosystems act less like isolated neighborhoods and more like an interconnected network, each speaking the same language, each influencing the others.

Why our gut matters the most

Among all these interconnected microbial communities, the gut stands out as the most dense, diverse, and influential hub. It not only carries the richest microbial population but also sits at the crossroads of digestion, metabolism, immunity, and brain signaling. Colonization begins at birth, shaped by delivery mode, breastfeeding, antibiotic exposure, and environment. Vaginal delivery and breastfeeding promote colonization with Lactobacillus and Bifidobacterium, while diverse exposures in early childhood expand microbial richness. In contrast, cesarean delivery tends to favor colonization by skin-associated and environmental microbes, often reducing microbial diversity and increasing the risk of allergies, autoimmune disorders, and metabolic diseases later in life. An overly sanitized environment can also limit microbial diversity and increase the risk of immune-mediated disease.

The gut microbiome contributes directly to digestion and metabolism by fermenting fiber into SCFAs, regulating nutrient absorption, and supporting systemic energy balance. It communicates with mitochondria, influences immune training, and constantly signals to the brain through neural, endocrine, and immune pathways. Keystone species are particularly important within the gut microbiome, exerting influence beyond their relative abundance. For example:

• Bacteroides and Prevotella both play central roles in breaking down complex carbohydrates and fibers.

• Faecalibacterium prausnitzii is a major producer of butyrate, which fuels colon cells, maintains the gut barrier, and reduces inflammation.

• Akkermansia muciniphila resides in the mucus lining of the gut, strengthening this barrier and supporting metabolic health.

• Bifidobacterium species are among the earliest colonizers of the infant gut, feeding on human milk oligosaccharides, and throughout life, they continue to support the integrity of the gut barrier and immune responses.

• Lactobacillus species help maintain mucosal pH through lactic acid production, inhibiting pathogens and promoting balance.

• Roseburia and Ruminococcus degrade complex fibers and generate beneficial SCFAs. When these species decline, the result is not only local inflammation but also systemic consequences that extend to the lungs, skin, and oral cavity.

In conclusion

The future of microbiome science lies in personalization and integration. Advances in sequencing now make it possible to map microbial “fingerprints,” enabling tailored diets and targeted interventions. The “old friends’ hypothesis” reminds us that humans co-evolved with environmental microbes that trained immune tolerance, organisms largely missing from modern life. Reintroducing their signals, whether through diet, lifestyle, or supplementation, may help restore balance.

Most importantly, the gut must be understood in context. It is a powerful hub, but it cannot be separated from other microbial communities. Oral, vaginal, skin, lung, and other biomes each bring unique roles, and their constant cross-talk with the gut ensures that an imbalance in one reverberates across the whole. For practitioners and health seekers, the takeaway is actionable: gut health matters, but only as part of a whole-body biome network. Recognizing this interconnectedness shifts both science and practice toward true whole-person care.

What’s the question this raises for you? I’ll do my best to address it in a future article.

Leave a comment

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

References

Afzaal, M., Saeed, F., Shah, Y. A., Hussain, M., M., Rabail, R., Socol, C. T., Hassoun, A., Pateiro, M., Lorenzo, J. M., Rusu, A. V., & Aadil, R. M. (2022). Human gut microbiota in health and disease: Unveiling the relationship. Frontiers in Microbiology, 13, Article 999001. https://doi.org/10.3389/fmicb.2022.999001

American Society for Microbiology. (2023). Gut microbiome communication: The gut-organ axis. https://asm.org/articles/2023/january/gut-microbiome-communication-the-gut-organ-axis

DeLeon, O., & Chang, E. B. (2025). Assessing the health of the gut microbial organ: Why and how? Journal of Clinical Investigation, 135(11), Article e184313. https://doi.org/10.1172/JCI184313

Grech, A., Collins, C. E., Holmes, A., Lal, R., Duncanson, K., Taylor, R., & Gordon, A. (2021). Maternal exposures and the infant gut microbiome: A systematic review with meta-analysis. Gut Microbes, 13(1), Article 1897210. https://doi.org/10.1080/19490976.2021.1897210

Hou, K., Wu, Z. X., Chen, X. Y., Wang, W., Zhang, M., Guo, Z., et al. (2022). Microbiota in health and diseases. Signal Transduction and Targeted Therapy, 7, Article 135. https://doi.org/10.1038/s41392-022-00974-4

McBurney, M. I., Davis, C., Fraser, C. M., Schneeman, B. O., Huttenhower, C., Verbeke, K., Walter, J., & Latulippe, M. E. (2019). Establishing what constitutes a healthy human gut microbiome: State of the science, regulatory considerations, and future directions. The Journal of Nutrition, 149(11), 1881–1895. https://doi.org/10.1093/jn/nxz154

Pantazi, A. C., Balasa, A. L., Mihai, C. M., Chisnoiu, T., Lupu, V. V., Kassim, M. A. K., Mihai, L., Frecus, C. E., Chirila, S. I., Lupu, A., Andrusca, A., Ionescu, C., Cuzic, V., & Cambrea, S. C. (2023). Development of gut microbiota in the first 1000 days after birth and potential interventions. Nutrients, 15(16), Article 3647. https://doi.org/10.3390/nu15163647

Salvadori, M., & Rosso, G. (2024). Update on the gut microbiome in health and diseases. World Journal of Methodology, 14(1), Article 89196. https://doi.org/10.5662/wjm.v14.i1.89196

Van Hul, M., Cani, P. D., Petitfils, C., De Vos, W. M., Tilg, H., & El-Omar, E. M. (2024). What defines a healthy gut microbiome? Gut, 73(11), 1893–1908. https://doi.org/10.1136/gutjnl-2024-333378

Yao, Y., Cai, X., Ye, Y., Wang, F., Chen, F., & Zheng, C. (2021). The role of microbiota in infant health: From early life to adulthood. Frontiers in Immunology, 12, Article 708472. https://doi.org/10.3389/fimmu.2021.708472

Zhu, S., Jiang, Y., Xu, K., Wang, Y., Zhang, W., Ruan, B., Ma, C., Liu, B., Wang, G., Zhang, S., Liu, Z., Fu, T., Xie, A., & Liu, C. (2020). The progress of gut microbiome research related to brain disorders. Journal of Neuroinflammation, 17, Article 25. https://doi.org/10.1186/s12974-020-1705-2

Of all the health buzzwords circulating today, none attracts more interest (or more misinformation) than “gut health." The term appears everywhere: in journal articles, patient consultations, supplement ads, and wellness blogs. Yet unlike cholesterol, blood pressure, or HbA1c, there is no single biomarker that can declare a gut ‘healthy’ or ‘unhealthy.’ That is because the gut isn’t just one organ. It is a living system: a gastrointestinal tract lined by barrier tissues, powered by enzymes, and inhabited by trillions of microbes. It is an immune ecosystem that trains tolerance and defense, and a neural network that constantly communicates with our brain. When we discuss gut health, what we really mean is how well these interwoven systems adapt and remain resilient in the face of stress. A healthy gut efficiently regulates digestion, immunity, metabolism, and even our mood. When these systems start to fail, the effects ripple outward, shaping risks for metabolic, autoimmune, and neurocognitive disease.

Why is defining gut health so challenging?

Unlike diabetes, which can be defined by blood glucose levels, or hypertension by systolic/diastolic cutoffs, gut health lacks a universally accepted diagnostic test. Instead, researchers and clinicians must rely on proxies:

• Symptoms such as bloating, diarrhea, or pain are useful but subjective, and are not always correlated with dysfunction.

• Inflammatory markers like calprotectin or C-reactive protein are valuable but incomplete on their own.

• Microbiome sequencing (mapping) is a promising science, but still lacks standardized clinical interpretation.

Each measure offers part of the overall picture, but no single measure tells the whole story. This is why gut health is best understood as a system property, the emergent outcome of multiple and interconnected physiological domains working in synchrony. To organize this complexity, researchers have outlined four key pillars that, together, can help us better understand gut health. Each can be assessed as a measurable biomarker, and when disrupted, each may drive distinct clinical consequences.

The four pillars of gut health

1. Digestion and absorption

The gut’s foundational task is efficient digestion and nutrient absorption. Enzymes, bile salts, and epithelial transporters convert food into usable molecules. Meanwhile, commensal microbes ferment fibers into short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate. These SCFAs regulate sugar and fat metabolism, fuel the cells of our colon, and exert anti-inflammatory effects. Microbes also synthesize key vitamins (K, and B group) and modulate mineral uptake.

Lab markers used to measure efficient digestion and nutrient absorption:

• Stool elastase for pancreatic function, fecal fat, breath tests for malabsorption.

• Serum nutrient panels: iron, B12, folate, vitamin D.

• SCFAs levels in stool or plasma.

If left unchecked, malabsorption can lead to digestive symptoms, as well as micronutrient deficiencies, anemia, fatigue, an increased risk of osteoporosis, and impaired metabolic regulation. Over time, this can weaken immune function and reduce resilience to stress.

2. Intestinal barrier integrity

The intestinal barrier is a selective gatekeeper. It is porous enough to absorb nutrients, impermeable enough to block pathogens and toxins. It is composed of epithelial cells sealed by tight junctions, mucus, antimicrobial peptides, and secretory IgA. Beyond serving as a physical wall, this barrier actively communicates with the immune and nervous systems, shaping systemic inflammation and overall health.

Lab markers used to measure effective intestinal barrier integrity:

• Lactose-mannitol permeability tests.

• Zonulin levels (still debated but commonly referenced).

• Calprotectin or LPS-binding protein as indirect signals of inflammation or translocation.

Barrier dysfunction, also known more generically as ‘leaky gut,’ allows bacterial products into circulation, triggering systemic inflammation. This state has been linked to food sensitivities, autoimmune disease, metabolic disorders, and neuroinflammation. Stress, alcohol, NSAIDs, and poor diet are common disruptors.

3. Microbiota balance

The gut microbiome is an ecosystem of bacteria, fungi, viruses, and archaea. A healthy microbiota is diverse, stable, and functionally redundant, traits that create resilience against infection, antibiotics, and dietary shifts. Its influence now extends far beyond digestion, with research linking microbial composition to immunity, mood, metabolism, and even chronic disease.

Lab markers used to measure gut microbiome balance:

• Sequencing-based diversity indices (alpha and beta diversity).

• Relative abundance of beneficial or pathogenic taxa.

• Stool organic acids and metabolomics for functional outputs.

Dysbiosis, the loss of beneficial species or overgrowth of pathobionts, has been associated with obesity, type 2 diabetes, inflammatory bowel disease, and depression. Low diversity also reduces ecosystem resilience, leaving the host more vulnerable to infections and chronic disease.

4. Immune and hormonal function

About 70% of our body’s immune system lives in the gut. This is where immune cells learn to make choices: tolerate food and friendly microbes while staying ready to attack real threats. If that training goes off track, the system can become over-reactive or sluggish, leading to widespread problems. The gut also has its own nervous system, often referred to as the “second brain.” With hundreds of millions of neurons, it runs digestion behind the scenes but also sends constant updates to the brain through the vagus nerve. This back-and-forth shapes how we process stress, how our gut moves food along, and even how we feel emotionally. Gut microbes play an active role in this conversation, producing the majority of the chemical messengers the brain uses, including serotonin, dopamine, and GABA. It regulates motility locally, but also influences mood, focus, and resilience through the gut-brain axis.

Lab markers used to measure efficient immune and hormonal function:

• Secretory IgA in stool for first-line immune defense.

• Inflammatory markers like CRP, IL-6, or TNF-α.

• Neurotransmitter metabolites (serotonin, dopamine, gamma-aminobutyric acid (GABA)) in urine or plasma.

When this gut-immune-brain network is disrupted, the results aren’t confined to digestion. Chronic low-grade inflammation, mood disorders such as anxiety or depression, reduced mental clarity, and even links to neurodegenerative disease can emerge.

Why gut health matters to whole-person health

Taken together, these four pillars position the gut as a central regulatory hub. When one pillar falters, the disturbance rarely stays local; it reverberates through the entire system. For example, the following all contribute to obesity and diabetes:

• Disrupted SCFA production

• Dysbiosis

• Barrier dysfunction

Further, a compromised intestinal barrier, paired with impaired microbial training of the immune system, has been implicated in:

• Autoimmune diseases like rheumatoid arthritis

• Allergic diseases

Breakdowns in the gut-brain communication and altered neurotransmitter production are increasingly recognized as drivers of:

• Anxiety

• Depression

• Other mental health disorders

In short, gut health is not simply about gastrointestinal comfort. For practitioners, it represents a foundation of systemic resilience, one that underpins disease prevention, cognitive performance, and long-term vitality. For practitioners and health seekers alike, this means gut health should be evaluated not through a single test or symptom, but through a constellation of markers, lifestyle factors, and functional assessments. Clinical tools, such as stool form, SCFA levels, microbial diversity, and inflammatory markers, provide useful signals; however, they must be interpreted in conjunction with one another, and clinicians must triangulate across multiple domains, including patient symptoms, lifestyle context, and functional testing.

P.S. The future of gut health is rapidly evolving, with personalized nutrition on the horizon, where diets and synbiotics can be tailored to each individual’s microbiome and health goals. Innovative therapies are emerging that may extend far beyond digestion, addressing systemic conditions through gut-based interventions. Yet even as science advances, everyday choices remain the most powerful levers: dietary diversity, fiber, and polyphenol intake, microbial exposure, stress management, and the mindful use of probiotics or fermented foods. These practices not only alleviate digestive discomfort but also promote whole-person health and enhance performance. Yet the gut does not act alone. Its influence depends on constant cross-talk with other microbial communities in the mouth, lungs, skin, and beyond.

What’s the question this raises for you? I’ll do my best to address it in a future article.

Leave a comment

──────────────────────────────

If this was useful, here’s where to go next:

→ You’re navigating chronic illness and want a clear roadmap: go here

→ You lead a clinic and want to bring this education to your patients: grab the sample curriculum here

→ You run a retreat and want to add science-backed depth to your program: go here

──────────────────────────────

References

Bischoff SC. 'Gut health': a new objective in medicine? BMC Med. 2011 Mar 14;9:24. doi: 10.1186/1741-7015-9-24. PMID: 21401922; PMCID: PMC3065426.

Brennan AM. Development of synthetic biotics as treatment for human diseases. Synth Biol (Oxf). 2022 Jan 31;7(1):ysac001. doi: 10.1093/synbio/ysac001. PMID: 35350191; PMCID: PMC8944296.

Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut. 2019 Aug;68(8):1516-1526. doi: 10.1136/gutjnl-2019-318427. Epub 2019 May 10. PMID: 31076401; PMCID: PMC6790068.

Cha RR, Sonu I. Fecal microbiota transplantation: present and future. Clin Endosc. 2025 May;58(3):352-359. doi: 10.5946/ce.2024.270. Epub 2025 Mar 25. PMID: 40468650; PMCID: PMC12138360.

Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med. 2024 Mar;19(2):275-293. doi: 10.1007/s11739-023-03374-w. Epub 2023 Jul 28. PMID: 37505311; PMCID: PMC10954893.

Dowling LR, Strazzari MR, Keely S, Kaiko GE. Enteric nervous system and intestinal epithelial regulation of the gut-brain axis. J Allergy Clin Immunol. 2022 Sep;150(3):513-522. doi: 10.1016/j.jaci.2022.07.015. PMID: 36075637.

Sadhu S, Paul T, Yadav N. Therapeutic engineering of the gut microbiome using synthetic biology and metabolic tools: a comprehensive review with E. coli Nissle 1917 as a model case study. Arch Microbiol. 2025 Aug 6;207(9):213. doi: 10.1007/s00203-025-04417-w. PMID: 40767874; PMCID: PMC12328466.

Wang LY, He LH, Xu LJ, Li SB. Short-chain fatty acids: bridges between diet, gut microbiota, and health. J Gastroenterol Hepatol. 2024 Sep;39(9):1728-1736. doi: 10.1111/jgh.16619. Epub 2024 May 23. PMID: 38780349.